INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6001, 0, 'Dicyclomine', 'Gastroesophageal Reflux', 'Antimuscarinic agents decrease gastric motility and relax the lower esophageal sphincter which promotes gastric retention and can aggravate reflux.  These drugs should be administered cautiously in patients with gastroesophageal reflux or hiatal hernia associated with reflux esophagitis.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6002, 0, 'Dicyclomine', 'Psychotic Disorders', 'Toxic psychosis manifested as confusion, disorientation, agitation, excitation, memory impairment, delusions and hallucinations may develop at toxic and therapeutic dosages of antimuscarinic agents.  Therapy with these agents should be administered cautiously in patients with mental disorders receiving antimuscarinic agents for control of drug-induced extrapyramidal effects, especially at the beginning of therapy or during dosage adjustment.  Psychiatric deterioration and psychotic flare-ups have also been reported following withdrawal of therapy.  Symptoms include delusions, hallucinations, aggression or violent behavior, and suicidal tendencies.  In high dosages, antimuscarinic agents may sometimes produce euphorigenic effects.  For this reason, it can be a drug of abuse.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6003, 0, 'Dicyclomine', 'Hepatic Insufficiency', 'Effects of hepatic impairment on pharmacokinetics, safety and efficacy of dicyclomine have not been studied.  Dicyclomine should be administered with caution in patients with hepatic impairment.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6004, 0, 'Dicyclomine', 'Hyperthyroidism', 'Caution is recommended when using dicyclomine in patients with hyperthyroidism.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6005, 0, 'Dicyclomine', 'Kidney Diseases', 'Effects of renal impairment on pharmacokinetics, safety and efficacy of dicyclomine have not been studied.  Dicyclomine is substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function.  Dicyclomine should be administered with caution in patients with renal impairment.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6006, 0, 'Dicyclomine', 'Hypertension', 'Cardiovascular effects of anticholinergics may exacerbate hypertension.  Therapy with anticholinergic agents should be administered cautiously in patients with hypertension.', '1', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6007, 0, 'Dicyclomine', 'Fever', 'Atropine-like agents may increase the risk of hyperthermia in patients with fever by producing anhidrosis.  Therapy with atropine-like agents should be administered cautiously in febrile patients.', '1', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6008, 0, 'Didanosine', 'Kidney Diseases', 'Didanosine (ddI) is primarily eliminated by the kidney.  Patients with renal impairment may be at greater risk for ddI-related toxicity due to decreased drug clearance.  Therapy with ddI should be administered cautiously at reduced dosages in patients with renal impairment.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6009, 0, 'Didanosine', 'Bone Marrow Failure Disorders', 'The nucleoside reverse transcriptase inhibitors, didanosine (ddI), zalcitabine (ddC) and stavudine (d4T), may infrequently cause bone marrow suppression at recommended dosages.  Anemia, leukopenia, thrombocytopenia and neutropenia have been reported.  Therapy with these agents should be administered cautiously in patients with preexisting bone marrow depression or blood dyscrasias.  Routine blood counts are recommended.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6010, 0, 'Didanosine', 'Liver Diseases', 'Hepatotoxicity including lactic acidosis, severe hepatomegaly with steatosis, fulminant hepatitis, and hepatic failure has been associated with the use of some nucleoside reverse transcriptase inhibitors (NRTIs) alone or in combination with other antiretroviral agents.  Therapy with NRTIs should be administered cautiously in patients with preexisting liver disease, a history of alcohol abuse, or hepatitis.  Therapy should be suspended if clinical or laboratory findings suggestive of lactic acidosis or pronounced hepatotoxicity occur.  The use of abacavir is contraindicated in patients with moderate to severe hepatic impairment as its safety and efficacy has not been established on these patients.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6011, 0, 'Didanosine', 'Pancreatitis', 'The reverse transcriptase inhibitors, didanosine (ddI), zalcitabine (ddC), stavudine (d4T) and lamivudine (3TC), may cause pancreatitis.  The incidence is generally low but is approximately 7% with ddI, and up to 15% in pediatric patients given 3TC.  Patients with a history of or known risk factors for pancreatitis, such as alcohol abuse or hypertriglyceridemia, should be monitored closely during therapy with these agents.  Therapy should be discontinued at the first signs or symptoms suggestive of pancreatitis (e.g., nausea, vomiting, abdominal pain, hyperamylasemia with dysglycemia, rising triglycerides, decreasing serum calcium), and preferably permanently discontinued if clinical pancreatitis develops.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6012, 0, 'Didanosine', 'Peripheral Nervous System Diseases', 'The nucleoside reverse transcriptase inhibitors, didanosine (ddI), zalcitabine (ddC), and stavudine (d4T), may commonly cause dose-related peripheral neuropathy, particularly in patients with advanced HIV disease.  Usually, the neuropathy resolves slowly following prompt discontinuation of therapy, but it can be irreversible.  These agents should be administered cautiously to patients with a history of neuropathy and avoided in patients with existing polyneuropathy.  Therapy may be reinstituted following resolution of symptoms in patients who have previously experienced neuropathy with these drugs, but reduced dosages are recommended.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6013, 0, 'Didanosine', 'Hyperuricemia', 'Didanosine (ddI) may infrequently cause hyperuricemia.  Patients with preexisting hyperuricemia or gout should be monitored for exacerbation of condition during ddI therapy.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6014, 0, 'Didanosine', 'Phenylketonurias', 'Videx (brand of didanosine, or ddI) chewable/dispersable buffered tablets contain 36.5 mg of phenylalanine per each 25, 50, 100, and 150 mg tablet.  The phenylalanine content should be considered when these products are used in patients who must restrict their intake of phenylalanine (i.e. phenylketonurics).', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6015, 0, 'Didanosine', 'Heart Failure', 'Didanosine (ddI) formulations have a high sodium content.  There are 265 mg of sodium per tablet and 1380 mg per packet of powder for oral solution, which may be of concern in patients with conditions that may be adversely affected by excessive amounts of sodium, such as congestive heart failure, hypertension, and fluid retention.  Each tablet also contains 8.6 mEq of magnesium.  Patients with significant renal impairment may not tolerate these loads.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6016, 0, 'Diflorasone (topical)', 'Diabetes Mellitus', 'Corticosteroids can raise blood glucose level by antagonizing the action and suppressing the secretion of insulin, which results in inhibition of peripheral glucose uptake and increased gluconeogenesis.  Therapy with topical corticosteroids rarely produces these effects but should be administered cautiously nonetheless in patients with diabetes mellitus, glucose intolerance, or a predisposition to hyperglycemia.  Systemic absorption of topical corticosteroids may occur depending on the vehicle and concentration of the preparation, the size of the application area, the integrity of the skin, and the duration of administration.  Use of occlusive dressings over the applied areas may also increase percutaneous absorption.  Given equivalent doses, small children are generally at the greatest risk because of their larger skin surface to body mass ratios.  If possible, the use of highly potent agents (e.g., augmented betamethasone, clobetasol, diflorasone, and halobetasol) should be avoided in children and limited to small areas for 2 weeks in adults.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6017, 0, 'Diflorasone (topical)', 'Diaper Rash', 'Topical corticosteroids, especially the potent agents (e.g., augmented betamethasone, clobetasol, diflorasone, and halobetasol), are generally not recommended for use in the treatment of diaper rash.  Topical corticosteroids may be systemically absorbed, depending on the vehicle and concentration of the preparation, the size of the application area, the duration of administration, and whether or not occlusive dressings are used.  Given equivalent doses, small children are usually at the greatest risk for systemic toxicity such as adrenal suppression, Cushing''s syndrome and intracranial hypertension because of their larger skin surface to body mass ratios.  If topical corticosteroids are necessary to treat diaper rash, medium- to low-potency agents should preferably be used, and parents should be advised not to put tight-fitting diapers or plastic pants over the rash, since occlusion of treated area may increase percutaneous drug absorption.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6018, 0, 'Diflorasone (topical)', 'Adrenocortical Hyperfunction', 'The use of topical corticosteroids may precipitate or aggravate conditions of hyperadrenocorticism.  Systemic absorption of these agents can produce reversible hypothalamic-pituitary-adrenal axis suppression.  Systemic absorption, depends on the vehicle and concentration of the preparation, the size of the application area, the duration of administration, and whether or not occlusive dressings are used.  Given equivalent doses, small children are generally at the greatest risk because of their larger skin surface to body mass ratios.  Patients with an altered skin barrier or liver failure are also at increased risk.  If possible, the use of highly potent agents (e.g., augmented betamethasone, clobetasol, diflorasone, and halobetasol) should be avoided in children and limited to small areas for 2 weeks in adults.  The development of symptoms such as menstrual irregularities, acneiform lesions, cataracts and cushingoid features during topical corticosteroid therapy may indicate excessive use.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6019, 0, 'Diflorasone (topical)', 'Infections', 'Topical corticosteroids may be systemically absorbed, depending on the vehicle and concentration of the preparation, the size of the application area, the duration of administration, and whether or not occlusive dressings are used.  Clinically significant local as well as systemic immunosuppressant and anti-inflammatory effects may occur, which can cause or exacerbate an infection.  Given equivalent doses, small children are generally at the greatest risk because of their larger skin surface to body mass ratios.  Therapy with topical corticosteroids should be administered cautiously in patients with latent or active infections, particularly if a potent agent is used on a large area for prolonged periods or if occlusive dressings are used.  Effective antimicrobial therapy or other appropriate treatment should be instituted to treat the infection.  If possible, the use of highly potent agents (e.g., augmented betamethasone, clobetasol, diflorasone, and halobetasol) should be avoided in children and limited to small areas for 2 weeks in adults.  Occlusive dressings should not be used in patients with skin infection.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6020, 0, 'Diflorasone (topical)', 'Toxic Optic Neuropathy', 'Prolonged use of corticosteroids may cause posterior subcapsular cataracts and elevated intraocular pressure, the latter of which may lead to glaucoma and/or damage to the optic nerves.  Therapy with topical corticosteroids rarely produces these effects but should be administered cautiously nonetheless in patients with a history of cataracts, glaucoma, or increased intraocular pressure, especially when potent agents (e.g., augmented betamethasone, clobetasol, diflorasone, and halobetasol) are used in the periorbital area.  Topical corticosteroids may be systemically absorbed, depending on the vehicle and concentration of the preparation, the size of the application area, the duration of administration, and whether or not occlusive dressings are used.  Given equivalent doses, small children are generally at the greatest risk because of their larger skin surface to body mass ratios.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6021, 0, 'Dihydroergotamine', 'Coronary Vasospasm', 'The use of ergot alkaloids is contraindicated in patients with conditions predisposing them to vasospastic reactions, including, ischemic heart disease (angina, history of myocardial infarction, silent ischemia), peripheral vascular disease, sepsis, shock, vascular surgery, uncontrolled hypertension, and severely impaired hepatic or renal function.  The vasoconstriction produced be ergot alkaloids may exacerbate these conditions.  Ergot alkaloids may cause vasospastic reactions other than coronary artery vasospasm such as peripheral vascular reactions, and colonic ischemia, causing muscle pains, numbness, coldness, pallor, and cyanosis of the digits.  In patients with compromised circulation, persistent vasospasm may result in gangrene or death.  Nitroprusside and heparin have been used to treat ergotamine- induced severe vasoconstriction.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6022, 0, 'Diiodohydroxyquinoline', 'Liver Diseases', 'The use of iodoquinol is contraindicated in patients with hepatic damage.  Iodoquinol is a halogenated 8-hydroxyquinolone that may have a prolonged effect in patients with liver dysfunction.  High dosages of iodoquinol have been associated with optic neuritis, optic atrophy, and peripheral neuropathy.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6023, 0, 'Diiodohydroxyquinoline', 'Peripheral Nervous System Diseases', 'The use of high dosages or prolonged therapy with iodoquinol has been associated with the development of peripheral neuropathy.  Therapy with iodoquinol should be administered cautiously in patients with peripheral neuropathy.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6024, 0, 'Diiodohydroxyquinoline', 'Vision Disorders', 'The use of iodoquinol has been associated with optic neuritis and optic atrophy when given in high dosages for prolonged periods.  Optic atrophy has been reported mostly in children treated for acrodermatitis enteropathica at daily dosages between 1300 to 3600 mg for up to two years.  Visual deterioration may be irreversible.  Therapy with iodoquinol should be administered cautiously in patients with or predisposed to visual defects.  Some clinicians also recommend not using iodoquinol and related agents in pediatric patients under 12 years of age.  Long-term therapy should be avoided in all patients.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6025, 0, 'Diiodohydroxyquinoline', 'Thyroid Diseases', 'Protein-bound serum iodine levels may be increased during treatment with iodoquinol and may, therefore, interfere with certain thyroid function tests.  Therapy with iodoquinol should be administered cautiously to patients with thyroid disease.', '1', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6026, 0, 'Dimercaprol', 'Liver Diseases', 'The use of dimercaprol is contraindicated in patients with impaired hepatic function, except for arsenic- associated jaundice.  Dimercaprol, not complexed to heavy metals, is metabolized by the liver to inactive forms in patients with normal hepatic function.  Hepatic impairment decreases the  metabolism of dimercaprol and can result in elimination of potentially nephrotoxic dimercaprol as well as increased CNS toxicity and hypertension.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6027, 0, 'Dimercaprol', 'Kidney Diseases', 'Dimercaprol is primarily eliminated by the kidney complexed with a heavy metal (lead, arsenic, mercury, gold).  Dimercaprol and heavy metals are nephrotoxic and dissociate at an acid pH.  Urinary alkalinization during dimercaprol therapy is necessary.  The serum concentration of dimercaprol is elevated in patients with oliguria and CNS toxicity and hypertension are possible.  Dimercaprol should be discontinued or used only with extreme caution if acute renal insufficiency develops during therapy.  Therapy with dimercaprol should be administered very cautiously and dosages reduced in patients with oliguria.  Close clinical monitoring of urine pH and renal function is necessary.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6028, 0, 'Dimercaprol', 'Peanut Hypersensitivity', 'Dimercaprol ampules are formulated with peanut oil.  Peanut oil may cause allergic reactions in some individuals.  Physicians should use caution in prescribing dimercaprol ampules for peanut-sensitive patients.  Medication and equipment necessary to treat allergic reactions should be available if the product is administered to peanut-allergic patients.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6029, 0, 'Dimercaprol', 'Glucosephosphate Dehydrogenase Deficiency', 'Dimercaprol-associated hemolysis has been reported in patients with glucose-6-phosphate dehydrogenase deficiency.  Therapy with dimercaprol should be administered with caution in patients with G6PD deficiency.  Clinical monitoring of erythropoietic function including hemolysis is recommended.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6030, 0, 'Dimercaprol', 'Hypertension', 'Dose-related increase in systolic and diastolic blood pressure, with or without accompanying tachycardia, is the most frequently reported adverse effect of dimercaprol therapy.  Blood pressure may rise 15 to 30 minutes following injection and usually returns to normal within 2 hours.  Therapy with dimercaprol should be administered cautiously in patients with hypertension.  Clinical monitoring of blood pressure is recommended.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6031, 0, 'Alteplase', 'Hemorrhagic Disorders', 'The use of thrombolytics is contraindicated in patients with an active bleed (internal), trauma/surgery (recent CPR/intracranial/intraspinal surgery within 2 months), bleeding diathesis, history of cerebrovascular (CV) accident, intracranial defect (aneurysm, arteriovenous malformation, neoplasm), or severe uncontrolled arterial hypertension (SBP>180/DBP>110).  Risk versus benefit should be carefully considered in the following conditions and thrombolytic therapy administered with caution in patients with recent (10 days) serious GI bleed or recent (10 days) surgical procedure (coronary bypass graft, obstetrical delivery, organ biopsy, puncture of noncompressible vessel), left heart thrombus, subacute bacterial endocarditis, hemostatic defect, CV disease, diabetic hemorrhagic retinopathy, or pregnancy.  Clinical monitoring of hematopoietic, bleeding and coagulation functions is recommended prior to initiation of thrombolytic therapy.  Measures of fibrinolytic activity and/or coagulation functions during infusion do not correlate with efficacy or risk of bleeding.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6032, 0, 'Dimethyl fumarate', 'Infections', 'Serious cases of herpes zoster have occurred in patients treated with dimethyl fumarate; patients should be monitored for signs/symptoms of herpes zoster while on dimethyl fumarate.  Other serious opportunistic infections have occurred with dimethyl fumarate, including cases of serious viral, fungal, and bacterial infections.  Patients with signs/symptoms consistent with any of these infections should undergo prompt diagnostic evaluation and receive appropriate treatment.  Withholding dimethyl fumarate treatment in patients with herpes zoster or other serious infections until the infection has resolved should be considered.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6033, 0, 'Dimethyl fumarate', 'Liver Failure', 'Dimethyl fumarate has not been studied in patients with liver dysfunction; although no dosage adjustment is needed, caution is recommended when using dimethyl fumarate in these patients.  Clinically significant cases of liver injury have been reported in patients treated with dimethyl fumarate in the postmarketing setting.  Signs/symptoms of liver injury, including elevation of serum aminotransferases to greater than 5-fold the upper limit of normal (ULN) and elevation of total bilirubin to greater than 2-fold ULN have been observed; these abnormalities resolved upon treatment discontinuation.  Elevations of hepatic transaminases (most no greater than 3 times ULN) were observed during controlled trials.  Serum aminotransferase, alkaline phosphatase, and total bilirubin levels should be obtained prior to and during treatment with dimethyl fumarate, as clinically indicated.  Therapy should be discontinued if clinically significant liver injury induced by dimethyl fumarate is suspected.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6034, 0, 'Dimethyl fumarate', 'Lymphopenia', 'The use of dimethyl fumarate may decrease lymphocyte counts.  Dimethyl fumarate has not been studied in patients with preexisting low lymphocyte counts; caution is advised in these patients.  CBC (including lymphocyte count) should be obtained before initiating treatment with dimethyl fumarate, 6 months after starting treatment, every 6 to 12 months thereafter, and as clinically indicated.  Interruption of therapy in patients with lymphocyte counts less than 0.5 x 10(9) cells/L persisting for more than 6 months and withholding treatment from patients with serious infections until resolution should be considered.  Caution is recommended and decisions about whether or not to restart dimethyl fumarate should be individualized based on clinical circumstances.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6035, 0, 'Dimethyl fumarate', 'Leukoencephalopathy, Progressive Multifocal', 'Progressive multifocal leukoencephalopathy (PML) has occurred in patients with multiple sclerosis (MS) treated with dimethyl fumarate; PML is an opportunistic viral infection of the brain caused by the John Cunningham virus (JC virus) that generally only occurs in immunocompromised patients and usually leads to death or severe disability.  Caution and monitoring are advised in patients with MS.  Dimethyl fumarate should be withheld at the first sign/symptom suggestive of PML and an appropriate diagnostic evaluation should be performed.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6036, 0, 'Dimethyl fumarate', 'Kidney Diseases', 'Dimethyl fumarate has not been studied in patients with renal dysfunction; although no dosage adjustment is needed, caution is recommended when using dimethyl fumarate in these patients.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6037, 0, 'Diltiazem', 'Aortic Valve Stenosis', 'The use of some calcium channel blockers (CCBs) is contraindicated in patients with advanced aortic stenosis.  CCBs whose pharmacologic effect is partially dependent on their ability to reduce afterload (e.g., diltiazem, nicardipine, nifedipine, verapamil) may be of less benefit in these patients due to a fixed impedance to flow across the aortic valve and may, in fact, worsen rather than improve myocardial oxygen balance.  Rarely, heart failure has developed following the initiation of these CCBs, particularly in patients receiving concomitant beta-blocker therapy.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6038, 0, 'Diltiazem', 'Atrioventricular Block', 'The use of some calcium channel blockers (CCBs) is contraindicated in patients with severe bradyarrhythmia, sick sinus syndrome (unless a functioning pacemaker is present), or heart block greater than the first degree (unless a functioning pacemaker is present).  CCBs like bepridil, diltiazem and verapamil have a negative effect on AV conduction and the SA node and may exacerbate these conditions.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6039, 0, 'Diltiazem', 'Shock, Cardiogenic', 'In general, calcium channel blockers (CCBs) should not be used in patients with hypotension (systolic pressure < 90 mm Hg) or cardiogenic shock.  Due to potential negative inotropic and peripheral vasodilating effects, the use of CCBs may further depress cardiac output and blood pressure, which can be detrimental in these patients.  The use of verapamil and diltiazem is specifically contraindicated under these circumstances.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6040, 0, 'Diltiazem', 'Coronary Artery Disease', 'Increased frequency, duration, and/or severity of angina, as well as acute myocardial infarction, have rarely developed during initiation or dosage increase of calcium channel blockers (CCBs), particularly in patients with severe obstructive coronary artery disease and those treated with immediate-release formulations.  The mechanism of this effect is not established.  Therapy with CCBs should be administered cautiously in patients with significant coronary artery disease.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6041, 0, 'Diltiazem', 'Liver Diseases', 'Calcium channel blockers (CCBs) are extensively metabolized by the liver.  The half-lives of CCBs may be prolonged substantially in patients with severe hepatic impairment, with the potential for significant drug accumulation.  In addition, the use of some CCBs has been associated with elevations in serum transaminases, both with and without concomitant elevations in alkaline phosphatase and bilirubin.  While these effects may be transient and reversible, some patients have developed cholestasis or hepatocellular injury.  Therapy with CCBs should be administered cautiously and often at reduced dosages in patients with significantly impaired hepatic function.  Periodic monitoring of liver function is advised.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6042, 0, 'Diltiazem', 'Heart Failure', 'Diltiazem has demonstrated a negative inotropic effect in isolated animal tissue preparations but rarely in clinical situations.  Hemodynamic studies in humans with normal ventricular function and in patients with a compromised myocardium have not shown a reduction in cardiac index nor consistent negative effects on contractility.  However, worsening of congestive heart failure has been reported in patients with preexisting impairment of ventricular function.  Therapy with diltiazem should be administered cautiously, if at all, in patients with severe left ventricular dysfunction (e.g., ejection fraction < 30%) or moderate to severe symptoms of cardiac failure and in patients with any degree of ventricular dysfunction if they are receiving a beta-adrenergic blocker.  Likewise, diltiazem should not be given to patients with acute myocardial infarction and pulmonary congestion documented by X-ray on admission, since associated heart failure may be acutely worsened.  Mild symptoms of cardiac failure should be under control, if possible, prior to initiating diltiazem therapy.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6043, 0, 'Diltiazem', 'Wolff-Parkinson-White Syndrome', 'The use of intravenous diltiazem is contraindicated for the management of atrial flutter or fibrillation in patients with an accessory AV tract (e.g., those with Wolff-Parkinson-White or Lown-Ganong-Levine syndrome).  Diltiazem can cause ventricular fibrillation and cardiac arrest in such patients, the mechanism of which is related to the drug''s ability to shorten the refractory period and accelerate antegrade conduction within the accessory pathway.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6044, 0, 'Diltiazem', 'Tachycardia, Ventricular', 'The use of intravenous diltiazem or verapamil is contraindicated in patients with ventricular tachycardia.  IV administration of a calcium channel blocker can precipitate cardiac arrest in such patients.  Marked hemodynamic deterioration and ventricular fibrillation have occurred in patients with wide-complex ventricular tachycardia (QRS >= 0.12 seconds) treated with IV verapamil.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6045, 0, 'Diltiazem', 'Kidney Diseases', 'Diltiazem is extensively metabolized by the liver and subsequently excreted in the urine, primarily as metabolites.  Limited data suggest that the pharmacokinetic disposition of diltiazem is not altered in the presence of renal insufficiency or even end-stage renal disease.  However, the effects of possible metabolite accumulation have not been studied.  The manufacturers recommend that therapy with diltiazem be administered cautiously in patients with impaired renal function.  Laboratory parameters of renal function should be monitored at regular intervals.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6046, 0, 'Dinutuximab', 'Infections', 'Because of their cytotoxic effects on rapidly proliferating tissues, antineoplastic agents frequently can, to varying extent, induce myelosuppression.  The use of these drugs may be contraindicated in patients with known infectious diseases.  All patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection during antineoplastic therapy.  Close clinical monitoring of hematopoietic function is recommended.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6047, 0, 'Dinutuximab', 'Cardiovascular Diseases', 'The use of monoclonal antibodies administered via IV infusion may cause serious infusion reactions, including bronchospasm, hypoxia, dyspnea, fluctuations in blood pressure, laryngeal edema and pulmonary edema.  Caution should be taken in patients with a history of cardiopulmonary disease as they may require additional post-infusion medications to manage respiratory complications.  It is recommended to administer required intravenous hydration and premedication with antihistamines, analgesics, and antipyretics before administration.  Monitor closely for signs and symptoms of infusion reactions during and for at least 4 hours following completion of each infusion in a setting where cardiopulmonary resuscitation medication and equipment are available.  Immediately interrupt or permanently discontinue treatment and institute supportive management for severe or prolonged infusion reactions as appropriate.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6048, 0, 'Dinutuximab', 'Tumor Lysis Syndrome', 'Tumor lysis syndrome (TLS) has occurred in patients receiving certain monoclonal antibodies.  Patients with high tumor burden and those with high circulating lymphocyte counts of greater than 25 X 10^9/L have a higher risk of developing TLS.  Consider tumor lysis prophylaxis prior to the infusion with anti-hyperuricemics and hydration beginning 12 to 24 hours prior to infusion.  It is recommended to correct electrolytes abnormalities, and monitor renal function in patients who develop TLS.  Monitor for signs and symptoms of TLS and temporary interruption or discontinuation of therapy might be required.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6049, 0, 'Dinutuximab', 'Water-Electrolyte Imbalance', 'Dinutuximab can cause electrolytes abnormalities, including hypokalemia, hyperkalemia, hypocalcemia, and hyponatremia.  Electrolyte abnormalities should be corrected prior to initiating nilotinib and should be monitored daily during therapy.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6050, 0, 'Dinutuximab', 'Hemolytic-Uremic Syndrome', 'Atypical hemolytic uremic syndrome in the absence of documented infection and resulting in renal insufficiency, electrolyte abnormalities, anemia, and hypertension can occur in patients treated with dinutuximab.  Atypical hemolytic uremic syndrome has recurred following rechallenge with dinutuximab.  Permanently discontinue therapy and institute supportive management for signs of hemolytic uremic syndrome.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6051, 0, 'Dinutuximab', 'Hypotension', 'Hypotension has been observed during therapy with dinutuximab.  This drug should be used with caution, especially in patients with tendency towards hypotension or taking other drugs known to cause hypotension.  It is recommended to administer required intravenous hydration prior to each infusion and to closely monitor blood pressure during treatment.  Interruption or discontinuation of treatment might be necessary if systolic blood pressure is less than lower limit of normal for age, or if it decreases by more than 15% compared to baseline.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6052, 0, 'Dinutuximab', 'Bone Marrow Failure Disorders', 'Myelosuppression has been reported during administration of dinutuximab.  In a clinical study, severe thrombocytopenia, anemia, neutropenia occurred more frequently in patients treated with dinutuximab/13-cis-retinoic acid group compared to those treated with 13-cis-retinoic acid alone.  Therapy with rituximab should be administered cautiously in patients with severe bone marrow suppression.  Clinical monitoring of hematopoietic function is recommended during therapy.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6053, 0, 'Dinutuximab', 'Neurotoxicity Syndromes', 'Dinutuximab causes serious neurologic adverse reactions including, severe neuropathic pain, peripheral neuropathy, neurologic disorders of the eye, prolong urinary retention, and transverse myelitis.  Discontinue treatment for severe unresponsive pain, severe sensory neuropathy, and moderate to severe peripheral motor neuropathy.  It might be necessary to permanently discontinue treatment in certain cases.  Care should be exercised when prescribing this agent to patients at risk for neurotoxicity.  It is recommended to administer required intravenous hydration and premedication with antihistamines, analgesics, and antipyretics before administration.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6054, 0, 'Dinutuximab', 'Posterior Leukoencephalopathy Syndrome', 'The use of dinutuximab may cause reversible posterior leukoencephalopathy syndrome (RPLS).  Caution and close monitoring is advised when prescribing this agent to patients at risk of RPLS.  It is recommended to administer appropriate treatment and discontinue therapy if RPLS is suspected.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6055, 0, 'Dinoprostone (topical)', 'Asthma', 'The use of dinoprostone may be associated with bronchospasm, decreased pulmonary blood flow, and/or increased pulmonary arterial pressure.  Dinoprostone induces contraction of smooth muscle, including smooth muscle of the respiratory tract.  Therapy with dinoprostone should be administered cautiously in patients with asthma, or history of childhood asthma, even in the absence of asthma attacks in adulthood.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6056, 0, 'Dinoprostone (topical)', 'Hypotension', 'Therapy with dinoprostone should be administered cautiously in patients with a history of hypotension.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6057, 0, 'Dinoprostone (topical)', 'Glaucoma', 'Caution should be exercised when administering dinoprostone topical in patients with a history of glaucoma.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6058, 0, 'Altretamine', 'Bone Marrow Failure Disorders', 'The use of altretamine is contraindicated in patients with severe bone marrow suppression.  Altretamine induces mild to moderate dose-related myelosuppression.  If white blood cell counts fall below 2000/mm3 and/or platelet counts fall below 75,000/mm3 during altretamine therapy, subsequent doses should be withheld at least 14 days and altretamine restarted at 200 mg/m2/day.  Clinical monitoring of hematopoietic function is recommended prior to each course of altretamine and the dose should be adjusted as clinically indicated.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6059, 0, 'Altretamine', 'Neurologic Manifestations', 'The use of altretamine is contraindicated in patients with severe neurological impairment.  Peripheral neuropathy as well as central nervous system symptoms of ataxia, vertigo, mood disorders, and disorders of consciousness has been noted during administration of altretamine.  However, altretamine has been administered safely to patients with cisplatin-associated neuropathy and to patients administered other alkylating agents.  Clinical monitoring of neurologic function should be performed prior to the initiation of each course of therapy and the dose adjusted as clinically indicated in these patients.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6060, 0, 'Altretamine', 'Hepatic Insufficiency', 'Altretamine is well-absorbed following oral administration in humans, but undergoes rapid and extensive demethylation in the liver, producing variation in altretamine plasma levels.  Patients with liver disease may be at higher risk for adverse effects from altretamine.  Caution is recommended when using this drug in patients with hepatic impairment as the pharmacokinetics of altretamine has not been evaluated.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6061, 0, 'Dipivefrin (ophthalmic)', 'Aphakia', 'Up to 30% of aphakic patients treated chronically with ophthalmic epinephrine (of which dipivefrin is a prodrug) may develop cystoid macular edema, which is generally reversible following withdrawal of the medication.  Ophthalmic epinephrine preparations should be administered cautiously with appropriate monitoring in patients with aphakia.  Therapy should be discontinued if blurred or distorted vision, central scotoma, and/or loss of visual acuity occur.  Slight visual impairment may respond to a reduction in the concentration or frequency of administration of the drug.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6062, 0, 'Dipivefrin (ophthalmic)', 'Glaucoma, Angle-Closure', 'The use of ophthalmic preparations of epinephrine, including dipivefrin (a prodrug of epinephrine), is contraindicated in patients with narrow-angle glaucoma or anatomically narrow angles.  These agents stimulate both alpha-1 and alpha-2 adrenergic receptors, thus topical administration can induce transient mydriasis, either with or without the use of concomitant miotic agents.  In patients with narrow angles, any degree of pupillary dilation can provoke an acute attack of angle-closure glaucoma.  In contrast, sympathomimetic agents with relative alpha-2 adrenergic selectivity such as apraclonidine and brimonidine produce little to no mydriasis at normally recommended dosages.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6063, 0, 'Disulfiram', 'Alcoholic Intoxication', 'The administration of disulfiram is contraindicated in patients in a state of alcohol intoxication.  The disulfiram- alcohol reaction may produce symptoms including flushing, throbbing in head and neck, throbbing headache, respiratory difficulty, nausea, vomiting, sweating, thirst, chest pain, palpitation, dyspnea, hyperventilation, tachycardia, hypotension, syncope, weakness, vertigo, blurred vision, and confusion.  Severe reactions may result in respiratory depression, cardiovascular collapse, arrhythmias, myocardial infarction, acute congestive heart failure, unconsciousness, convulsions, and death.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6064, 0, 'Disulfiram', 'Heart Diseases', 'The use of disulfiram is contraindicated in patients with cardiac disease.  The potential for a disulfiram- alcohol reaction, symptoms of which can include cardiovascular effects such as palpitation, tachycardia, chest pain, hypotension, syncope and, in severe cases, cardiovascular collapse, arrhythmias, myocardial infarction, and acute congestive heart failure, may present a particular danger to these patients.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6065, 0, 'Disulfiram', 'Psychotic Disorders', 'The use of disulfiram is contraindicated in patients with psychosis.  Disulfiram may precipitate psychotic reactions and mood disorders, particularly when given in high dosages or with metronidazole or isoniazid.  In some cases, however, the sudden withdrawal of alcohol alone can unmask underlying psychotic disorders.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6066, 0, 'Disulfiram', 'Liver Diseases', 'Hepatic toxicity, hepatitis, and hepatic failure resulting in transplantation or death have been reported with the use of disulfiram.  Hepatic toxicity has occurred in patient with and without prior history of abnormal liver function.  Extreme caution and close monitoring is advised if used in patients with liver impairment.  Baseline and liver tests are suggested in all patients to detect any hepatic abnormalities.  Patients should be advised to immediately notify their health provider if any symptoms of hepatitis occur (weakness, fatigue, anorexia, nausea, vomiting, jaundice, or dark urine).', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6067, 0, 'Dipyridamole', 'Bronchial Spasm', 'Dipyridamole is a phosphodiesterase inhibitor and can exacerbate bronchospasm, particularly in patients with reactive airway disease and/or chronic obstructive pulmonary disease (COPD).  Therapy with dipyridamole is contraindicated in patients with active wheezing and should be administered cautiously in patients with asthma or COPD.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6068, 0, 'Dipyridamole', 'Long QT Syndrome', 'Serious adverse reactions associated with the administration of intravenous dipyridamole have included cardiac death, fatal and non- fatal myocardial infarction, ventricular fibrillation, symptomatic ventricular tachycardia, stroke, transient cerebral ischemia, seizures, anaphylactoid reaction and bronchospasm.  There have been reported cases of asystole, sinus node arrest, sinus node depression and conduction block.  Patients with abnormalities of cardiac impulse formation/conduction or severe coronary artery disease may be at increased risk for these events.  Caution is recommended.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6069, 0, 'Dipyridamole', 'Hypotension', 'Dipyridamole can cause peripheral vasodilation.  Therapy with dipyridamole should be administered cautiously in patients with hypotension.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6070, 0, 'Dipyridamole', 'Myasthenia Gravis', 'Myasthenia gravis patients receiving therapy with cholinesterase inhibitors may experience worsening of their disease in the presence of dipyridamole.  Caution should be exercised with these patients.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6071, 0, 'Docusate', 'Inflammatory Bowel Diseases', 'The use of laxatives is contraindicated in patients with inflammatory bowel disease.  Patients with inflammatory bowel disease may experience colonic perforation with use of stimulant laxatives.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6072, 0, 'Docusate', 'Intestinal Obstruction', 'The use of laxatives is contraindicated in patients with intestinal obstruction disorders.  Patients with intestinal obstruction disorders may need their underlying condition treated to correct the constipation.  Some laxatives require reduction in the colon to their active form to be effective which may be a problem in patients with intestinal obstruction.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6073, 0, 'Dobutamine', 'Asthma', 'Dobutamine injection contains sodium metabisulfite, a sulfite that may cause anaphylactic symptoms and life-threatening or less severe asthmatic episodes in susceptible people, such as asthmatic patients.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6074, 0, 'Dobutamine', 'Arrhythmias, Cardiac', 'Dobutamine and arbutamine produce stimulation of the beta receptors of the heart.  The use of these agents has been associated with an increase in heart rate, ventricular ectopy, atrial fibrillation, hypertension, enhanced A-V conduction, and arrhythmias.  Therapy with dobutamine or arbutamine should be administered cautiously in patients with cardiac conduction disorders.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6075, 0, 'Dobutamine', 'Hypotension', 'The use of dobutamine and arbutamine has been infrequently associated with significant hypotension especially in dehydrated patients secondary to beta-2 mediated vasodilation.  Hypovolemia should be corrected before administering dobutamine or arbutamine.  Blood pressure and ECG should be monitored at regular intervals.  Monitoring of cardiac output and pulmonary wedge pressure may also be desired.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6076, 0, 'Dobutamine', 'Cardiomyopathy, Hypertrophic', 'The use of dobutamine or arbutamine is contraindicated in patients with idiopathic hypertrophic subaortic stenosis (IHSS).  Dobutamine or arbutamine may increase the pressure gradient within the left ventricle and thereby worsen cardiac output in patients with IHSS.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6077, 0, 'Dobutamine', 'Hypokalemia', 'The use of dobutamine has been associated with hypokalemia.  Therapy with dobutamine should be administered cautiously to patients with hypokalemia.  Frequent monitoring of serum potassium along with appropriate electrolyte replacement is recommended.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6078, 0, 'Disopyramide', 'Cardiomyopathies', 'Antiarrhythmic agents can induce severe hypotension (particularly with IV administration) or induce or worsen congestive heart failure (CHF).  Patients with primary cardiomyopathy or inadequately compensated CHF are at increased risk.  Antiarrhythmic agents should be administered cautiously and dosage and/or frequency of administration modified in patients with hypotension or adequately compensated CHF.  Alternative therapy should be considered unless these conditions are secondary to cardiac arrhythmia.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6079, 0, 'Disopyramide', 'Arrhythmias, Cardiac', 'Antiarrhythmic agents can induce or worsen ventricular arrhythmias.  Ventricular tachycardia, ventricular fibrillation, and torsades de pointes have occurred in some patients.  Patients with underlying cardiac dysfunction, bradycardia, hypokalemia, hypomagnesemia, or high antiarrhythmic serum concentrations are at increased risk for drug-induced arrhythmias.  Therapy with antiarrhythmics should be used with extreme caution in patients with or predisposed to arrhythmias.  Evidence of improved survival is lacking for use of antiarrhythmic therapy in asymptomatic, non-life-threatening arrhythmias.  Therapy with antiarrhythmic agents should be reserved for patients with life-threatening arrhythmias.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6080, 0, 'Disopyramide', 'Anticholinergic Syndrome', 'Disopyramide has anticholinergic activity, and therapy with disopyramide should be administered with extreme caution in patients who may be adversely affected by this.  Disopyramide should not be used in patients with glaucoma, myasthenia gravis, or urinary retention unless adequate overriding measures are taken.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6081, 0, 'Disopyramide', 'Sick Sinus Syndrome', 'The use of disopyramide is contraindicated in patients with cardiogenic shock, second- or third-degree AV block in the absence of a functional artificial pacemaker, or congenital QT prolongation.  Therapy with disopyramide should be administered with extreme caution in patients with sick sinus syndrome (bradycardia-tachycardia),  Wolff-Parkinson White syndrome, or bundle-branch block.  The effect of disopyramide in these conditions has not been determined.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6082, 0, 'Disopyramide', 'Water-Electrolyte Imbalance', 'Electrolyte imbalance can alter the therapeutic effectiveness of antiarrhythmic agents.  Hypokalemia and hypomagnesemia can reduce the effectiveness of antiarrhythmic agents.  In some cases, these disorders can exaggerate the degree of QTc prolongation and increase the potential for torsade de pointes.  Hyperkalemia can potentiate the toxic effects of antiarrhythmic agents.  Electrolyte imbalance should be corrected prior to initiating antiarrhythmic therapy.  Clinical monitoring of cardiac function and electrolyte concentrations is recommended.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6083, 0, 'Disopyramide', 'Liver Diseases', 'Disopyramide is partially metabolized by the liver.  The plasma half-life of disopyramide is prolonged in patients with hepatic dysfunction.  Therapy with disopyramide should be administered cautiously and dosages reduced in patients with compromised hepatic function.  Clinical monitoring of cardiac function (ECG) and hepatic function is recommended.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6084, 0, 'Disopyramide', 'Hypoglycemia', 'Rare cases of hypoglycemia have been reported during administration of disopyramide.  Therapy with disopyramide should be administered cautiously in patients with diabetes mellitus or other conditions that alter normal glucoregulatory mechanisms such as chronic malnutrition, congestive heart failure, renal or hepatic dysfunction, or drugs (beta blockers).', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6085, 0, 'Disopyramide', 'Kidney Diseases', 'Disopyramide is primarily eliminated by the kidney.  Approximately 50% of disopyramide is excreted in the urine as unchanged drug.  The serum concentration of disopyramide is increased and the elimination half-life is prolonged in patients with renal impairment.  Patients with renal impairment may be at increased risk of disopyramide-associated toxicity such as hypotension, conduction disturbances, or worsening of congestive heart failure.  Therapy with disopyramide should be administered cautiously and dosage and/or frequency of administration modified in patients with compromised renal function.  Clinical monitoring of cardiac function (ECG) and renal function is recommended.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6086, 0, 'Docetaxel', 'Infections', 'Because of their cytotoxic effects on rapidly proliferating tissues, antineoplastic agents frequently can, to varying extent, induce myelosuppression.  The use of these drugs may be contraindicated in patients with known infectious diseases.  All patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection during antineoplastic therapy.  Close clinical monitoring of hematopoietic function is recommended.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6087, 0, 'Docetaxel', 'Edema', 'Severe fluid retention characterized by peripheral edema, generalized edema, pleural effusion, dyspnea at rest, cardiac tamponade, or abdominal distention due to ascites has been reported during docetaxel therapy.   Therapy with docetaxel should be administered cautiously to patients adversely affected by fluid retention.  Prophylaxis with a five day dexamethasone premedication regimen is recommended, however, fluid retention has occurred despite this pretreatment.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6088, 0, 'Docetaxel', 'Eye Diseases', 'Cystoid macular edema has been reported with the use of docetaxel.  Patients with impaired vision should undergo a prompt and comprehensive ophthalmologic examination prior to therapy with this agent.  If cystoid macular edema is diagnosed, treatment should be discontinued and appropriate treatment initiated.  Alternative non-taxane cancer treatment should be considered.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6089, 0, 'Docetaxel', 'Liver Diseases', 'Docetaxel is extensively metabolized by the liver.  Total body clearance of docetaxel has been reported to be reduced as much as 27% in patients with mild to moderate hepatic impairment resulting in a 38% increase of docetaxel serum concentration.  Patients with elevated transaminase levels (>1.5 times the upper limits of normal) and alkaline phosphatase (>2.5 times the upper limits of normal) should not be administered docetaxel.  The incidence of docetaxel related deaths is increased in patients with impaired hepatic function.  Bilirubin, transaminase, and alkaline phosphatase levels should be obtained prior to each cycle of docetaxel therapy.  Patients with combined abnormalities of transaminases and alkaline phosphatase should not be treated with this agent.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6090, 0, 'Docetaxel', 'Bone Marrow Failure Disorders', 'The use of docetaxel is contraindicated in patients with a neutrophil count < 1500/mm3.  Docetaxel induces dose-related myelosuppression resulting in neutropenia, thrombocytopenia, and anemia.  Neutropenia occurs in all patients administered 60-100 mg/m2 of docetaxel.  Grade 4 neutropenia (< 500/mm3) occurs in nearly all patients administered 100 mg/m2 of docetaxel.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, or local infection.  Therapy should be administered cautiously to patients with compromised bone marrow reserve and should be withheld until neutrophil levels is > 1500/mm3 and/or platelet counts is > 100,000/mm3.  A 25% reduction in dosage is recommended during subsequent cycles following severe neutropenia (< 500/mm3).  It is recommended to performed frequent blood cell counts on all patients receiving docetaxel.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6091, 0, 'Docetaxel', 'Alcoholism', 'The alcohol content in a dose of docetaxel injection may affect the central nervous system.  Cases of intoxication have been reported with some formulations of docetaxel due to the alcohol content.  Close monitoring is recommended in alcoholic patients.  Consideration should be given to the alcohol content in docetaxel injection on the ability to drive or use machines immediately after the infusion.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6092, 0, 'Docetaxel', 'Paresthesia', 'Severe neurosensory symptoms such as paresthesia, dysesthesia, and pain have been reported during docetaxel therapy.  Therapy with docetaxel should be administered cautiously to patients with or predisposition to neurosensory symptoms.  Although reversible with discontinuation of docetaxel therapy, the dosage must be adjusted if neurosensory symptoms occur and therapy discontinued if symptoms persist.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6093, 0, 'Aluminum hydroxide', 'Constipation', 'Aluminum containing antacids may produce constipation, which may lead to intestinal obstruction.  Osteomalacia and hypophosphatemia may be produced in patients with renal dysfunction who are not receiving dialysis.  Patients with renal dysfunction, intestinal obstruction, osteomalacia, or hypophosphatemia should use antacids with low or no aluminum content.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6094, 0, 'Doxapram', 'Heart Diseases', 'The use of CNS stimulants is contraindicated in patients with significant cardiovascular impairment such as uncompensated heart failure, severe coronary disease, severe hypertension (including that associated with hyperthyroidism or pheochromocytoma), cardiac structural abnormalities, serious arrhythmias, etc.  Sudden death has been reported in adults and children taking CNS stimulant treatment.  Additionally, stroke, myocardial infarction, chest pain, syncope, arrhythmias and other symptoms have been reported in adults under treatment.  A careful assessment of the cardiovascular status should be done in patients being considered for treatment.  This includes family history, physical exam and further cardiac evaluation (EKG and echocardiogram).  Patients who develop symptoms should have a detailed cardiac evaluation and if needed, treatment should be suspended.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6095, 0, 'Doxapram', 'Craniocerebral Trauma', 'The use of doxapram is contraindicated in patients with head injury, cerebral vascular accident, or cerebral edema.  Existing coma may worsen with doxapram administration.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6096, 0, 'Doxapram', 'Lung Diseases', 'The use of doxapram is contraindicated in patients with mechanical disorders of ventilation such as mechanical obstruction, muscle paresis, flail chest, pneumothorax, acute bronchial asthma, pulmonary fibrosis or other conditions resulting in restriction of chest wall, muscles of respiration or alveolar expansion.  Doxapram is not effective in stimulating respiration in these patients.  Doxapram should not be used in patients under mechanical ventilation.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6097, 0, 'Doxapram', 'Epilepsy', 'The use of doxapram is contraindicated in patients with seizure disorders.  In high doses, doxapram may produce tonic-clonic seizures by CNS stimulation effects.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6098, 0, 'Doxapram', 'Bipolar Disorder', 'Central nervous system (CNS) stimulants may induce a mixed/manic episode in patients with bipolar disorder.  Prior to initiating treatment, screen patients for risk factors for developing a manic episode (e.g., comorbid or history of depressive symptoms or a family history of suicide, bipolar disorder, and depression).  Close monitoring is recommended when using these agents in patients with bipolar disorders.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6099, 0, 'Doxapram', 'Psychotic Disorders', 'Central nervous system (CNS) stimulants may exacerbate symptoms of behavior disturbance and thought disorder in patients with a preexisting psychotic disorder.  Close monitoring is recommended when using these agents in patients with psychotic disorders.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6100, 0, 'Doxapram', 'Kidney Diseases', 'Overall CNS stimulants should be administered with caution in patients with significantly impaired renal function as the reduction in the rate of elimination may alter the therapeutic response.  The dosage should be adjusted accordingly.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6101, 0, 'Alvimopan', 'Intestinal Obstruction', 'Peripheral opioid receptor antagonists are contraindicated in patients with known or suspected gastrointestinal obstruction, and in patients at increased risk of recurrent obstruction, due to the potential for gastrointestinal perforation.  Cases of gastrointestinal perforation have been reported in patients with opioid-induced constipation and advanced illness with conditions that may be associated with localized or diffuse reduction of structure integrity in the wall of the GI tract such as peptic ulcer, diverticular disease, Crohn''s disease, infiltrative GI tract malignancies or peritoneal metastases.  It is recommended to monitor for the development of severe, persistent, or worsening abdominal pain and to discontinue treatment in patients who develop symptoms.  The overall risk- benefit profile should be carefully evaluated before using these agents in patients with these conditions.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6102, 0, 'Dofetilide', 'Long QT Syndrome', 'Dofetilide is contraindicated in patients with congenital or acquired long QT syndromes.  Dofetilide should not be used in patients with a baseline QT interval of QTc >440 msec (500 msec in patients with ventricular conduction abnormalities).', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6103, 0, 'Dofetilide', 'Kidney Diseases', 'Dofetilide is contraindicated in patients with severe renal impairment (calculated creatinine clearance <20 mL/min).  The risk of QT interval prolongation, Torsade de Pointes, and ventricular arrhythmias is directly related to dofetilide plasma concentration.  A reduced creatinine clearance will increase dofetilide plasma concentration.  In patients with mild and moderate renal impairment, the risk of arrhythmias can be reduced by controlling the plasma concentration through adjustment of the initial dofetilide dose according to creatinine clearance.  Patients undergoing dialysis were not included in clinical studies, and appropriate dosing recommendations for these patients are unknown.  There is no information about the effectiveness of hemodialysis in removing dofetilide from plasma.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6104, 0, 'Dofetilide', 'Water-Electrolyte Imbalance', 'Dofetilide should be avoided in patients that experience symptoms that may be associated with altered electrolyte balance, such as excessive or prolonged diarrhea, sweating, or vomiting or loss of appetite or thirst, these conditions should immediately be reported to their health care provider.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6105, 0, 'Dofetilide', 'Hepatic Insufficiency', 'Dofetilide has not been studied in patients with severe hepatic impairment.  Dofetilide should be used with particular caution in these patients.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6106, 0, 'Dofetilide', 'Hypokalemia', 'Serum potassium should be maintained within the normal range before dofetilide treatment is initiated and should be maintained within the normal range while the patient remains on dofetilide therapy.  In clinical trials, potassium levels were generally maintained above 3.6 to 4.0 mEq/L.  Exercise care when using this agent in patients with hypokalemia.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6107, 0, 'Doxorubicin', 'Infections', 'Because of their cytotoxic effects on rapidly proliferating tissues, antineoplastic agents frequently can, to varying extent, induce myelosuppression.  The use of these drugs may be contraindicated in patients with known infectious diseases.  All patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection during antineoplastic therapy.  Close clinical monitoring of hematopoietic function is recommended.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6108, 0, 'Doxorubicin', 'Cardiomyopathies', 'Myocardial damage, including acute left ventricular failure can occur with doxorubicin.  The risk of cardiomyopathy is proportional to the cumulative exposure with incidence rates from 1% to 20% for cumulative doses ranging from 300 mg/m2 to 500 mg/m2 when doxorubicin is administered every 3 weeks.  The risk of cardiomyopathy is further increased with concomitant cardiotoxic therapy.  Additionally, doxorubicin can also cause arrhythmias, including life-threatening events at any point during treatment.  Assess LVEF before and regularly during and after treatment with doxorubicin.  Doxorubicin is contraindicated in patients with severe myocardial insufficiency and recent myocardial infarction (past 6 months).', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6109, 0, 'Doxorubicin', 'Liver Diseases', 'Doxorubicin is contraindicated in patients with severe hepatic impairment (defined as Child Pugh Class C or serum bilirubin level greater than 5 mg/dL).  Doxorubicin is primarily metabolized by the liver and its clearance is reduced in the presence of hepatic dysfunction, increasing the risk for toxicity.  Therapy with doxorubicin should be administered cautiously and at a reduced dosage in patients with moderate or mild hepatic function.  Close clinical monitoring of hepatic function prior to initiation of doxorubicin therapy is recommended.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6110, 0, 'Doxorubicin', 'Bone Marrow Failure Disorders', 'Doxorubicin induces dose-related myelosuppression, primarily affecting leukocytes.  Therapy with doxorubicin should be withheld in patients whose bone marrow function is severely depressed by prior irradiation or chemotherapy or whose marrow function is recovering from previous cytotoxic therapy.  If the need outweighs the risk, extreme caution should be exercised in administering doxorubicin and the dosage should be reduced.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding.  Close clinical monitory of hematopoietic function is recommended.  Doxorubicin is contraindicated in patients with severe persistent drug-induced myelosuppression', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6111, 0, 'Donepezil', 'Bradycardia', 'Due to their pharmacological action, cholinesterase inhibitors can have a vagotonic effect on the sinoatrial and atrioventricular nodes producing bradycardia or heart block.  Therapy with cholinesterase inhibitors should be administered cautiously in patients with preexisting bradycardia or underlying cardiac conduction abnormalities.  Syncopal episodes have been reported in patients with and without cardiac abnormalities.  Atropine may be used to reverse bradycardia produced by cholinesterase inhibitors.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6112, 0, 'Donepezil', 'Bronchial Spasm', 'Cholinesterase inhibitors inhibit the hydrolysis of acetylcholine.  The enhanced effect of acetylcholine produces constriction of the bronchi, increased bronchial secretions, and bronchospasm.  Therapy with cholinesterase inhibitors should be administered cautiously in patients with respiratory dysfunction, history of asthma or obstructive pulmonary disease.  Monitoring respiratory function during dosage initiation and adjustment is recommended.  Use of atropine along with discontinuation of the cholinesterase inhibitor may be required for serious respiratory distress.  Neostigmine may produce more severe muscarinic side effects than does pyridostigmine and ambenonium.  However, the duration of action is longest for ambenonium and shortest for edrophonium.  Echothiophate iodide ophthalmic may be systemically absorbed and cautious use is recommended in these patients.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6113, 0, 'Donepezil', 'Coronary Artery Disease', 'The use of cholinesterase inhibitors  has been associated with a constriction of coronary arteries.  Therapy with cholinesterase inhibitors should be administered cautiously in patients with coronary artery disease.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6114, 0, 'Donepezil', 'Parkinsonian Disorders', 'Cholinesterase inhibitors should be used with caution in patients with parkinsonism.  Some of these drugs might be contraindicated in these patients (refer to specific prescribing information).  Symptoms of Parkinson''s disease may be exacerbated with the increase in cholinergic activity.  Caregivers and patients should be advised.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6115, 0, 'Donepezil', 'Peptic Ulcer', 'The use of cholinesterase inhibitors is associated with an increase in gastric acid secretion and gastric contractions.  Therapy with cholinesterase inhibitors should be administered cautiously in patients with peptic ulcer disease.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6116, 0, 'Donepezil', 'Seizures', 'Cholinesterase inhibitors have been associated with convulsions and tremor.  Therapy with cholinesterase inhibitors should be administered cautiously in patients with seizure disorders.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6117, 0, 'Donepezil', 'Hyperthyroidism', 'Many of the manifestations of hyperthyroidism may be exacerbated by increased levels of acetylcholine produced by cholinesterase inhibitors.  Therapy with cholinesterase inhibitors should be administered cautiously to patients with hyperthyroidism.  Monitoring of thyroid levels is recommended.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6118, 0, 'Donepezil', 'Liver Diseases', 'Donepezil is extensively metabolized by the liver (CYP450-2D6/3A4) to two active and various minor forms.  The clearance of donepezil was decreased 20% in patients with stable alcoholic cirrhosis compared to healthy patients.  Care should be exercised when using donepezil in patients with liver disease.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6119, 0, 'Doxepin', 'Depressive Disorder', 'A variety of abnormal thinking and behavior changes have been reported to occur in association with the use of most anxiolytics, sedatives and hypnotics.  Some of these changes include decreased inhibition, aggressiveness, agitation, and hallucinations.  These drugs can cause or exacerbate mental depression and cause suicidal behavior and ideation.  Therapy with these drugs should be administered cautiously in patients with a history of depression or other psychiatric disorders.  Patients should be monitored for any changes in mood or behavior.  It may be prudent to refrain from dispensing large quantities of medication to these patients.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6120, 0, 'Doxepin', 'Anticholinergic Syndrome', 'The use of doxepin is contraindicated in patients with glaucoma, or a tendency to urinary retention.  These disorders should be ruled out before starting treatment, especially in elderly patients.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6121, 0, 'Doxepin', 'Cardiovascular Diseases', 'Tricyclic and tetracyclic antidepressants (TCAs) may cause orthostatic hypotension, reflex tachycardia, syncope, and dizziness, particularly during initiation of therapy or rapid escalation of dosage.  Imipramine appears to have the greatest propensity to induce these effects, while secondary amines such as nortriptyline may do so less frequently.  Tolerance to the hypotensive effects often develops after a few doses to a few weeks.  Rarely, collapse and sudden death have occurred secondary to severe hypotension.  Other reported adverse cardiovascular effects include tachycardia, arrhythmias, heart block, hypertension, thrombosis, thrombophlebitis, myocardial infarction, strokes, congestive heart failure, and ECG abnormalities such as PR and QT interval prolongation.  Therapy with TCAs should be avoided during the acute recovery phase following myocardial infarction, and should be administered only with extreme caution in patients with hyperthyroidism, a history of cardiovascular or cerebrovascular disease, or a predisposition to hypotension.  Close monitoring of cardiovascular status, including ECG changes, is recommended at all dosages.  Many of the newer antidepressants, including bupropion and the selective serotonin reuptake inhibitors (SSRIs), are considerably less or minimally cardiotoxic and may be appropriate alternatives.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6122, 0, 'Doxepin', 'Pheochromocytoma', 'Tricyclic and tetracyclic antidepressants (TCAs) may potentiate the effects of circulating catecholamines.  Enhanced sympathetic activity can provoke hypertensive crises in patients with pheochromocytoma or other tumors of the adrenal medulla, such as some neuroblastomas.  Therapy with TCAs should be administered cautiously in patients with these tumors.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6123, 0, 'Doxepin', 'Acute Myocardial Infarction Recovery', 'The use of most tricyclic antidepressants is contraindicated in patients that are going through the acute recovery period after a myocardial infarction.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6124, 0, 'Doxepin', 'Epilepsy', 'Tricyclic antidepressants (TCAs), can lower the seizure threshold and trigger seizures.  These drugs should be used with extreme caution in patients with a history of seizures, or other predisposing factors, such as head trauma, CNS abnormalities, and alcoholism.  Daily dose restrictions might apply for specific antidepressants.  Physicians are encouraged to get additional dosing recommendations on the manufacturer''s prescribing information.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6125, 0, 'Doxepin', 'Glaucoma', 'Some hypnotic drugs can have an anticholinergic effect and should be used with caution in patients with glaucoma, and trouble urinating due to retention or enlarged prostate.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6126, 0, 'Doxepin', 'Liver Diseases', 'In general, anxiolytics, sedatives and hypnotics are extensively metabolized by the liver.  Their plasma clearance may be decreased and their half-life prolonged in patients with impaired hepatic function.  Therapy with these drugs should be administered cautiously in patients with liver disease (some are not recommended in severe liver impairment), and the dosage should be adjusted accordingly.  Laboratory testing is recommended prior and during treatment.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6127, 0, 'Doxepin', 'Bipolar Disorder', 'A major depressive episode can be the initial presentation of bipolar disorder.  Patients with depressive symptoms should be adequately screened to determine if they are at risk for bipolar disorder prior to initiating treatment with doxepin.  This screening should include a detailed psychiatric history, including a family history of suicide, bipolar disorder, and depression.  It should be noted that doxepin is not approved for use in treating bipolar depression.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6128, 0, 'Doxepin', 'Bone Marrow Failure Disorders', 'The use of tricyclic and tetracyclic antidepressants (TCAs) has rarely been associated with bone marrow suppression.  Leukopenia, agranulocytosis, thrombocytopenia, anemia, eosinophilia, purpura, and pancytopenia have been reported with some TCAs.  Patients with preexisting bone marrow suppression or blood dyscrasias receiving TCAs should be monitored closely during therapy for further decreases in blood counts.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6129, 0, 'Doxepin', 'Diabetes Mellitus', 'Both elevation and lowering of blood sugar levels have been reported with the use of some tricyclic antidepressants (TCAs).  Rarely, these effects have also occurred with maprotiline, a tetracyclic antidepressant.  Patients with diabetes should be monitored for worsening control of blood glucose when treated with these agents, particularly during dosage escalation or whenever dosage has been altered.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6130, 0, 'Doxepin', 'Schizophrenia', 'Tricyclic antidepressants (TCAs) may aggravate symptoms of psychosis in schizophrenic patients, particularly those with paranoid symptomatology.  Depressed patients, usually those with bipolar disorder, may experience a switch from depression to mania or hypomania.  These occurrences have also been reported rarely with the tetracyclic antidepressant, maprotiline.  Therapy with these agents should be administered cautiously in patients with schizophrenia, bipolar disorder, or a history of mania.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6131, 0, 'Doxepin', 'Tardive Dyskinesia', 'Tricyclic and tetracyclic antidepressants (TCAs) have anticholinergic activity, to which elderly patients are particularly sensitive.  Tertiary amines such as amitriptyline and trimipramine tend to exhibit greater anticholinergic effects than other agents in the class.  As with other drugs that possess anticholinergic activity, TCAs may aggravate tardive dyskinesia or induce previously suppressed symptoms.  Patients with tardive dyskinesia requiring therapy with TCAs should be monitored for exacerbation of the condition.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6132, 0, 'Doxepin', 'Alcoholic Intoxication', 'Tricyclic antidepressants can enhance the response to alcohol.  In patients who may use alcohol excessively, it should be borne in mind that the potentiation may increase the danger inherent in any suicide attempt or overdosage.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6133, 0, 'Doxepin', 'Neutropenia', 'The use of some tricyclic antidepressants has been associated with neutropenia (ANC < 500/mm3) and agranulocytosis (ANC < 500/mm3).  Leukocyte and differential blood counts should be performed in patients that develop fever and sore throat during treatment.  Therapy should be discontinued if there is evidence of pathologic neutrophil depression.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6134, 0, 'Doxepin', 'Thyroid Diseases', 'Most tricyclic antidepressants should be administered with caution in hyperthyroid patients or those receiving thyroid medication as they may develop arrhythmias when these drugs are given.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6135, 0, 'Doxepin', 'Urinary Retention', 'Due to their anticholinergic properties, tricyclic antidepressants should be administered with caution in patients with history of urinary retention.  Particularly doxepin hydrochloride capsules are contraindicated in patients with tendency to urinary retention.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6136, 0, 'Doxepin (topical)', 'Anticholinergic Syndrome', 'Doxepin possesses anticholinergic activity and is systemically absorbed when applied topically.  Therapy with doxepin should be administered cautiously in patients with conditions adversely affected by anticholinergic activity, such as urinary retention, angle-closure glaucoma or elevated intraocular pressure, gastrointestinal obstructive disorders, or dementia.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6137, 0, 'Doxepin (topical)', 'Liver Failure', 'Doxepin topical is systemically absorbed and metabolized by the liver to an active form.  Parent drug and metabolites are eliminated by the kidney.  Renal and hepatic impairment alter the metabolism and elimination of doxepin and/or its metabolites.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6138, 0, 'Dorzolamide (ophthalmic)', 'Hematologic Diseases', 'Sulfonamides may be systemically absorbed when applied to the skin, eye, or mucosal membranes.  The use of sulfonamides has been associated with hematologic toxicity, including methemoglobinemia, sulfhemoglobinemia,  leukopenia, granulocytopenia, eosinophilia, hemolytic anemia, aplastic anemia, purpura, clotting disorder, thrombocytopenia, hypofibrinogenemia, and hypoprothrombinemia.  Therapy with topical sulfonamides should be administered cautiously in patients with preexisting blood dyscrasias or bone marrow suppression.  Complete blood counts should be obtained regularly during prolonged therapy (>2 weeks), and patients should be instructed to immediately report any signs or symptoms suggestive of blood dyscrasia such as fever, sore throat, local infection, bleeding, pallor, dizziness, or jaundice.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6139, 0, 'Dorzolamide (ophthalmic)', 'Hypersensitivity, Immediate', 'Sulfonamides may be systemically absorbed when applied to the skin, eye, or mucosal membranes.  The use of sulfonamides is associated with large increases in the risk of Stevens-Johnson syndrome, toxic epidermal necrolysis and other serious dermatologic reactions, although these phenomena are rare as a whole.  Hepatitis, pneumonitis, and interstitial nephritis have also occurred in association with sulfonamide hypersensitivity.  Therapy with topical sulfonamides should be administered cautiously in patients with severe allergies, bronchial asthma or AIDS, since these patients may be at increased risk for potentially severe hypersensitivity reactions.  Patients should be instructed to promptly report signs and symptoms that may precede the onset of cutaneous manifestations of the Stevens-Johnson syndrome, such as high fever, severe headache, stomatitis, conjunctivitis, rhinitis, urethritis, and balanitis.  Sulfonamide therapy should be stopped at once if a rash develops.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6140, 0, 'Dorzolamide (ophthalmic)', 'Porphyrias', 'Sulfonamides may be systemically absorbed when applied to the skin, eye, or mucosal membranes.  Therapy with topical sulfonamides should be administered cautiously in patients with porphyria, since these drugs can precipitate an acute attack.  The use of oral sulfonamides is considered contraindicated in patients with porphyria.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6141, 0, 'Dorzolamide (ophthalmic)', 'Crystalluria', 'Sulfonamides may be systemically absorbed when applied to the skin, eye, or mucosal membranes.  The use of sulfonamides has been associated with crystalluria due to precipitation of the sulfonamide and/or its N4-acetyl metabolite in the urinary tract.  Renal toxicity such as uro- and nephrolithiasis, nephritis, toxic nephrosis, hematuria, proteinuria, and elevated BUN and creatinine has been reported.  Hydration and adequate urinary output (> 1.5 L/day) should be maintained during sulfonamide administration.  Patients who are dehydrated (e.g., due to severe diarrhea or vomiting) may be at increased risk for the development of crystalluria and lithiasis and should be encouraged to consume additional amounts of liquid.  Renal function tests and urinalysis should be performed regularly during prolonged therapy (> 2 weeks).', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6142, 0, 'Dorzolamide (ophthalmic)', 'Liver Diseases', 'Sulfonamides may be systemically absorbed when applied to the skin, eye, or mucosal membranes.  Hepatotoxicity, including jaundice, diffuse hepatocellular necrosis, hypersensitivity hepatitis and hepatic failure, has rarely been reported in patients receiving sulfonamides.  In addition, sulfonamides are partially metabolized by the liver and may accumulate in patients with hepatic impairment.  Therapy with topical sulfonamides should be administered cautiously in patients with liver disease.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6143, 0, 'Dorzolamide (ophthalmic)', 'Kidney Diseases', 'Sulfonamides may be systemically absorbed when applied to the skin, eye, or mucosal membranes.  Once absorbed, sulfonamides and their metabolites are eliminated by the kidney.  Patients with renal impairment may be at greater risk for adverse effects from sulfonamides due to decreased drug clearance.  Additionally, sulfonamides may cause renal toxicity secondary to crystalluria, including uro- and nephrolithiasis, nephritis, toxic nephrosis, hematuria, proteinuria, and elevated BUN and creatinine.  Hydration and adequate urinary output (> 1.5 L/day) should be maintained during sulfonamide administration.  Renal function tests and urinalysis should be performed regularly during prolonged therapy (> 2 weeks).  Some manufacturers of topical sulfonamide products do not recommend their use in patients with impaired renal function.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6144, 0, 'Dorzolamide (ophthalmic)', 'Urethral Obstruction', 'Sulfonamides may be systemically absorbed when applied to the skin, eye, or mucosal membranes.  Once absorbed, sulfonamides are excreted and concentrated in the urine.  Therapy with topical sulfonamides should be administered cautiously in patients with urinary obstruction or retention, since excessive drug accumulation may occur.  These patients may also be at increased risk for sulfonamide crystalluria, which may be associated with renal toxicity such as uro- and nephrolithiasis, nephritis, toxic nephrosis, hematuria, proteinuria, and elevated BUN and creatinine.  A urinary output of at least 1.5 L/day should be maintained during sulfonamide administration.  Renal function tests and urinalysis should be performed regularly during prolonged therapy (> 2 weeks).', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6145, 0, 'Doxazosin', 'Hypotension', 'Peripheral alpha 1- adrenergic receptor blocking agents (aka alpha 1- blockers) cause vasodilation and can produce marked hypotension, especially orthostatic hypotension with syncope or other postural symptoms such as dizziness, lightheadedness, and palpitations.  Orthostatic effects are most common during initiation of therapy and often occur within 90 minutes after the first dose.  However, they can also occur following a dosage increase or resumption of therapy after an interruption of more than a few days.  Agents with alpha 1a specificity, such as tamsulosin, act primarily on the prostate but are not devoid of hypotensive effects.  Therapy with peripheral alpha-1 blockers should be administered cautiously in patients with or predisposed to hypotensive or syncopal episodes.  Caution is also advised in patients who are dehydrated (e.g., due to severe or prolonged diarrhea or vomiting), since they may be more sensitive to the hypotensive effect of the drugs.  Therapy should be initiated with the lowest dosage possible and titrated gradually based on patient response and tolerance in accordance with the individual product package labeling.  During initiation or reinstitution of therapy and following an increase in dosage, patients should be advised not to rise abruptly from a sitting or recumbent position and to avoid situations where injury could result if syncope occur.  Concomitant use of alcohol, extensive periods of standing, prolonged or intense exercise, and exposure to heat can also precipitate orthostatic hypotension and should be minimized.  If dizziness, lightheadedness or palpitations occur, the patient should sit or lie down, and seek medical attention if symptoms are recurrent or bothersome.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6146, 0, 'Doxazosin', 'Liver Diseases', 'Doxazosin is metabolized by the liver and subsequently excreted in the bile, primarily as metabolites, some of which are pharmacologically active.  In patients with cirrhosis (Child-Pugh Class A) given a single 2 mg dose, there was a 40% increase in exposure to doxazosin compared to patients with normal hepatic function.  The clearance was reduced by 30%, while elimination half-life was not significantly changed.  Therapy with doxazosin should be administered cautiously in patients with significantly impaired hepatic or biliary function, since drug and/or metabolite accumulation may occur.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6147, 0, 'Doxazosin', 'Neutropenia', 'Slight but sometimes clinically significant decreases in white blood cell and neutrophil counts have occurred during treatment with some of the peripheral alpha 1-adrenergic receptor blocking agents (aka alpha 1-blockers), including doxazosin.  Reported cases were generally asymptomatic and reversible.  Patients with preexisting neutropenia or bone marrow depression may require closer monitoring during therapy with alpha 1-blockers.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6148, 0, 'Doxycycline', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6149, 0, 'Doxycycline', 'Liver Diseases', 'The use of tetracyclines has rarely been associated with hepatotoxicity.  Histologic fatty changes of the liver, elevated liver enzymes, and jaundice have been reported, primarily in patients treated with large doses of intravenous tetracycline hydrochloride (no longer available in the U.S.) but also in patients receiving high oral doses of these drugs.  Therapy with tetracyclines should be administered cautiously in patients with preexisting liver disease or biliary obstruction.  Reduced dosages may be appropriate, particularly with minocycline and doxycycline, since the former is metabolized by the liver and the latter undergoes enterohepatic recycling.  Liver function tests are recommended prior to and during therapy, and the concomitant use of other potentially hepatotoxic drugs should be avoided.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6150, 0, 'Doxycycline', 'Esophageal Diseases', 'The use of oral tetracycline capsules and tablets has been associated with esophageal irritation and ulceration in patients who ingested the drug without sufficient fluid shortly before bedtime.  Therapy with solid formulations of tetracyclines should preferably be avoided in patients with esophageal obstruction, compression or dyskinesia.  If the drugs are used, patients should be advised not to take the medication just before retiring and to drink fluids liberally.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6151, 0, 'Doripenem', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6152, 0, 'Doripenem', 'Kidney Diseases', 'Carbapenems are primarily eliminated by the kidney.  Patients with renal impairment may be at greater risk for adverse effects from carbapenems, including seizures and other central nervous system disturbances, due to decreased drug clearance.  Dosage adjustments should be considered, with modifications based on degree of renal impairment and severity of infection in accordance with the individual product package labeling.  Renal function tests should be performed periodically during therapy.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6153, 0, 'Doripenem', 'Central Nervous System Diseases', 'The intravenous use of carbapenems has been associated with central nervous system adverse effects such as seizures (up to 1.5%) and, less frequently, somnolence, encephalopathy, myoclonus, tremor, paresthesia, confusion, agitation, depression, and hallucinations.  Therapy with carbapenems, regardless of route of administration, should be administered cautiously in patients with or predisposed to seizures or other neurologic disturbances.  The normally recommended dosages should not be exceeded in such patients.  In those with a known seizure disorder, anticonvulsant therapy should be continued during carbapenem therapy.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6154, 0, 'Doripenem', 'Diseases requiring hemodialysis', 'In patients undergoing hemodialysis, carbapenems are recommended only if the benefit outweighs the potential risk of seizures.  Carbapenems are removed by hemodialysis and should be administered after dialysis to avoid premature removal of the drug.  There is not enough information regarding the use of some carbapenems such as meropenem for injection in patients on dialysis.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6155, 0, 'Dolasetron', 'Long QT Syndrome', 'Dolasetron may cause acute but usually reversible and self-limiting interval changes in the electrocardiogram, including PR, QTc and JT prolongation and QRS widening.  The incidence and severity of these changes are related to serum levels of the active metabolite, hydrodolasetron.  Cardiovascular morbidity such as heart block and cardiac arrhythmias may occur rarely.  Therapy with dolasetron should be administered cautiously in patients with or predisposed to prolongation of cardiac conduction intervals.  Risk factors include hypokalemia; hypomagnesemia; use of diuretics that may induce electrolyte abnormalities; use of antiarrhythmic agents or other drugs that may cause QTc prolongation; cumulative high-dose anthracycline therapy; significant bradycardia; congestive heart failure; myocardial ischemia; and atrial fibrillation.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6156, 0, 'Doxercalciferol', 'Hypercalcemia', 'Vitamin D analogs such as calciferol and ergocalciferol should not be given to patients with hypercalcemia, malabsorption syndrome, or evidence of vitamin D toxicity.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6157, 0, 'Doxercalciferol', 'Liver Diseases', 'Vitamin D analogs are fat soluble and oral formulations require bile for adequate intestinal absorption.  Hepatic and/or biliary dysfunction decrease the absorption of vitamin D analogs.  Metabolites of vitamin D analogs are primarily excreted in bile and feces.  Ergocalciferol, cholecalciferol, and dihydrotachysterol undergo hepatic hydroxylation during metabolic activation.  Hepatic impairment can alter the metabolic and therapeutic activity of certain vitamin D analogs.  Alternative vitamin D analogs such as calcifediol (requires renal activation) and calcitriol (active form) may be considered in patients with compromised hepatic function.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6158, 0, 'Abciximab', 'Hemorrhagic Disorders', 'The use of gp11b/111a platelet inhibitors is contraindicated in patients with active internal bleeding, recent significant gastrointestinal or genitourinary bleeding (within 6 weeks), recent trauma or major surgery (within 6 weeks), history of bleeding diathesis, recent stroke (within 4 weeks), history of hemorrhage stroke or residual neurologic deficit, intracranial defect (aneurysm, arteriovenous malformation, neoplasm), uncontrolled hypertension (SBP > 180; DBP > 110), or thrombocytopenia (<100,000/mm3).  Thrombocytopenia, serious GI/GU bleeding, hemorrhagic retinopathy, and bleeding at the arterial access have been reported during gp11b/111a platelet inhibitor therapy.  Clinical monitoring of hemoglobin and hematocrit (H/H), platelet count, prothrombin time (PT) and activated partial prothrombin time (aPTT) is recommended prior to initiation of, during and following gp11b/111a platelet inhibitor therapy.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6159, 0, 'Dronedarone', 'Cardiomyopathies', 'Dronedarone has shown to double the risk of death in patients with symptomatic heart failure and recent decompensation requiring hospitalization or NYHA Class IV heart failure.  It has also shown to double the risk of stroke and death and hospitalization due to heart failure in patients with atrial fibrillation.  Other patients at risk include patients with second or third degree AV block, or sick sinus syndrome (except when used in conjunction with a functioning pacemaker), patients with bradycardia < 50 bpm, and patients with QT interval prolongation.  The use of dronedarone is contraindicated in these patients.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6160, 0, 'Dronedarone', 'Liver Diseases', 'Dronedarone is extensively metabolized by the liver.  There is little clinical experience with moderate hepatic impairment and none in patients with severe hepatic impairment.  No dosage adjustment is recommended for patients with moderate hepatic impairment, however its use is contraindicated in patients with severe hepatic impairment.  Additionally hepatocellular liver injury, including acute liver failure has been reported in patients using dronedarone in the postmarketing setting.  Patients should be advised to report immediately any symptoms suggesting hepatic injury, such as anorexia, nausea, vomiting, fever, malaise, fatigue, right upper quadrant pain, jaundice, dark urine or itching.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6161, 0, 'Amantadine', 'Psychotic Disorders', 'Amantadine may precipitate or exacerbate psychotic symptoms.  Rarely, suicide attempts and suicidal ideation have also been reported, some of which occurred in patients with no prior history of psychiatric illness who were taking short courses of amantadine for influenza.  Therapy with amantadine should be administered cautiously in patients with a history of psychiatric disorders, emotional instability, or substance abuse, and particularly if they are elderly.  It may be prudent to refrain from dispensing large quantities of amantadine to these patients to prevent intentional overdose, which is potentially fatal.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6162, 0, 'Amantadine', 'Kidney Diseases', 'Amantadine is primarily eliminated by the kidney.  Patients with renal impairment may be at greater risk for adverse effects from amantadine due to decreased drug clearance.  Therapy with amantadine should be administered cautiously in patients with renal impairment.  Dosage adjustments are recommended for patients with moderate to severe renal dysfunction.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6163, 0, 'Amantadine', 'Epilepsy', 'Amantadine may rarely precipitate or exacerbate seizure activity.  Patients with epilepsy or predisposed to seizures should be monitored closely for increased seizure activity during therapy with amantadine.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6164, 0, 'Amantadine', 'Hypotension', 'Dopamine agonists may impair the systemic regulation of blood pressure, with resultant orthostatic hypotension, especially during dose escalation.  Therapy with dopamine agonists should be monitored carefully in patients with Parkinson''s disease since they may have an impaired ability to respond to an orthostatic challenge, and also in patients receiving antihypertensive drugs.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6165, 0, 'Amantadine', 'Heart Failure', 'Amantadine may occasionally cause peripheral edema and, rarely, congestive heart failure.  Patients with edema or congestive heart failure should be monitored closely for exacerbation of their condition.  Dosage adjustments may be necessary.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6166, 0, 'Droxidopa', 'Cardiovascular disease', 'Droxidopa is directly metabolized in vivo to norepinephrine via decarboxylation.  As such, it may exacerbate certain cardiovascular conditions by increasing blood pressure and heart rate.  Therapy with droxidopa should be considered cautiously in patients with ischemic heart disease, arrhythmias, or congestive heart failure.  Additionally, droxidopa may exacerbate supine hypertension in patients with neurogenic orthostatic hypotension.  Patients should be advised to elevate the head of the bed while resting or sleeping.  Blood pressure should be monitored both in supine position and the head- elevated sleeping position.  If hypertension persists, then droxidopa dosage should be reduced or discontinued.  If hypertension is not well managed, it can increase the risk of cardiovascular events, especially stroke.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6167, 0, 'Droxidopa', 'Kidney Diseases', 'Droxidopa and its metabolites is primarily cleared by the kidneys.  Patients with mild and moderate renal impairment did not show adverse reactions in clinical trials.  However, the clinical experience in patients with severe renal function (GFR < 30 mL/min) is limited.  Caution is advised in patients with severe renal impairment.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6168, 0, 'Dronabinol', 'Seizures', 'Seizures and seizure- like activity have been reported in patients using dronabinol.  Caution is advised in patients with history of a seizure disorder, as dronabinol may lower seizure threshold.  Therapy should be discontinued immediately in patients who develop seizures and medical attention should be sought immediately.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6169, 0, 'Dronabinol', 'Heart Diseases', 'The use of some antiemetics such as dronabinol and nabilone has been associated with occasional hypotension, possible hypertension, syncope or tachycardia.  Therapy with these drugs should be administered cautiously in patients with cardiac disease.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6170, 0, 'Dronabinol', 'Psychotic Disorders', 'Some antiemetics such as dronabinol and nabilone may precipitate or exacerbate psychotic symptoms or anxiety, depression, hallucinations or psychosis.  Therapy with these drugs should be administered cautiously in patients with a history of psychiatric disorders, emotional instability, or depression, and particularly if they are elderly.  Careful psychiatric monitoring is advised.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6171, 0, 'Dronabinol', 'Substance-Related Disorders', 'Some antiemetics as dronabinol and nabilone have a significant potential for abuse.  Therapy with these drugs should be administered cautiously in patients with a history of substance abuse.  It may be prudent to refrain from dispensing large quantities of dronabinol to these patients.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6172, 0, 'Doxylamine', 'Depressive Disorder', 'A variety of abnormal thinking and behavior changes have been reported to occur in association with the use of most anxiolytics, sedatives and hypnotics.  Some of these changes include decreased inhibition, aggressiveness, agitation, and hallucinations.  These drugs can cause or exacerbate mental depression and cause suicidal behavior and ideation.  Therapy with these drugs should be administered cautiously in patients with a history of depression or other psychiatric disorders.  Patients should be monitored for any changes in mood or behavior.  It may be prudent to refrain from dispensing large quantities of medication to these patients.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6173, 0, 'Doxylamine', 'Anticholinergic Syndrome', 'Antihistamines often have anticholinergic activity, to which elderly patients are particularly sensitive.  Therapy with antihistamines should be administered cautiously, if at all, in patients with preexisting conditions that are likely to be exacerbated by anticholinergic activity, such as urinary retention or obstruction; angle-closure glaucoma, untreated intraocular hypertension, or uncontrolled primary open-angle glaucoma; and gastrointestinal obstructive disorders.  Conventional, first-generation antihistamines such as the ethanolamines (bromodiphenhydramine, carbinoxamine, clemastine, dimenhydrinate, diphenhydramine, doxylamine, phenyltoloxamine) tend to exhibit substantial anticholinergic effects.  In contrast, the newer, relatively nonsedating antihistamines (e.g., cetirizine, fexofenadine, loratadine) reportedly have low to minimal anticholinergic activity at normally recommended dosages and may be appropriate alternatives.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6174, 0, 'Doxylamine', 'Asthma', 'It has been suggested that the anticholinergic effect of antihistamines may reduce the volume and cause thickening of bronchial secretions, resulting in obstruction of respiratory tract.  Some manufacturers and clinicians recommend that therapy with antihistamines be administered cautiously in patients with asthma or chronic obstructive pulmonary disease.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6175, 0, 'Doxylamine', 'Cardiovascular Diseases', 'Antihistamines may infrequently cause cardiovascular adverse effects related to their anticholinergic and local anesthetic (quinidine-like) activities.  Tachycardia, palpitation, ECG changes, arrhythmias, hypotension, and hypertension have been reported.  Although these effects are uncommon and usually limited to overdosage situations, the manufacturers and some clinicians recommend that therapy with antihistamines be administered cautiously in patients with cardiovascular disease, hypertension, and/or hyperthyroidism.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6176, 0, 'Doxylamine', 'Liver Diseases', 'Limited pharmacokinetic data are available for the older, first-generation antihistamines.  Many appear to be primarily metabolized by the liver, and both parent drugs and metabolites are excreted in the urine.  Patients with renal and/or liver disease may be at greater risk for adverse effects from antihistamines due to drug and metabolite accumulation.  Therapy with antihistamines should be administered cautiously in such patients.  Lower initial dosages may be appropriate.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6177, 0, 'Doxylamine', 'Glaucoma', 'Some hypnotic drugs can have an anticholinergic effect and should be used with caution in patients with glaucoma, and trouble urinating due to retention or enlarged prostate.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6178, 0, 'Doxylamine', 'Respiratory Insufficiency', 'Oral anxiolytic, sedative, and hypnotic agents may cause respiratory depression and apnea when given in high dosages or following acute overdose.  However, some patients may be susceptible at commonly used dosages, including the elderly, debilitated or severely ill patients, those receiving other CNS depressants, and those with limited ventilatory reserve, chronic pulmonary insufficiency or other respiratory disorders.  Therapy with anxiolytic, sedative, and hypnotic agents should be administered cautiously in these patients.  Appropriate monitoring and individualization of dosage are recommended.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6179, 0, 'Drospirenone', 'Hyperkalemia', 'The progestin drospirenone (DRSP) has antialdosterone activity, including the potential for hyperkalemia in high-risk patients.  The use of DRSP-containing combination hormone is contraindicated in patients with conditions that predispose to hyperkalemia (renal impairment, hepatic impairment, and adrenal insufficiency).  Use caution when prescribing these agents to women who regularly take other medications that can increase potassium, such as nonsteroidal anti-inflammatory drugs (NSAIDs), potassium-sparing diuretics, potassium supplements, angiotensin converting enzyme (ACE) inhibitors, angiotensin-II receptor antagonists, heparin and aldosterone antagonists.  It is recommended to monitor serum potassium concentrations during the first month of dosing in high-risk patients who take strong CYP3A4 inhibitors long-term and concomitantly.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6180, 0, 'Drospirenone', 'Eye Diseases', 'Estrogens and progestogens may cause retinal thrombosis.  Oral contraceptives should be discontinued if there is unexplained partial or complete loss of vision; onset of proptosis or diplopia; papilledema; or retinal vascular lesions.  Therapy with these agents should be administered cautiously in patients who have preexisting ocular problems and appropriate diagnostic and therapeutic measures should be instituted.  Contact lens wearers who develop visual changes or changes in lens tolerance should be assessed by an ophthalmologist.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6181, 0, 'Droperidol', 'Cardiovascular Diseases', 'Cases of QT prolongation and/or torsade de pointes have been reported in patients receiving droperidol at doses at or below recommended doses.  Extreme caution is recommended when using this agent in patients with risk factors for development of prolonged QT syndrome, such as clinically significant bradycardia, any clinically significant cardiac disease, treatment with Class I and Class III antiarrhythmics, treatment with monoamine oxidase inhibitors (MAOI''s), concomitant treatment with other drug products known to prolong the QT interval, and electrolyte imbalance, in particular hypokalemia and hypomagnesemia, or concomitant treatment with drugs that may cause electrolyte imbalance.  It is advisable that all patients undergo a 12-lead ECG prior to administration to determine if a prolonged QT interval (i.e., QTc greater than 440 msec.  for males or 450 msec.  for females) is present.  If there is a prolonged QT interval, droperidol should not be administered.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6182, 0, 'Droperidol', 'Long QT Syndrome', 'The use of droperidol is contraindicated in patients with known or suspected QT prolongation (i.e., QTc interval greater than 440 msec.  for males or 450 msec.  for females), including those patients with congenital long QT syndrome.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6183, 0, 'Droperidol', 'Liver Failure', 'Droperidol should be administered with caution in patients with liver and kidney dysfunction because of the importance of these organs in the metabolism and excretion of drugs.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6184, 0, 'Droperidol', 'Pheochromocytoma', 'Droperidol should be used with caution in patients with diagnosed or suspected pheochromocytoma as severe hypertension and tachycardia have been observed after its administration.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6185, 0, 'Duloxetine', 'Liver Diseases', 'Postmarketing studies have reported that duloxetine and some other SNRIs like milnacipran may aggravate preexisting liver disease.  The use of duloxetine delayed-release and milnacipran should be avoided in patients with chronic liver disease or cirrhosis.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6186, 0, 'Duloxetine', 'Kidney Diseases', 'The use of duloxetine should be avoided in patients with severe renal impairment (GFR <30 mL/min).', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6187, 0, 'Duloxetine', 'Depressive Disorder', 'Adult and pediatric patients with depression and other psychiatric disorders may experience worsening of their symptoms and may have the emergence of suicidal thoughts and behavior.  Patients should be monitored appropriately and observed closely for worsening of their symptoms, suicidality or changes in their behavior, especially during the first few months of treatment, and at times of dose changes.  Discontinuing the medication should be considered if symptoms are persistently worse, or abrupt in onset.  It may be prudent to refrain from dispensing large quantities of medication to these patients.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6188, 0, 'Duloxetine', 'Diabetes Mellitus', 'In clinical trials, treatment with duloxetine delayed-release worsened the glycemic control in some patients with diabetes.  Caution should be used when using duloxetine in diabetic patients and their glycemic levels should be checked regularly.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6189, 0, 'Duloxetine', 'Glaucoma', 'SNRI antidepressants cause pupillary dilation that may trigger an angle closure attack in patients with anatomically narrow angle without iridectomy.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6190, 0, 'Duloxetine', 'Hypertension', 'Selective serotonin and norepinephrine reuptake inhibitor antidepressants (SNRIs) have been associated with sustained increases in blood pressure.  Therapy with SNRI antidepressants should be administered cautiously in patients with preexisting hypertension.  Blood pressure should be assessed prior to initiating treatment and monitored regularly.  The dose should be reduced or discontinued if necessary.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6191, 0, 'Duloxetine', 'Hyponatremia', 'Treatment with SNRI antidepressants can cause hyponatremia.  Caution should be used when treating patients with hyponatremia or at greater risk of hyponatremia such as the elderly, patients taking diuretics or who are volume depleted.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6192, 0, 'Duloxetine', 'Mania', 'Therapy with SNRI antidepressants can cause activation of mania and hypomania and should be used with caution in patients with personal or family history of mania, hypomania, bipolar disorder, and other mood disorders.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6193, 0, 'Duloxetine', 'Seizures', 'SNRI antidepressants may trigger seizures and should be administered with caution in patients with a seizure disorder.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6194, 0, 'Duloxetine', 'Urethral Obstruction', 'SNRI antidepressants have a noradrenergic effect and can affect urethral resistance.  Caution should be used in patients with a history of dysuria, prostatic hypertrophy, prostatitis, and other lower urinary tract obstructive disorders.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6195, 0, 'Dulaglutide', 'Gastroparesis', 'Dulaglutide slows gastric emptying and has not been studied in patients with gastroparesis, therefore it is not recommended in these patients.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6196, 0, 'Dulaglutide', 'Pancreatitis', 'The use of GLP-1 receptor agonists has been associated with rare reports of acute pancreatitis.  Other antidiabetic therapies should be considered in patients with a previous history of pancreatitis, although it is not known if they are at increased risk.  Patients receiving treatment with GLP-1 receptor agonists should be observed carefully for signs and symptoms of pancreatitis.  If this diagnosis is suspected, the treatment should be discontinued immediately and appropriate management should be initiated.  Treatment with GLP-1 receptor agonists should be permanently discontinued if pancreatitis is confirmed.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6197, 0, 'Dulaglutide', 'Thyroid Neoplasms', 'GLP-1 receptor agonist antidiabetic drugs are contraindicated in patients with a personal or family history of medullary thyroid carcinoma and in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN2).  Carcinogenicity studies in rodents and limited postmarketing data suggest that GLP-1 inhibitors may cause a dose-related and treatment duration-related increase in risk of thyroid C-cell tumors, although a causal relationship has not been established.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6198, 0, 'Dulaglutide', 'Kidney Diseases', 'There have been reports of acute renal failure and worsening of chronic renal failure sometimes requiring hemodialysis in patients treated with GLP-1 receptor inhibitors.  Some of these events occurred in patients without known underlying renal disease.  These drugs should be used with caution in patients with renal impairment, especially during treatment initiation or dose escalation.  Patients should be monitored, especially if they report severe gastrointestinal reactions such as nausea, vomiting, diarrhea, or dehydration.  The frequency of gastrointestinal events is increased as renal function declines.  There is limited clinical experience with most of these drugs in patients with severe renal impairment.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6199, 0, 'Dupilumab', 'Helminthiasis', 'Patients with preexisting-existing helminth infections should be treated prior to therapy with dupilumab.  It is recommended to discontinue treatment with dupilumab if patients become infected while on treatment and if they are not responding to treatment.  Discontinue treatment with dupilumab until the infection resolves.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6200, 0, 'Dupilumab', 'Vision Disorders', 'Conjunctivitis and keratitis may occur while on treatment with dupilumab.  Care should be exercised when using this agent in patients with visual defects.  Patients should be closely monitored for new onset or worsening eye symptoms.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6201, 0, 'Durvalumab', 'Adrenal Insufficiency', 'Durvalumab can cause immune-mediated adrenal insufficiency.  Adrenal function should be monitored in patients with adrenal insufficiency or with borderline adrenal function and in patients with prolonged periods of stress due to major surgery, intensive care, etc.  It is recommended to monitor patients for clinical signs and symptoms of adrenal insufficiency and to institute appropriate measures as necessary.  Monitor as clinically indicated prior to and periodically during treatment and withhold, reduce dose, or discontinue therapy with durvalumab as necessary.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6202, 0, 'Durvalumab', 'Colitis', 'Immune-mediated colitis has been reported with the use of durvalumab.  Monitor patients for signs and symptoms of diarrhea or colitis.  It is recommended to administer corticosteroids at a dose of 1 to 2 mg/kg/day prednisone equivalents followed by corticosteroid taper for severe or life-threatening colitis.  It is recommended to interrupt or to permanently discontinue durvalumab for life-threatening or for recurrent colitis.  Care should be taken when using durvalumab in patients with inflammatory bowel disease.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6203, 0, 'Durvalumab', 'Diabetes Mellitus', 'Durvalumab can cause type 1 diabetes mellitus.  Monitor for hyperglycemia or other signs and symptoms of diabetes.  Withhold treatment in cases of severe hyperglycemia until metabolic control is achieved.  Permanently discontinue durvalumab for life-threatening hyperglycemia.  If appropriate interrupt treatment according to manufacturer recommendations.  Care should be exercised when using durvalumab in diabetic patients.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6204, 0, 'Durvalumab', 'Infections', 'Durvalumab may alter the normal immune response and increase susceptibility to infections.  Monitor patients for signs and symptoms of infection and withhold durvalumab treatment for Grade 3 or higher infections, particularly in patients with urinary tract infections.  Resume once clinically stable.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6205, 0, 'Durvalumab', 'Liver Diseases', 'Durvalumab can cause immune-mediated hepatitis.  Caution is recommended when using durvalumab in patients with moderate or severe hepatic impairment as this agent has not been studied in these patients.  Monitor patients for signs and symptoms of hepatitis during and after treatment discontinuation.  Periodic hepatic function test should be performed according to medical practices.  Administer corticosteroids as appropriate according to manufacturer recommendations.  It is recommended to interrupt or permanently discontinue treatment with durvalumab for severe or life-threatening transaminase or total bilirubin elevation.  Care should be taken when using durvalumab in patients with liver disease.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6206, 0, 'Durvalumab', 'Kidney Diseases', 'Durvalumab can cause immune-mediated nephritis.  Monitor patients for abnormal renal function tests prior to and periodically during treatment.  It is recommended to administer corticosteroids at a dose of 1 to 2 mg/kg/day prednisone equivalents followed by corticosteroid taper for life-threatening increased serum creatinine.  Withhold or permanently discontinue durvalumab based on severity.  If appropriate modify the dose according to manufacturer recommendations.  Care should be taken when using durvalumab in patients with renal dysfunction.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6207, 0, 'Durvalumab', 'Thyroid Diseases', 'Durvalumab can cause immune-mediated thyroid disorders.  Monitor thyroid function prior to and periodically during treatment.  Administer hormone-replacement therapy for hypothyroidism or initiate medical management for control of hyperthyroidism.  Continue durvalumab for hypothyroidism and interrupt for hyperthyroidism based on the manufacturer recommendation.  Care should be taken when using this agent in patients with thyroid disease.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6208, 0, 'Durvalumab', 'Pneumonia', 'Durvalumab can cause immune-mediated pneumonitis.  Monitor patients for signs and symptoms of pneumonitis.  Evaluate patients with suspected pneumonitis with radiographic imaging.  It is recommended to administer corticosteroids at a dose of 1 to 2 mg/kg/day prednisone equivalents for moderate pneumonitis or 1 to 4 mg per kg per day or equivalent corticosteroid for more severe pneumonitis, followed by a taper.  It is recommended to interrupt or permanently discontinue durvalumab based on the severity of symptoms.  Care should be exercised when using this agent in patients with suspected pneumonitis.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6209, 0, 'Dutasteride', 'Liver Diseases', 'Finasteride and dutasteride are extensively metabolized by the liver.  Therapy with these drugs should be administered cautiously in patients with liver disease as exposure could be higher.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6210, 0, 'Dyphylline', 'Kidney Diseases', 'Dyphylline is eliminated almost entirely by the kidney.  Drug accumulation may occur in patients with impaired renal function.  Like other methylxanthines, high plasma levels of the drug may be associated with severe cardio- and neurotoxicity, sometimes without any previous warning.  Therapy with dyphylline should be administered cautiously in patients with renal impairment.  Dosage adjustments may be necessary.  The relationship between plasma dyphylline levels and therapeutic as well as toxic effects has not been determined.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6211, 0, 'Dyphylline', 'Peptic Ulcer', 'Methylxanthines are known to stimulate peptic acid secretion.  Therapy with products containing methylxanthines should be administered with extreme caution in patients with active peptic ulcer disease.  Some manufacturers consider their use to be contraindicated under such circumstance.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6212, 0, 'Dyphylline', 'Cardiotoxicity', 'Like other methylxanthines, dyphylline at high dosages may be associated with positive inotropic and chronotropic effects on the heart.  Therapy with dyphylline and products containing dyphylline should be administered cautiously in patients with severe cardiac disease, hypertension, hyperthyroidism, or recent myocardial infarction.  The relationship between plasma dyphylline levels and therapeutic as well as toxic effects has not been determined.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6213, 0, 'Dyphylline', 'Gastroesophageal Reflux', 'Methylxanthines increase gastric acidity and may also relax lower esophageal sphincter, which can lead to gastric reflux into the esophagus.  Therapy with products containing methylxanthines should be administered cautiously in patients with significant gastroesophageal reflux.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6214, 0, 'Ambrisentan', 'Liver Failure', 'Endothelin receptor antagonists (ERAs) have been associated with aminotransferase elevations, hepatotoxicity, and cases of liver failure.  Hepatic function should be assessed before treatment initiation and closely monitored during treatment.  Therapy should be discontinued if aminotransferase elevations are accompanied by increases in bilirubin, or clinical symptoms of hepatotoxicity such as nausea, vomiting, fever, abdominal pain or jaundice.  Treatment should be avoided in patients with elevated aminotransferases at baseline as monitoring for hepatotoxicity may be more difficult.  In general, the use of ERAs is not recommended for patients with moderate to severe hepatic impairment.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6215, 0, 'Ambrisentan', 'Kidney Diseases', 'There is no information on the exposure to ambrisentan in patients with severe renal impairment.  Additionally, the impact of hemodialysis on the disposition of ambrisentan has not been studied, hence caution is advised.  No dosage adjustment is required in patients with mild or moderate renal impairment.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6216, 0, 'Ambrisentan', 'Anemia', 'Clinical studies have shown that most endothelin receptor antagonists decrease hemoglobin concentration and hematocrit levels.  There are some postmarketing reports of anemia cases which needed blood transfusion.  Hemoglobin and hematocrit levels should be measured prior to treatment initiation and should be monitored periodically thereafter.  Initiation of therapy is not recommended in patients with clinically significant anemia.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6217, 0, 'Ambrisentan', 'Water-Electrolyte Imbalance', 'Peripheral edema and fluid retention are known clinical consequences of pulmonary hypertension and also known effects of endothelin receptor antagonists.  Caution and monitoring is recommended if these agents are used in patients with underlying left ventricular dysfunction or underlying heart failure, as they have an increased risk for developing significant fluid retention that may need treatment or require discontinuation.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6218, 0, 'Eletriptan', 'Coronary Artery Disease', 'The group of drugs known as 5-hydroxytryptamine1 receptor (5-HT1) agonists can cause vasospastic reactions, including coronary vasospasm, peripheral vascular ischemia, and colonic ischemia.  Rarely, serious adverse cardiac events including acute myocardial infarction, arrhythmia, cardiac arrest, and death have been reported within a few hours following the administration of 5-HT1 agonists, in some cases even in patients with no prior history or findings of coronary artery disease (CAD).  Significant elevation in blood pressure, including hypertensive crisis, has also been reported on rare occasions in patients with and without a history of hypertension, as have transient increases in blood pressure and peripheral vascular resistance.  In general, patients with potentially unrecognized CAD as predicted by the presence of risk factors (e.g., hypertension, hypercholesterolemia, tobacco use, obesity, diabetes, strong family history of CAD, female with surgical or physiological menopause, or male over 40 years of age) should not be administered 5-HT1 agonists unless a cardiovascular evaluation provides satisfactory clinical evidence indicating the lack of CAD, ischemic heart disease, or other significant underlying cardiovascular disease.  As a precaution, the manufacturers recommend that the first dose be administered under medical surveillance in such patients, and that electrocardiographic monitoring be considered during the interval immediately following administration to help detect any asymptomatic cardiac ischemia that may occur.  Periodic cardiovascular evaluations should be performed during intermittent, long-term use.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6219, 0, 'Eletriptan', 'Cardiovascular Diseases', 'The use of 5-hydroxytryptamine receptor (5-HT1) agonists is contraindicated in patients with a history or current symptoms or signs of ischemic cardiac, cerebrovascular, and/or peripheral vascular diseases.  In addition, these agents should not be used in patients with any other significant underlying cardiovascular disease or uncontrolled hypertension.  5-HT1 agonists can cause vasospastic reactions, including coronary vasospasm, peripheral vascular ischemia, and colonic ischemia.  Some serious adverse cardiac events including acute myocardial infarction, arrhythmia, cardiac arrest, and death have been reported within a few hours following the administration of 5-HT1 agonists, in some cases even in patients with no prior history or findings of coronary artery disease (CAD).  Significant elevation in blood pressure, including hypertensive crisis, has also been reported on rare occasions in patients with and without a history of hypertension, as have transient increases in blood pressure and peripheral vascular resistance.  Cerebrovascular events have included cerebral hemorrhage, subarachnoid hemorrhage, and stroke, some resulting in fatalities.  However, the relationship to 5-HT1 agonists is uncertain and, in a number of cases, the cerebrovascular events may have been primary where symptoms were mistaken to be migraine.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6220, 0, 'Eletriptan', 'Liver Diseases', 'Eletriptan is primarily metabolized by the liver.  In patients with mild to moderate hepatic impairment, increases of 18% in the peak plasma concentration (Cmax) and 34% in the systemic exposure (AUC) of eletriptan were observed.  Dosage adjustments should not be necessary in this patient population.  There are no data concerning the use of eletriptan in patients with severe hepatic impairment, thus it is not recommended.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6221, 0, 'Efavirenz', 'Hypercholesterolemia', 'Increases in total cholesterol and triglycerides have resulted during treatment with efavirenz.  Lipid levels monitoring should be performed before starting treatment and at periodic intervals during therapy.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6222, 0, 'Efavirenz', 'Liver Diseases', 'Efavirenz is primarily metabolized by the liver.  Patients with liver disease may be at greater risk for adverse effects from efavirenz due to decreased drug clearance.  Therapy with efavirenz should be administered cautiously in patients with liver disease.  In addition, elevations in serum transaminases to greater than five times the upper limit of normal as well as acute liver failure requiring transplantation have occurred during therapy with efavirenz, most often in patients with a prior history of Hepatitis B and/or C.  Monitoring of liver function tests is recommended in these patients.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6223, 0, 'Efavirenz', 'Mental Disorders', 'During clinical trials, there have been infrequent reports of delusions and inappropriate behavior associated with the use of efavirenz, predominantly in patients with a history of mental illness or substance abuse.  Severe acute depression, including suicide attempts and suicidal ideation, has also been reported but was not limited to efavirenz treated patients.  Therapy with efavirenz should be administered cautiously in patients with a current or past history of psychiatric illness, emotional instability, or substance abuse.  If symptoms develop or worsen during treatment, discontinuation of efavirenz may be necessary.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6224, 0, 'Efavirenz', 'Long QT Syndrome', 'QTc prolongation has been observed with the use of efavirenz.  Alternatives to efavirenz should be considered when administered to patients at higher risk of torsade de pointes or when coadministered with a medication with known risk of torsade de pointes.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6225, 0, 'Efavirenz', 'Seizures', 'Convulsions have been observed in adult and pediatric patients receiving efavirenz, generally in the presence of known medical history of seizures.  Caution should be taken with any patient with a history of seizures.  Anticonvulsant medication such as phenytoin and phenobarbital may require periodic monitoring of plasma levels.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6226, 0, 'Eliglustat', 'Kidney Diseases', 'The use of drugs eliglustat should be avoided in patients with end-stage renal disease (estimated creatinine clearance (eCrCl) less than 15 mL/min not on dialysis or requiring dialysis).  No dosage adjustment is recommended in patients with mild, moderate, or severe renal impairment (eCrCl at least 15 mL/min).  In the case of CYP450 2D6 intermediate metabolizers, or poor metabolizers, eliglustat should be avoided in those patients with any degree of renal impairment.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6227, 0, 'Eliglustat', 'Liver Diseases', 'The use of drugs eliglustat is contraindicated in patients with moderate or severe hepatic impairment and in those patients, who are CYP450 2D6 extensive metabolizers with mild hepatic impairment and taking a strong or moderate CYP450 2D6 inhibitor due to the risk of cardiac arrhythmias from prolongation of the PR, QTc, and/or QRS cardiac intervals.  This agent is contraindicated in patients who are CYP450 2D6 extensive metabolizers, intermediate metabolizers and taking a strong or moderate CYP450 2D6 inhibitor concomitantly with a strong or moderate CYP450 3A inhibitor.  In the case of CYP450 2D6 intermediate metabolizers, or poor metabolizers, eliglustat is contraindicated in those patients with any degree of hepatic impairment or those taking a strong CYP450 3A inhibitor.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6228, 0, 'Eliglustat', 'Heart Diseases', 'The use of eliglustat is contraindicated in patients who are CYP2D6 extensive metabolizers or intermediate metabolizers taking a strong or moderate CYP2D6 inhibitor concomitantly with a strong or moderate CYP3A inhibitor or those who are intermediate metabolizers or poor metabolizers taking a strong CYP3A inhibitor due to the risk of a significant increase in drug plasma concentrations.  Eliglustat is predicted to cause increases in EKG intervals (PR, QTc, and QRS) at high plasma concentrations and could result in arrhythmias; therefore, its use is not recommended in patients with preexisting cardiac disease (congestive heart failure, recent myocardial infarction, heart block, arrhythmias), or long QT syndrome.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6229, 0, 'Edoxaban', 'Hemorrhage', 'The use of factor Xa inhibitors is contraindicated in patients with active pathological bleeding as these agents increase the risk of bleeding and can cause serious or fatal hemorrhages.  Caution is recommended when prescribing factor Xa inhibitors to patients at increased risk of bleeding, including patients undergoing procedures where bleeding may cause serious complications.  Such patients include those undergoing spinal/epidural anesthesia or spinal puncture; these patients are at high risk of an epidural or spinal hematoma, which can result in long-term or permanent paralysis.  In general, when using factor Xa inhibitors, the risk of thrombotic events should be weighed against the risk of bleeding.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6230, 0, 'Edoxaban', 'Kidney Diseases', 'Edoxaban is eliminated primarily as unchanged drug in the urine.  Blood levels of edoxaban are increased in patients with renal dysfunction.  The use of edoxaban is not recommended in patients with CrCl < 15 mL/min.  It is recommended to reduce the dose to 30 mg once daily in these patients.  The clearance of edoxaban is not significantly affected by hemodialysis.  Care should be exercised when using this agent in patients with renal dysfunction.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6231, 0, 'Edoxaban', 'Hepatic Insufficiency', 'The use of factor Xa inhibitors (including apixaban and edoxaban) is not recommended in patients with moderate or severe liver dysfunction (Child-Pugh B or C) as these patients may have intrinsic coagulation abnormalities.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6232, 0, 'Edoxaban', 'Heart Valve Diseases', 'The use of some factor Xa inhibitors (including apixaban, edoxaban, and rivaroxaban) is not recommended in patients with prosthetic heart valves; safety and efficacy have not been established in such patients.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6233, 0, 'Edoxaban', 'Antiphospholipid Syndrome', 'Direct acting oral anticoagulants including factor Xa inhibitors and some thrombin inhibitors as dabigatran, are not recommended for use in patients with antiphospholipid syndrome (APS).  Treatment with these drugs has been associated with increased rates of recurrent thrombotic events, especially in patients with triple positive APS.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6234, 0, 'Eltrombopag', 'Hepatitis C', 'Eltrombopag has shown to increase the risk of hepatic decompensation in patients with chronic hepatitis C in treatment with interferon and ribavirin.  Clinical trials reported that ascites and encephalopathy occurred more frequently on these patients than in the placebo arm.  Patients with chronic hepatitis and receiving antiviral treatment should be closely monitored.  The manufacturers also recommend to discontinue eltrombopag if the antiviral therapy is discontinued.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6235, 0, 'Eltrombopag', 'Hepatic Insufficiency', 'Eltrombopag can cause liver enzyme elevations.  Monitor ALT, AST and bilirubin prior to treatment initiation, and every 2 weeks during dose adjustment phase and then monthly.  If abnormalities are confirmed, monitor serum liver tests weekly until resolved or stabilized.  Treatment should be discontinued if ALT levels increase to greater than or equal to 3 x ULN in patients with normal liver function, or greater or equal to 3 x baseline in patients with pretreatment transaminase elevations that are progressively increasing, persist for 4 weeks or more, also have an increase in bilirubin, or also have clinical symptoms of liver injury or hepatic decompensation.  Hepatic impairment influences the exposure to eltrombopag.  The initial dose should be reduced in patients with chronic ITP or severe aplastic anemia who have hepatic impairment.  No dose adjustment is required on patients with chronic hepatitis C and hepatic impairment.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6236, 0, 'Eltrombopag', 'Cataract', 'In clinical trials, eltrombopag developed or worsened cataracts in 7% of the patients receiving treatment.  A baseline ocular examination prior to administration of eltrombopag is recommended, and regular monitoring for signs and symptoms of cataracts should be performed regularly during treatment.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6237, 0, 'Eltrombopag', 'Thromboembolism', 'Thromboembolic complications may result from increases in platelet counts with TPO receptor agonists such as avatrombopag, lusutrombopag, and eltrombopag.  Consider the potential for increased risk of thromboembolism when administering these medications to patients with known risk factors for thromboembolism, including genetic prothrombotic conditions (Factor V Leiden, Prothrombin 20210 A, Antithrombin deficiency or Protein C or S deficiency).', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6238, 0, 'Eculizumab', 'Meningococcal Infections', 'Eculizumab is contraindicated in patients with unresolved serious Neisseria meningitidis infection, in those who are not currently vaccinated against Neisseria meningitidis, unless the risks of delaying treatment outweigh the risks of developing a meningococcal infection.  Life-threatening and fatal meningococcal infections have occurred in patients treated with eculizumab.  The use of eculizumab increases a patient''s susceptibility to serious meningococcal infections (septicemia and/or meningitis).  Closely monitor patients for early signs and symptoms of meningococcal infection and evaluate patients immediately if an infection is suspected.  Meningococcal infection may become rapidly life-threatening or fatal if not recognized and treated early.  It is recommended to discontinue eculizumab in patients who are undergoing treatment for serious meningococcal infections.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6239, 0, 'Eculizumab', 'Infections', 'Serious and sometimes fatal infections have been reported in patients receiving immunosuppressive agents.  Patients receiving immunosuppressants are at increased risk of developing bacterial, viral, fungal, and protozoal infections, and new or reactivated viral infections including opportunistic infections.  Caution should be exercised when considering their use in patients with severe or chronic infections.  It is recommended to interrupt therapy in patients who develop a new infection while undergoing treatment and to monitor these patients closely for any sign or symptom indicative of infection.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6240, 0, 'Eculizumab', 'Leukoencephalopathy, Progressive Multifocal', 'Immunosuppressive agents may increase the risk of progressive multifocal leukoencephalopathy (PML).  Certain agents are contraindicated in patients who have or have had PML.  Patients receiving chronic immunosuppressant or immunomodulatory therapy or who have systemic medical conditions resulting in significantly compromised immune system function should not be treated with these agents.  Healthcare professionals should monitor patients for any new sign or symptom suggestive of PML.  Withhold therapy dosing immediately and perform an appropriate diagnostic evaluation at the first sign or symptom suggestive of PML.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6241, 0, 'Eculizumab', 'Thrombotic Microangiopathies', 'Thrombotic microangiopathy (TMA) complications have occurred after treatment discontinuation or after a missed dose of eculizumab.  It is recommended to monitor patients with atypical hemolytic uremic syndrome for signs and symptoms of thrombotic microangiopathy (TMA) complications for at least 12 weeks.  If TMA complications occur after eculizumab discontinuation, consider reinstitution of treatment, plasma therapy or appropriate organ-specific supportive measures.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6242, 0, 'Elotuzumab', 'Infections', 'Because of their cytotoxic effects on rapidly proliferating tissues, antineoplastic agents frequently can, to varying extent, induce myelosuppression.  The use of these drugs may be contraindicated in patients with known infectious diseases.  All patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection during antineoplastic therapy.  Close clinical monitoring of hematopoietic function is recommended.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6243, 0, 'Elotuzumab', 'Cardiovascular Diseases', 'The use of monoclonal antibodies administered via IV infusion may cause serious infusion reactions, including bronchospasm, hypoxia, dyspnea, fluctuations in blood pressure, laryngeal edema and pulmonary edema.  Caution should be taken in patients with a history of cardiopulmonary disease as they may require additional post-infusion medications to manage respiratory complications.  It is recommended to administer required intravenous hydration and premedication with antihistamines, analgesics, and antipyretics before administration.  Monitor closely for signs and symptoms of infusion reactions during and for at least 4 hours following completion of each infusion in a setting where cardiopulmonary resuscitation medication and equipment are available.  Immediately interrupt or permanently discontinue treatment and institute supportive management for severe or prolonged infusion reactions as appropriate.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6244, 0, 'Elotuzumab', 'Tumor Lysis Syndrome', 'Tumor lysis syndrome (TLS) has occurred in patients receiving certain monoclonal antibodies.  Patients with high tumor burden and those with high circulating lymphocyte counts of greater than 25 X 10^9/L have a higher risk of developing TLS.  Consider tumor lysis prophylaxis prior to the infusion with anti-hyperuricemics and hydration beginning 12 to 24 hours prior to infusion.  It is recommended to correct electrolytes abnormalities, and monitor renal function in patients who develop TLS.  Monitor for signs and symptoms of TLS and temporary interruption or discontinuation of therapy might be required.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6245, 0, 'Elotuzumab', 'Liver Diseases', 'The use of elotuzumab has been associated with elevations in liver enzymes.  Care should be exercised when using this agent in patients with liver impairment.  It is recommended to monitor liver enzymes before the start of therapy and periodically as clinically appropriate.  Interrupt treatment upon Grade 3 or higher elevation of liver enzymes.  After return to baseline values, continuation of treatment may be considered.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6246, 0, 'Amcinonide', 'Diabetes Mellitus', 'Corticosteroids can raise blood glucose level by antagonizing the action and suppressing the secretion of insulin, which results in inhibition of peripheral glucose uptake and increased gluconeogenesis.  Therapy with topical corticosteroids rarely produces these effects but should be administered cautiously nonetheless in patients with diabetes mellitus, glucose intolerance, or a predisposition to hyperglycemia.  Systemic absorption of topical corticosteroids may occur depending on the vehicle and concentration of the preparation, the size of the application area, the integrity of the skin, and the duration of administration.  Use of occlusive dressings over the applied areas may also increase percutaneous absorption.  Given equivalent doses, small children are generally at the greatest risk because of their larger skin surface to body mass ratios.  If possible, the use of highly potent agents (e.g., augmented betamethasone, clobetasol, diflorasone, and halobetasol) should be avoided in children and limited to small areas for 2 weeks in adults.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6247, 0, 'Amcinonide', 'Diaper Rash', 'Topical corticosteroids, especially the potent agents (e.g., augmented betamethasone, clobetasol, diflorasone, and halobetasol), are generally not recommended for use in the treatment of diaper rash.  Topical corticosteroids may be systemically absorbed, depending on the vehicle and concentration of the preparation, the size of the application area, the duration of administration, and whether or not occlusive dressings are used.  Given equivalent doses, small children are usually at the greatest risk for systemic toxicity such as adrenal suppression, Cushing''s syndrome and intracranial hypertension because of their larger skin surface to body mass ratios.  If topical corticosteroids are necessary to treat diaper rash, medium- to low-potency agents should preferably be used, and parents should be advised not to put tight-fitting diapers or plastic pants over the rash, since occlusion of treated area may increase percutaneous drug absorption.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6248, 0, 'Amcinonide', 'Adrenocortical Hyperfunction', 'The use of topical corticosteroids may precipitate or aggravate conditions of hyperadrenocorticism.  Systemic absorption of these agents can produce reversible hypothalamic-pituitary-adrenal axis suppression.  Systemic absorption, depends on the vehicle and concentration of the preparation, the size of the application area, the duration of administration, and whether or not occlusive dressings are used.  Given equivalent doses, small children are generally at the greatest risk because of their larger skin surface to body mass ratios.  Patients with an altered skin barrier or liver failure are also at increased risk.  If possible, the use of highly potent agents (e.g., augmented betamethasone, clobetasol, diflorasone, and halobetasol) should be avoided in children and limited to small areas for 2 weeks in adults.  The development of symptoms such as menstrual irregularities, acneiform lesions, cataracts and cushingoid features during topical corticosteroid therapy may indicate excessive use.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6249, 0, 'Amcinonide', 'Infections', 'Topical corticosteroids may be systemically absorbed, depending on the vehicle and concentration of the preparation, the size of the application area, the duration of administration, and whether or not occlusive dressings are used.  Clinically significant local as well as systemic immunosuppressant and anti-inflammatory effects may occur, which can cause or exacerbate an infection.  Given equivalent doses, small children are generally at the greatest risk because of their larger skin surface to body mass ratios.  Therapy with topical corticosteroids should be administered cautiously in patients with latent or active infections, particularly if a potent agent is used on a large area for prolonged periods or if occlusive dressings are used.  Effective antimicrobial therapy or other appropriate treatment should be instituted to treat the infection.  If possible, the use of highly potent agents (e.g., augmented betamethasone, clobetasol, diflorasone, and halobetasol) should be avoided in children and limited to small areas for 2 weeks in adults.  Occlusive dressings should not be used in patients with skin infection.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6250, 0, 'Amcinonide', 'Toxic Optic Neuropathy', 'Prolonged use of corticosteroids may cause posterior subcapsular cataracts and elevated intraocular pressure, the latter of which may lead to glaucoma and/or damage to the optic nerves.  Therapy with topical corticosteroids rarely produces these effects but should be administered cautiously nonetheless in patients with a history of cataracts, glaucoma, or increased intraocular pressure, especially when potent agents (e.g., augmented betamethasone, clobetasol, diflorasone, and halobetasol) are used in the periorbital area.  Topical corticosteroids may be systemically absorbed, depending on the vehicle and concentration of the preparation, the size of the application area, the duration of administration, and whether or not occlusive dressings are used.  Given equivalent doses, small children are generally at the greatest risk because of their larger skin surface to body mass ratios.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6251, 0, 'Edetate calcium disodium anhydrous', 'Hepatitis', 'Edetate calcium disodium should not be given to patients with active hepatitis.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6252, 0, 'Edetate calcium disodium anhydrous', 'Kidney Diseases', 'The use of calcium EDTA is contraindicated in patients with anuria and active renal disease.  Dose-related nephrotoxicity (usually reversible) associated with EDTA has included dysuria, oliguria, proteinuria, large renal epithelial cells in urine, renal insufficiency/failure, and acute tubular necrosis.  Impaired renal function decreases the elimination of EDTA and may increase its nephrotoxicity.  Adequate hydration (avoid excess hydration in patients with lead encephalopathy) and established urine flow prior to initiation of EDTA therapy is necessary.  Clinical monitoring of renal function and calcium, phosphorus, and zinc levels is recommended.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6253, 0, 'Edetate calcium disodium anhydrous', 'Diabetes Mellitus', 'EDTA may chelate zinc present in exogenous insulin and alter glucose concentrations and insulin requirements in patients with diabetes.  Insulin dosages may need to be adjusted in diabetic patients administered EDTA.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6254, 0, 'Edrophonium', 'Bradycardia', 'Due to their pharmacological action, cholinesterase inhibitors can have a vagotonic effect on the sinoatrial and atrioventricular nodes producing bradycardia or heart block.  Therapy with cholinesterase inhibitors should be administered cautiously in patients with preexisting bradycardia or underlying cardiac conduction abnormalities.  Syncopal episodes have been reported in patients with and without cardiac abnormalities.  Atropine may be used to reverse bradycardia produced by cholinesterase inhibitors.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6255, 0, 'Edrophonium', 'Bronchial Spasm', 'Cholinesterase inhibitors inhibit the hydrolysis of acetylcholine.  The enhanced effect of acetylcholine produces constriction of the bronchi, increased bronchial secretions, and bronchospasm.  Therapy with cholinesterase inhibitors should be administered cautiously in patients with respiratory dysfunction, history of asthma or obstructive pulmonary disease.  Monitoring respiratory function during dosage initiation and adjustment is recommended.  Use of atropine along with discontinuation of the cholinesterase inhibitor may be required for serious respiratory distress.  Neostigmine may produce more severe muscarinic side effects than does pyridostigmine and ambenonium.  However, the duration of action is longest for ambenonium and shortest for edrophonium.  Echothiophate iodide ophthalmic may be systemically absorbed and cautious use is recommended in these patients.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6256, 0, 'Edrophonium', 'Coronary Artery Disease', 'The use of cholinesterase inhibitors  has been associated with a constriction of coronary arteries.  Therapy with cholinesterase inhibitors should be administered cautiously in patients with coronary artery disease.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6257, 0, 'Edrophonium', 'Parkinsonian Disorders', 'Cholinesterase inhibitors should be used with caution in patients with parkinsonism.  Some of these drugs might be contraindicated in these patients (refer to specific prescribing information).  Symptoms of Parkinson''s disease may be exacerbated with the increase in cholinergic activity.  Caregivers and patients should be advised.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6258, 0, 'Edrophonium', 'Peptic Ulcer', 'The use of cholinesterase inhibitors is associated with an increase in gastric acid secretion and gastric contractions.  Therapy with cholinesterase inhibitors should be administered cautiously in patients with peptic ulcer disease.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6259, 0, 'Edrophonium', 'Seizures', 'Cholinesterase inhibitors have been associated with convulsions and tremor.  Therapy with cholinesterase inhibitors should be administered cautiously in patients with seizure disorders.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6260, 0, 'Edrophonium', 'Hyperthyroidism', 'Many of the manifestations of hyperthyroidism may be exacerbated by increased levels of acetylcholine produced by cholinesterase inhibitors.  Therapy with cholinesterase inhibitors should be administered cautiously to patients with hyperthyroidism.  Monitoring of thyroid levels is recommended.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6261, 0, 'Elagolix', 'Hepatic Insufficiency', 'Compared to women with normal liver function, those with moderate hepatic impairment had approximately 3-fold higher elagolix exposures and those with severe hepatic impairment had approximately 7-fold higher elagolix exposures.  Because of these increased exposures and risk for bone loss, the use of elagolix is contraindicated in women with severe hepatic impairment (Child-Pugh C).  In women with moderate hepatic impairment (Child-Pugh B) elagolix 150 mg is recommended once daily with the duration of treatment limited to 6 months.  No dose adjustment is needed for women with mild hepatic impairment (Child-Pugh A).', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6262, 0, 'Elagolix', 'Osteoporosis', 'Elagolix is contraindicated in women with known osteoporosis because of the risk of further bone loss.  Elagolix causes a dose-dependent decrease in bone mineral density (BMD), which is greater with increasing duration of use and may not be completely reversible after stopping treatment.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6263, 0, 'Elagolix', 'Mental Disorders', 'Suicidal ideation and behavior, has been reported in women treated with elagolix in the endometriosis clinical trials.  Women with a history of suicidality or depression had a higher incidence of depression compared to women without such a history.  Promptly evaluate patients with depressive symptoms to determine whether the risks of continued therapy outweigh the benefits.  Patients with new or worsening depression, anxiety or other mood changes should be referred to a mental health professional.  Advise patients to seek immediate medical attention for suicidal ideation and behavior.  Reevaluate the benefits and risks of continuing elagolix if such events occur.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6264, 0, 'Eluxadoline', 'Constipation', 'The use of eluxadoline is contraindicated in patients with history of chronic or severe constipation or sequelae from constipation, or known or suspected mechanical gastrointestinal obstruction.  These patients may be at risk for severe complications of bowel obstruction.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6265, 0, 'Eluxadoline', 'Pancreatitis', 'Pancreatitis, with or without sphincter of Oddi spasm has been reported in patients taking either the 75 mg or 100 mg dosage of eluxadoline, including serious cases resulting in hospitalization, primarily in patients without a gallbladder.  Fatal cases have also been reported.  The use of eluxadoline is contraindicated in patients without a gallbladder and in other patients at risk of pancreatitis such as patients with alcoholism, patients with known or suspected bile duct obstruction, history of pancreatitis or structural disease of the pancreas.  In patients with a gallbladder, the alcohol intake of the patient should be evaluated before starting treatment.  Patients should be monitored for any signs or symptoms suggestive of pancreatitis.  Patients should be instructed to stop treatment immediately and seek medical attention.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6266, 0, 'Eluxadoline', 'Hepatic Insufficiency', 'Eluxadoline is contraindicated in patients with severe hepatic impairment, as these patients are at risk for significantly increased plasma concentrations (16- fold), and there is no information to support the safety on these patients.  In patients with mild to moderate hepatic impairment the plasma concentrations are increased to a lesser extent.  It is recommended to decrease the dose to 75 mg twice a day on these patients and monitor regularly for impaired mental or physical abilities and for any other eluxadoline related adverse reactions.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6267, 0, 'Elvitegravir', 'Liver Diseases', 'The use of elvitegravir is not recommended for use in patients with severe hepatic impairment (Child-Pugh Class C).  No dosage adjustment is required in patients with mild (Child-Pugh Class A) or moderate (Child-Pugh Class B) hepatic impairment.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6268, 0, 'Elvitegravir', 'Kidney Diseases', 'The use of elvitegravir is not recommended in patients with severe renal impairment (estimated creatinine clearance below 30 mL per minute).  No dosage adjustment is recommended in patients with estimated creatinine clearance greater than or equal to 30 mL per minute.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6269, 0, 'Emtricitabine', 'Hepatitis B', 'Severe acute exacerbations of HBV have been reported in HBV-infected patients who have discontinued products containing emtricitabine and/or tenofovir disoproxil fumarate (DF) and may occur with discontinuation of tenofovir alafenamide-containing products.  It is recommended that all patients with HIV-1 infection be tested for the presence of chronic HBV before or when initiating products containing emtricitabine, tenofovir DF, or tenofovir alafenamide.  Hepatic function should be monitored closely with both clinical and laboratory follow-up for at least several months in HBV-infected patients who discontinue antihepatitis B therapy.  If appropriate, initiation or resumption of antihepatitis B therapy may be warranted, especially in patients with advanced liver disease or cirrhosis, since posttreatment exacerbation of hepatitis may lead to hepatic decompensation and liver failure.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6270, 0, 'Emtricitabine', 'Diseases requiring hemodialysis', 'Emtricitabine is removed by hemodialysis.  When started within 1.5 hours of emtricitabine dosing, about 30% of the dose was removed over a 3-hour hemodialysis session (blood flow rate of 400 mL/min and a dialysate flow rate of 600 mL/min).  If dosing on day of hemodialysis, emtricitabine should be administered after hemodialysis.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6271, 0, 'Emtricitabine', 'Kidney Diseases', 'Emtricitabine is primarily eliminated by the kidney.  Dosage adjustment of emtricitabine is recommended for patients with CrCl below 50 mL/min or in patients with ESRD requiring dialysis, in accordance with the manufacturer product information.  Clinical response to treatment and renal function should be closely monitored.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6272, 0, 'Emapalumab', 'Infections', 'Serious and sometimes fatal infections have been reported in patients receiving immunosuppressive agents.  Patients receiving immunosuppressants are at increased risk of developing bacterial, viral, fungal, and protozoal infections, and new or reactivated viral infections including opportunistic infections.  Caution should be exercised when considering their use in patients with severe or chronic infections.  It is recommended to interrupt therapy in patients who develop a new infection while undergoing treatment and to monitor these patients closely for any sign or symptom indicative of infection.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6273, 0, 'Empagliflozin', 'Kidney Diseases', 'The glucose lowering effects of sodium-glucose cotransporter 2 (SGLT2) inhibitors is decreased in patients with worsening renal function.  Additionally, patients with renal impairment function (eGFR less than 60 mL/min/1.73 m2) the elderly, and patients on loop diuretics may be more likely to experience adverse reactions related to volume depletion such as hypotension and acute kidney injury during therapy.  Renal function should be evaluated prior to treatment initiation and monitored regularly in at-risk patients.  Assess volume status and correct volume depletion before initiating therapy.  The use of SGLT-2 inhibitors in patients undergoing dialysis is contraindicated.  In both patients with and without type 2 diabetes, beneficial effects in chronic kidney disease and heart failure have been observed with SGLT2 inhibitor therapy.  The manufacturer''s product labeling should be consulted for indication specific renal dosing for SGLT2 inhibitors.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6274, 0, 'Empagliflozin', 'Hypotension', 'Sodium-glucose cotransporter 2 (SGLT-2) inhibitors cause intravascular volume contraction which may lead to symptomatic hypotension after treatment initiation especially in the elderly, in patients with impaired renal function, patients with low systolic blood pressure, or those using diuretics .  Volume status should be assessed and corrected before starting treatment and patients should be monitored during therapy.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6275, 0, 'Empagliflozin', 'Infections', 'An increase in the risk of genital mycotic infections has been reported with the use of a sodium-glucose cotransporter 2 (SGLT-2) inhibitors.  Care should be exercised when using this agent in patients who have a history of genital mycotic infections or who are uncircumcised as these patients are more likely to develop genital mycotic infections.  Monitor and treat appropriately.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6276, 0, 'Amifampridine', 'Seizures', 'Amifampridine is contraindicated in patients with a history of seizures.  Seizures have been observed in patients without a history of seizures at the recommended doses.  Seizures may be dose-dependent.  Consider discontinuation or dose-reduction in patients who have a seizure while on treatment.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6277, 0, 'Amifampridine', 'Liver Diseases', 'Amifampridine is extensively metabolized by N-acetyltransferase 2 (NAT2) and hepatic impairment may cause an increase in exposure.  The effects of amifampridine have not been studied in patients with hepatic impairment.  It is recommended to start treatment with amifampridine in patients with any degree of hepatic impairment at the lowest recommended starting dosage (15 mg/day) and monitor for adverse reactions.  Consider dosage modification or discontinuation in patients with hepatic impairment as clinically appropriate.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6278, 0, 'Amifampridine', 'Kidney Diseases', 'Renal clearance is an elimination pathway for amifampridine and the inactive metabolite, 3-N-acetyl amifampridine, and exposure of amifampridine is higher in subjects with renal impairment.  Patients with renal impairment should be initiated at the lowest recommended starting dosage (15 mg/day), and patients should be closely monitored for adverse reactions.  Consider dosage modification or discontinuation in patients with renal impairment as clinically appropriate.  Caution is recommended as the safety, efficacy, and pharmacokinetics of amifampridine have not been studied in patients with end-stage renal disease.  No dosage recommendation can be made for patients with end-stage renal disease.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6279, 0, 'Enalapril', 'Angioedema', 'The use of these agents is contraindicated in patients with hereditary angioedema or a history of idiopathic angioedema.  Patients with a history of angioedema unrelated to ACE inhibitors may be at increased risk of angioedema while receiving an ACE inhibitor.  Patients should be advised to immediately report any signs or symptoms suggestive of angioedema (swelling of face, extremities, eyes, lips, or tongue, or difficulty swallowing or breathing) and to stop taking the medication until otherwise directed by their physician.  Emergency therapy and/or measures to prevent airway obstruction are required for angioedema involving the tongue, glottis, or larynx.  Treatment with ACE inhibitors should be discontinued permanently if angioedema develops in association with therapy.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6280, 0, 'Enalapril', 'Bone Marrow Failure Disorders', 'ACE inhibitors may cause bone marrow suppression, rarely in uncomplicated individuals but more frequently in patients with renal impairment, especially if they also have a collagen-vascular disease such as systemic lupus erythematosus or scleroderma.  Neutropenia, agranulocytosis, aplastic anemia, hemolytic anemia, eosinophilia and thrombocytopenia have been reported, mostly with captopril.  Therapy with ACE inhibitors should be administered cautiously in patients with preexisting blood dyscrasias or complications that may increase the risk of bone marrow depression during ACE inhibitor therapy.  Monitoring of blood counts, particularly white blood cells, should be considered.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6281, 0, 'Enalapril', 'Heart Failure', 'ACE inhibitors can cause marked renal impairment in patients whose renal function depends on the activity of the renin-angiotensin-aldosterone system.  In addition, symptomatic and sometimes excessive hypotension can occur in susceptible individuals, particularly during the initiation of treatment, which may compromise renal and myocardial perfusion.  In patients with severe congestive heart failure (CHF), treatment with ACE inhibitors may be associated with oliguria and/or progressive azotemia and, rarely, renal failure, myocardial ischemia and death.  Therapy with ACE inhibitors should be initiated under very close medical supervision in patients with severe CHF, especially when accompanied by volume and/or sodium depletion.  Patients should be monitored closely for several hours after an initial dose until blood pressure has stabilized, and followed closely for the first 2 weeks of treatment and whenever the dosage of ACE inhibitor or diuretic is increased.  If feasible, the risk of severe hypotension may be minimized by reducing or temporarily withholding the dosing of diuretics and/or liberalizing dietary sodium intake for 2 to 3 days prior to starting ACE inhibitor therapy.  In patients who experience a worsening of renal function, discontinuation of ACE inhibitor therapy is usually not required provided there is symptomatic improvement of the heart failure and renal deterioration is well-tolerated.  Transient hypotension is also not a contraindication to further treatment with ACE inhibitors.  After blood pressure stabilizes, therapy can usually be reinstated with caution, although a lower dosage of the ACE inhibitor and/or dosage reduction or discontinuation of concomitantly administered diuretics may be necessary.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6282, 0, 'Enalapril', 'Diseases requiring hemodialysis', 'Anaphylactoid reactions have been reported in patients undergoing hemodialysis with high-flux polyacrylonitrile membranes and treated concomitantly with an ACE inhibitor.  The frequency and mechanism of this interaction have not been established, and it is not known whether the interaction occurs with other membrane types.  Therapy with ACE inhibitors should be administered cautiously in patients requiring hemodialysis.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6283, 0, 'Enalapril', 'Hyperkalemia', 'In patients with hyperkalemia, especially those associated with impaired renal function or congestive heart failure, ACE inhibitors may further raise serum potassium levels.  Therapy with ACE inhibitors should be administered cautiously in patients with or predisposed to hyperkalemia, and serum potassium levels should be carefully monitored.  Risk factors for the development of hyperkalemia during ACE inhibitor therapy include renal insufficiency, diabetes mellitus, and the concomitant use of potassium-sparing diuretics, potassium supplements, and/or potassium-containing salt substitutes.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6284, 0, 'Enalapril', 'Hypotension', 'ACE inhibitors can cause symptomatic hypotension, most often during the initiation of therapy and in patients who are volume- and/or sodium-depleted or treated for congestive heart failure (CHF).  Therapy with ACE inhibitors should be administered cautiously in such patients and in those predisposed to hypovolemic or hyponatremic states (e.g., patients on diuretic therapy, especially if it was recently instituted; those on dietary salt restriction; those with severe or prolonged diarrhea or vomiting; and renal dialysis patients).  Volume and/or sodium depletion should be corrected prior to initiating therapy with ACE inhibitors, and the patient should be hemodynamically stable.  If concomitant diuretics and/or dietary sodium restriction are employed, reducing or temporarily withholding the dosing of diuretics and/or liberalizing dietary sodium intake for 2 to 3 days in advance can help minimize the risk of severe hypotension in patients who are able to tolerate such adjustments.  ACE inhibitors should also be used cautiously in patients in whom excessive hypotension may have serious consequences, such as patients with coronary or cerebrovascular insufficiency.  Patients at risk for excessive hypotension should initiate ACE inhibitor therapy under very close medical supervision, and followed closely for the first 2 weeks of treatment and whenever the dosage of ACE inhibitor or diuretic is increased.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6285, 0, 'Enalapril', 'Liver Diseases', 'Rarely, elevations of liver enzymes and/or serum bilirubin have occurred with the use of ACE inhibitors.  Patients receiving ACE inhibitors who develop jaundice or marked elevations of hepatic enzymes should discontinue the ACE inhibitor and receive appropriate medical follow-up.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6286, 0, 'Enalapril', 'Kidney Diseases', 'With the exception of fosinopril, ACE inhibitors (and/or their active metabolites in some cases) are primarily eliminated by the kidney and may accumulate in patients with renal impairment.  ACE inhibitors can also worsen renal function in some patients by blocking the effect of angiotensin II-mediated efferent arteriolar vasoconstriction, thereby decreasing glomerular filtration.  Therapy with ACE inhibitors should be administered cautiously in patients with preexisting renal dysfunction, particularly those with renovascular disease.  Patients with moderate to severe renal impairment usually require lower or less frequent doses and smaller increments in dose.  In addition, a dosage reduction or discontinuation of any concomitantly administered diuretics may be helpful.  Fosinopril probably does not require dosage adjustments unless hepatic function is also significantly impaired.  
In patients with bilateral renal artery stenosis or renal artery stenosis in a solitary kidney, ACE inhibitors may reduce renal perfusion to a critically low level.  Renal function should be monitored closely for the first few weeks of therapy.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6287, 0, 'Enfortumab vedotin', 'Hepatic Insufficiency', 'Avoid the use of enfortumab vedotin in patients with moderate or severe hepatic impairment as it has not been studied in these patients.  No adjustment in the starting dose is required when treating patients with mild hepatic impairment.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6288, 0, 'Enfortumab vedotin', 'Hyperglycemia', 'Hyperglycemia occurred in patients treated with enfortumab vedotin, including death, and diabetic ketoacidosis (DKA) in those with and without preexisting-existing diabetes mellitus.  The incidence of Grade 3-4 hyperglycemia increased consistently in patients with higher body mass index and in patients with higher baseline A1C.  Closely monitor blood glucose levels in patients with, or at risk for, diabetes mellitus or hyperglycemia.  If blood glucose is elevated (>250 mg/dL), withhold treatment.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6289, 0, 'Enfortumab vedotin', 'Peripheral Nervous System Diseases', 'Peripheral neuropathy, predominantly sensory, occurred in 49% of the patients treated with enfortumab vedotin in clinical trials.  Peripheral neuropathy occurred in patients with or without preexisting peripheral neuropathy.  Monitor patients for symptoms of new or worsening peripheral neuropathy and consider dose interruption or dose reduction when peripheral neuropathy occurs.  Permanently discontinue treatment in patients that develop Grade >3 peripheral neuropathy.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6290, 0, 'Enasidenib', 'Hyperbilirubinemia', 'The use of enasidenib may interfere with bilirubin metabolism through inhibition of UGT1A1.  It is recommended to advise patients to report any changes to the color of their skin or the whites of their eyes to their healthcare provider for further evaluation.  Evaluate for signs and symptoms of jaundice to rule out any conditions that may cause hyperbilirubinemia.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6291, 0, 'Encorafenib', 'Hepatic Insufficiency', 'A recommended dose of encorafenib has not been established for patients with moderate (Child-Pugh Class B) or severe (Child-Pugh Class C) hepatic impairment.  Caution and monitoring is advised if used on these patients.  Dose adjustment for is not recommended in patients with mild hepatic impairment (Child-Pugh Class A).', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6292, 0, 'Encorafenib', 'Long QT Syndrome', 'Encorafenib is associated with dose-dependent QTc interval prolongation in some patients.  Monitor patients who already have or who are at significant risk of developing QTc prolongation, including patients with known long QT syndromes, clinically significant bradyarrhythmias, severe or uncontrolled heart failure and those taking other medicinal products associated with QT prolongation.  Correct hypokalemia and hypomagnesemia prior to and during therapy with encorafenib.  Withhold, reduce dose, or permanently discontinue for QTc > 500 ms.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6293, 0, 'Encorafenib', 'Kidney Diseases', 'A recommended dose of encorafenib has not been established for patients with severe renal impairment (CrCl < 30 mL/min).  Caution and monitoring is advised if used on these patients.  No dose adjustment is recommended for patients with mild to moderate renal impairment (CrCl 30 to < 90 mL/min).', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6294, 0, 'Entecavir', 'Liver Diseases', 'Hepatotoxicity including lactic acidosis, severe hepatomegaly with steatosis, fulminant hepatitis, and hepatic failure has been associated with the use of some nucleoside reverse transcriptase inhibitors (NRTIs) alone or in combination with other antiretroviral agents.  Therapy with NRTIs should be administered cautiously in patients with preexisting liver disease, a history of alcohol abuse, or hepatitis.  Therapy should be suspended if clinical or laboratory findings suggestive of lactic acidosis or pronounced hepatotoxicity occur.  The use of abacavir is contraindicated in patients with moderate to severe hepatic impairment as its safety and efficacy has not been established on these patients.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6295, 0, 'Entecavir', 'Diseases requiring hemodialysis', 'Entecavir is removed by hemodialysis.  Following a single 1 mg dose of entecavir administered two hours before the hemodialysis session, approximately 13% of the dose was removed over four hours of hemodialysis.  Entecavir should be administered after hemodialysis.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6296, 0, 'Entecavir', 'Kidney Diseases', 'Entecavir is primarily eliminated by the kidney.  Compared to patients with normal renal function (CrCl above 80 mL/min), peak plasma concentration (Cmax) and systemic exposure (AUC) of a single 1 mg dose of entecavir increased by 30% and 150%, respectively, in patients with moderate renal dysfunction (CrCl 30 to 49 mL/min), and 89% and 422%, respectively, in patients with severe renal dysfunction (CrCl below 30 mL/min).  Systemic exposure was increased even further in patients with end-stage renal disease managed on dialysis.  These patients had an approximately 8-fold increase in entecavir AUC compared to patients with normal renal function.  Renal clearance of entecavir decreased by 65% and 89%, respectively, in patients with moderate and severe renal dysfunction.  Dosage adjustment of entecavir is recommended for patients with CrCl below 50 mL/min, including patients on dialysis, in accordance with the manufacturer''s product labeling.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6297, 0, 'Enoxaparin', 'Hemophilia A', 'Anticoagulants should be given with extreme caution to patients with hemophilia or other congenital or acquired bleeding tendencies.  The risk of hemorrhage may be increased in these patients.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6298, 0, 'Enoxaparin', 'Liver Diseases', 'Anticoagulants should be given with extreme caution to patients at increased risk for hemorrhage, including patients who have severe liver disease with impaired hemostasis.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6299, 0, 'Enoxaparin', 'Peptic Ulcer', 'Anticoagulants are contraindicated in patients with active major bleeding or those patients at risk for hemorrhage.  Hemorrhage due to heparin derivatives may be treated with protamine sulfate 1%.  However, protamine sulfate may not completely neutralize the anti- Factor Xa activity.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6300, 0, 'Enoxaparin', 'Diabetic Retinopathy', 'The use of anticoagulants may increase the risk of bleeding in patients with hypertensive or diabetic retinopathy.  Therapy with anticoagulants should be administered with extreme caution in such patients.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6301, 0, 'Enoxaparin', 'Endocarditis, Subacute Bacterial', 'Anticoagulants should be given with extreme caution to patients with subacute bacterial endocarditis.  The risk of hemorrhage may be increased in these patients.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6302, 0, 'Enoxaparin', 'Hemorrhage', 'The use of heparin is contraindicated in patients with uncontrollable active bleeding, except when the bleeding is due to disseminated intravascular coagulation.  Hemorrhage can occur at virtually any site in patients receiving heparin.  An unexplained drop in hematocrit or blood pressure, or any other unexplained symptom, should lead to serious consideration of a hemorrhagic event.  Therapy with heparin should be used with extreme caution in patients with known bleeding disorders or disease states that may predispose to hemorrhage during heparin administration, including hemophilia, thrombocytopenia, certain vascular purpuras, ulcerative gastrointestinal lesions, diverticulitis, ulcerative colitis, severe liver disease, subacute bacterial endocarditis, severe hypertension, myeloproliferative disorders, and threatened abortion.  Blood coagulation tests (e.g., whole blood clotting time, activated partial thromboplastin time) should be performed at appropriate intervals during full-dose heparin administration.  In addition, periodic platelet counts, hematocrits, and tests for occult blood in stool are recommended during the entire course of heparin therapy.  There is usually no need to monitor coagulation parameters in patients receiving low-dose heparin, except in patients undergoing major surgery.  For low molecular weight heparin (LMWH), coagulation tests such as prothrombin time (PT) and aPTT are relatively insensitive measures of LMWH activity and not suitable for routine monitoring.  Anti-Factor Xa may be used to monitor the anticoagulant effect of LMWH in patients with significant renal impairment, abnormal coagulation parameters, or bleeding during therapy.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6303, 0, 'Enoxaparin', 'Hypertension', 'Heparin should be used with extreme caution in patients with uncontrolled or severe hypertension as these conditions may predispose the patient to hemorrhage during heparin administration.  Blood coagulation tests (e.g., whole blood clotting time, activated partial thromboplastin time) should be performed at appropriate intervals during full-dose heparin administration.  In addition, periodic platelet counts, hematocrits, and tests for occult blood in stool are recommended during the entire course of heparin therapy.  Clinical monitoring of blood pressure is recommended.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6304, 0, 'Enoxaparin', 'Kidney Diseases', 'Systemic exposure and the risk of bleeding may be increased when heparin is used in the presence of severe renal impairment.  Therapy with heparin should be administered cautiously in patients with significantly impaired renal function.  A reduction in dosage may be necessary.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6305, 0, 'Enoxaparin', 'Thrombocytopenia', 'The use of heparin is contraindicated in patients with severe thrombocytopenia.  Acute thrombocytopenia can occur in patients receiving heparin, with a reported incidence of up to 30%.  Platelet counts should be obtained before and periodically during heparin administration, including regular and repeated use of heparin flush solutions if given for longer than 5 days.  Mild thrombocytopenia with counts above 100,000/mm3 may remain stable or reverse despite continued heparin administration.  However, thrombocytopenia of any degree should be closely monitored.  Therapy should be discontinued if the count falls below 100,000/mm3 or if recurrent thrombosis develops, and an alternative, nonheparin anticoagulant (e.g., argatroban, bivalirudin, lepirudin) administered if necessary.  Heparin-induced thrombocytopenia (HIT) is a serious antibody-mediated reaction resulting from irreversible aggregation of platelets.  HIT may progress to the development of venous and arterial thromboses, a condition referred to as heparin-induced thrombocytopenia and thrombosis (HITT).  Thrombotic events may also be the initial presentation for HITT, and may include deep vein thrombosis, pulmonary embolism, cerebral vein thrombosis, limb ischemia, stroke, myocardial infarction, mesenteric thrombosis, renal artery thrombosis, skin necrosis, gangrene of the extremities that may lead to amputation, and possibly death.  Both HIT and HITT can occur up to several weeks after the discontinuation of heparin therapy.  Patients presenting with thrombocytopenia or thrombosis after discontinuation of heparin should be evaluated for HIT and HITT.  Following an episode, any future use of heparin should be avoided, and use of low-molecular weight heparin should consider the potential for cross-reactivity with the HIT antibody and approached with extreme caution, if not otherwise contraindicated.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6306, 0, 'Enoxaparin', 'Premature Birth', 'Some preparations (i.e., multiple-dose vials) of low molecular weight heparin (LMWH) contain benzyl alcohol as a preservative.  Benzyl alcohol in bacteriostatic saline intravascular flush and endotracheal tube lavage solutions has been associated with fatalities and severe respiratory and metabolic complications in low-birthweight premature infants.  Symptoms include a striking onset of gasping respiration, hypotension, bradycardia, and cardiovascular collapse.  The manufacturers recommend that use of these products be avoided in all neonates whenever possible.  Nevertheless, many experts feel that, in the absence of benzyl alcohol-free equivalents, the amount of the preservative present in these formulations should not necessarily preclude their use if they are clearly indicated.  The American Academy of Pediatrics considers benzyl alcohol in low doses (such as when used as a preservative in some medications) to be safe for newborns.  LMWHs are not approved for use in pediatric patients.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6307, 0, 'Amifostine', 'Dehydration', 'Patients who are dehydrated should not receive amifostine therapy and appropriate hydration prior to administration of amifostine is necessary.  Hypotensive episodes have occurred in 62% of patients receiving amifostine.  Amifosine reduces the cumulative renal toxicity associated with cisplatin therapy.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6308, 0, 'Amifostine', 'Hypotension', 'Patients who are hypotensive or in state of dehydration, or those that are unable to discontinue antihypertensive treatment 24 hours prior to amifostine administration should not receive amifostine.  Transient hypotensive episodes have occurred in 62% of patients receiving amifostine.  Three percent of patients required discontinuation of amifostine.  Therapy with amifostine should be administered cautiously in patients adversely affected by hypotensive effects such as cardiovascular conditions of arrhythmia, angina, or CHF or cerebrovascular conditions of or history of stroke or ischemic attacks.  Clinical monitoring of blood pressure is necessary.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6309, 0, 'Amifostine', 'Hypocalcemia', 'Hypocalcemic effects during amifostine therapy are rare, but appear to result from inhibition of parathyroid hormone secretion and bone resorption and from increased urinary calcium elimination.  Therapy with amifostine should be administered cautiously in patients with or predisposed to hypocalcemia, including hypoparathyroidism.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6310, 0, 'Entacapone', 'Hypotension', 'Dopamine agonists may impair the systemic regulation of blood pressure, with resultant orthostatic hypotension, especially during dose escalation.  Therapy with dopamine agonists should be monitored carefully in patients with Parkinson''s disease since they may have an impaired ability to respond to an orthostatic challenge, and also in patients receiving antihypertensive drugs.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6311, 0, 'Entacapone', 'Psychotic Disorders', 'Ordinarily, patients with major psychotic disorder should not be treated with dopaminergic antiparkinson agents, because of the risk of exacerbating psychosis.  Hallucinations and psychotic-like behavior have been reported with dopaminergic medications.  In addition, certain medications used to treat psychosis may exacerbate the symptoms of Parkinson''s disease and may decrease the effectiveness of these drugs.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6312, 0, 'Entacapone', 'Hepatic Insufficiency', 'Entacapone should be used with caution in patients with hepatic impairment, as the AUC and Cmax of the drug approximately doubled in patients with documented liver disease compared to patients with normal liver function.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6313, 0, 'Enzalutamide', 'Kidney Diseases', 'Enzalutamide has not been assessed in patients with severe renal impairment or end-stage renal disease.  Caution is advised if used on these patients.  No initial dosage adjustment is required on patients with mild to moderate renal impairment.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6314, 0, 'Enzalutamide', 'Seizures', 'Seizures occurred in 0.5% of patients receiving enzalutamide in clinical trials.  Patients with predisposing factors for seizures were generally excluded.  Caution is advised if using in patients with possible predisposing factors such as history of seizures, history of trauma or head injury, cerebrovascular accident or transient ischemic attack, Alzheimer''s disease, meningioma or brain tumor or infection, and any unexplained loss of consciousness in the past 12 months.  Enzalutamide should be discontinued permanently in any patient who develops a seizure during treatment.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6315, 0, 'Entrectinib', 'Heart Failure', 'The occurrence of congestive heart failure (CHF) was reported in 3.4% of the patients in clinical trials with entrectinib.  Assess left ventricular ejection fraction (LVEF) prior to initiation of entrectinib in patients with symptoms or known risk factors for CHF.  Monitor patients for clinical signs and symptoms of CHF, including shortness of breath and edema.  For patients with myocarditis, with or without a decreased ejection fraction, MRI or cardiac biopsy may be required to make the diagnosis.  For patients with new onset or worsening CHF, withhold treatment, institute appropriate medical management, and reassess LVEF.  Based on the severity of CHF or worsening LVEF, resume entrectinib at a reduced dose upon recovery to baseline or permanently discontinue.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6316, 0, 'Entrectinib', 'Liver Failure', 'Entrectinib has not been studied in patients with moderate (total bilirubin > 1.5 to 3 times ULN) and severe (total bilirubin > 3 times ULN) hepatic impairment, caution is advised.  No dose adjustment is recommended for patients with mild (total bilirubin = 1.5 times ULN) hepatic impairment.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6317, 0, 'Entrectinib', 'Long QT Syndrome', 'Entrectinib can prolong the QT interval.  Monitor patients who already have or who are at significant risk of developing QTc interval prolongation, including patients with known long QT syndromes, clinically significant bradyarrhythmias, severe or uncontrolled heart failure and those taking other medicinal products associated with QT prolongation.  Assess QT interval and electrolytes at baseline and periodically during treatment, adjusting frequency based upon risk factors such as congestive heart failure, electrolyte abnormalities, or concomitant medications.  Based on the severity of QTc interval prolongation, withhold entrectinib and then resume at same or reduced dose, or permanently discontinue.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6318, 0, 'Entrectinib', 'Kidney Diseases', 'Entrectinib has not been studied in patients with severe renal impairment (CrCl < 30 mL/min).  Caution is advised if used on these patients.  No dose adjustment is recommended for patients with mild or moderate renal impairment (CrCl 30 to < 90 mL/min).', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6319, 0, 'Epinephrine', 'Cardiovascular Diseases', 'Sympathomimetic agents may cause adverse cardiovascular effects, particularly when used in high dosages and/or in susceptible patients.  In cardiac tissues, these agents may produce positive chronotropic and inotropic effects via stimulation of beta- 1 adrenergic receptors.  Cardiac output, oxygen consumption, and the work of the heart may be increased.  In the peripheral vasculature, vasoconstriction may occur via stimulation of alpha-1 adrenergic receptors.  Palpitations, tachycardia, arrhythmia, hypertension, reflex bradycardia, coronary occlusion, cerebral vasculitis, myocardial infarction, cardiac arrest, and death have been reported.  Some of these agents, particularly ephedra alkaloids (ephedrine, ma huang, phenylpropanolamine), may also predispose patients to hemorrhagic and ischemic stroke.  Therapy with sympathomimetic agents should generally be avoided or administered cautiously in patients with sensitivity to sympathomimetic amines, hyperthyroidism, or underlying cardiovascular or cerebrovascular disorders.  These agents should not be used in patients with severe coronary artery disease or severe/uncontrolled hypertension.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6320, 0, 'Epinephrine', 'Dehydration', 'The use of sympathomimetic amines has been infrequently associated with significant hypotension especially in dehydrated patients secondary to the drug''s beta-2 mediated vasodilation.  Hypovolemia should be corrected, if possible, before administering sympathomimetic amines.  Blood pressure and ECG should be monitored at regular intervals.  Monitoring of cardiac output and pulmonary wedge pressure may also be desired.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6321, 0, 'Epinephrine', 'Parkinson Disease', 'Epinephrine should be administered with caution to patients with Parkinson''s disease as these patients may experience psychomotor agitation or notice a temporary worsening of symptoms.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6322, 0, 'Epinephrine', 'Acidosis', 'Acidosis, hypoxia, and hypercapnia may reduce the effectiveness of sympathomimetic amines in raising blood pressure.  These conditions should be corrected before initiating therapy with sympathomimetic amines, if possible.  Monitoring the patients acid-base balance, carbon dioxide levels, and oxygen saturation is recommended.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6323, 0, 'Epinephrine', 'Diabetes Mellitus', 'Sympathomimetic agents may cause increases in blood glucose concentrations.  These effects are usually transient and slight but may be significant with dosages higher than those normally recommended.  Therapy with sympathomimetic agents should be administered cautiously in patients with diabetes mellitus.  Closer monitoring of blood glucose concentrations may be appropriate.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6324, 0, 'Eptifibatide', 'Kidney Diseases', 'The use of eptifibatide is contraindicated in patients dependent of dialysis.  Approximately 50% of eptifibatide is cleared by the kidney in patients with normal renal function.  Total drug clearance is decreased by approximately 50% and steady-state plasma eptifibatide concentrations are doubled in patients with an estimated CrCl <50 mL/min.  Therefore, the infusion dose should be reduced to 1 mcg/kg/min in such patients Clinical monitoring of renal function is recommended.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6325, 0, 'Eptifibatide', 'Hemorrhagic Disorders', 'The use of gp11b/111a platelet inhibitors is contraindicated in patients with active internal bleeding, recent significant gastrointestinal or genitourinary bleeding (within 6 weeks), recent trauma or major surgery (within 6 weeks), history of bleeding diathesis, recent stroke (within 4 weeks), history of hemorrhage stroke or residual neurologic deficit, intracranial defect (aneurysm, arteriovenous malformation, neoplasm), uncontrolled hypertension (SBP > 180; DBP > 110), or thrombocytopenia (<100,000/mm3).  Thrombocytopenia, serious GI/GU bleeding, hemorrhagic retinopathy, and bleeding at the arterial access have been reported during gp11b/111a platelet inhibitor therapy.  Clinical monitoring of hemoglobin and hematocrit (H/H), platelet count, prothrombin time (PT) and activated partial prothrombin time (aPTT) is recommended prior to initiation of, during and following gp11b/111a platelet inhibitor therapy.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6326, 0, 'Epinephrine (ophthalmic)', 'Aphakia', 'Up to 30% of aphakic patients treated chronically with ophthalmic epinephrine (of which dipivefrin is a prodrug) may develop cystoid macular edema, which is generally reversible following withdrawal of the medication.  Ophthalmic epinephrine preparations should be administered cautiously with appropriate monitoring in patients with aphakia.  Therapy should be discontinued if blurred or distorted vision, central scotoma, and/or loss of visual acuity occur.  Slight visual impairment may respond to a reduction in the concentration or frequency of administration of the drug.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6327, 0, 'Epinephrine (ophthalmic)', 'Cardiovascular Diseases', 'Topically applied epinephrine is systemically absorbed, with the potential for producing clinically significant systemic effects.  In cardiac tissues, epinephrine produces positive chronotropic and inotropic effects via stimulation of beta-1 adrenergic receptors.  Cardiac output, oxygen consumption, and the work of the heart are increased.  In the peripheral vasculature, vasoconstriction may occur via stimulation of alpha-1 adrenergic receptors.  Palpitations, tachycardia, extrasystoles, arrhythmia and hypertension have been reported rarely during the use of ophthalmic epinephrine products, but may be more likely if the corneal epithelium is damaged or permeability is increased by tonometry, surgery, inflammation, or topical application of a local anesthetic.  Therapy with ophthalmic epinephrine should be administered cautiously in patients with corneal abrasion, sensitivity to sympathomimetic amines, hyperthyroidism or underlying cardiovascular or cerebrovascular disorders, especially coronary insufficiency, cardiac arrhythmia, or hypertension.  Dipivefrin, a prodrug of epinephrine, is associated with considerably fewer and milder local and systemic adverse effects and may be preferable in some of these patients.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6328, 0, 'Epinephrine (ophthalmic)', 'Glaucoma, Angle-Closure', 'The use of ophthalmic preparations of epinephrine, including dipivefrin (a prodrug of epinephrine), is contraindicated in patients with narrow-angle glaucoma or anatomically narrow angles.  These agents stimulate both alpha-1 and alpha-2 adrenergic receptors, thus topical administration can induce transient mydriasis, either with or without the use of concomitant miotic agents.  In patients with narrow angles, any degree of pupillary dilation can provoke an acute attack of angle-closure glaucoma.  In contrast, sympathomimetic agents with relative alpha-2 adrenergic selectivity such as apraclonidine and brimonidine produce little to no mydriasis at normally recommended dosages.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6329, 0, 'Epinephrine (ophthalmic)', 'Prostatic Hyperplasia', 'Topically applied epinephrine is systemically absorbed, with the potential for producing clinically significant systemic effects.  In patients with prostatic hypertrophy, urinary difficulty may develop or worsen due to smooth muscle contraction in the bladder neck via stimulation of alpha-1 adrenergic receptors.  Therapy with ophthalmic epinephrine products should be administered cautiously in patients with prostate enlargement.  Dipivefrin, a prodrug of epinephrine, is associated with considerably fewer and milder local and systemic adverse effects and may be preferable in some of these patients.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6330, 0, 'Epinephrine (ophthalmic)', 'Diabetes Mellitus', 'Topically applied sympathomimetic agents are systemically absorbed, particularly during prolonged or indiscriminate use.  Slight increases in blood glucose concentrations may occur with the use of these drugs.  Therapy with topical sympathomimetic agents should be administered cautiously in patients with diabetes mellitus.  Closer monitoring of blood glucose concentrations may be appropriate.  It is important that the recommended dosages of the individual products not be exceeded.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6331, 0, 'Erdafitinib', 'Hyperphosphatemia', 'Increases in phosphate levels are a pharmacodynamic effect of erdafitinib.  Hyperphosphatemia was reported as adverse reaction in 76% of patients after initiating treatment, with 32% requiring phosphate binders during treatment.  Caution and monitoring of phosphate levels is advised in all patients, especially in those at risk or hyperphosphatemia.  Follow the manufacturer''s dose modification guidelines if required.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6332, 0, 'Erdafitinib', 'Eye Diseases', 'Erdafitinib can cause ocular disorders, including central serous retinopathy/retinal pigment epithelial detachment (CSR/RPED) resulting in visual field defect.  Perform monthly ophthalmological examinations during the first 4 months of treatment and every 3 months afterwards, and urgently at any time for visual symptoms.  Ophthalmological examination should include assessment of visual acuity, slit lamp examination, fundoscopy, and optical coherence tomography.  Caution and close monitoring is advised in patients with retinal disorders.  Follow manufacturers dose modification guidelines in patients at risk or with ocular adverse reactions.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6333, 0, 'Erdafitinib', 'Liver Failure', 'The pharmacokinetics of erdafitinib in patients with severe renal impairment, renal impairment requiring dialysis, moderate or severe hepatic impairment is unknown.  Caution is advised if used in these patients.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6334, 0, 'Eplerenone', 'Diabetes Mellitus, Type 2', 'The use of eplerenone is contraindicated in patients with type II diabetes mellitus and microalbuminuria.  These patients are at increased risk of developing persistent hyperkalemia, which is the principal adverse effect of eplerenone and can lead to potentially life-threatening cardiac arrhythmias.  In a study of such patients treated with a 200 mg/day dose, the frequency of maximum serum potassium levels exceeding 5.5 mEq/L was 33% with eplerenone alone and 38% in combination with enalapril.  In other patient populations, the frequency has been reported at 1% for the 200 mg/day dose and 8.7% for the 400 mg/day dose.  Careful monitoring of serum potassium levels is necessary in patients treated with eplerenone who are at risk for the development of hyperkalemia, especially during initiation of therapy, after dosage adjustment, and during illness that could alter renal function.  In clinical trials, monitoring occurred every 2 weeks for the first 1 to 2 months, then monthly thereafter.  Eplerenone should be withdrawn immediately if hyperkalemia develops, and measures should be initiated to lower serum potassium if it exceeds 6.5 mEq/L.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6335, 0, 'Eplerenone', 'Hyperkalemia', 'The use of eplerenone is contraindicated in the presence of elevated serum potassium concentrations (> 5.5 mEq/L).  Eplerenone is a blocker of aldosterone binding at the mineralocorticoid receptor and can cause hyperkalemia, which may result in life-threatening cardiac arrhythmias.  Careful monitoring of serum potassium levels is necessary in patients who are at risk for the development of hyperkalemia (including those receiving concomitant ACE inhibitors or angiotensin II receptor antagonists), especially during initiation of therapy, after dosage adjustment, and during illness that could alter renal function.  In clinical trials, monitoring occurred every 2 weeks for the first 1 to 2 months, then monthly thereafter.  Eplerenone should be withdrawn immediately if hyperkalemia develops, and measures should be initiated to lower serum potassium if it exceeds 6.5 mEq/L.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6336, 0, 'Eplerenone', 'Kidney Diseases', 'The use of eplerenone is contraindicated in patients with renal impairment as defined by serum creatinine above 2.0 mg/dL for males or 1.8 mg/dL for females, or a creatinine clearance (CrCl) below 50 mL/min.  These patients are at increased risk of developing persistent hyperkalemia, which is the principal adverse effect of eplerenone and can lead to potentially life-threatening cardiac arrhythmias.  The incidence of hyperkalemia increases with decreasing renal function.  In clinical studies of eplerenone, serum potassium levels exceeding 5.5 mEq/L were observed in 10.4% of treated patients with baseline calculated CrCl less than 70 mL/min, 5.6% of patients with baseline CrCl 70 to 100 mL/min, and 2.6% of patients with baseline CrCl greater than 100 mL/min.  Careful monitoring of serum potassium levels is necessary in patients treated with eplerenone who are at risk for the development of hyperkalemia, especially during initiation of therapy, after dosage adjustment, and during illness that could alter renal function.  In clinical trials, monitoring occurred every 2 weeks for the first 1 to 2 months, then monthly thereafter.  Eplerenone should be withdrawn immediately if hyperkalemia develops, and measures should be initiated to lower serum potassium if it exceeds 6.5 mEq/L.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6337, 0, 'Eplerenone', 'Liver Diseases', 'Eplerenone is primarily metabolized by the liver.  In patients with moderate (Child-Pugh Class B) hepatic impairment given eplerenone 400 mg, the steady-state peak plasma concentration (Cmax) and systemic exposure (AUC) of eplerenone were increased by 3.6% and 42%, respectively, compared to those in normal subjects.  In 16 patients with mild to moderate hepatic impairment who received 400 mg of eplerenone, no elevations in serum potassium above 5.5 mmol/L were observed.  Their mean increase in serum potassium was 0.12 mEq/L compared to 0.13 mEq/L in normal controls.  No adjustment of the starting dosage is recommended for patients with mild to moderate hepatic impairment.  The use of eplerenone in patients with severe hepatic impairment has not been evaluated, thus caution is advised.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6338, 0, 'Epoprostenol', 'Heart Failure', 'The use of epoprostenol is contraindicated in patients with heart failure due to reduced severe left ventricular systolic dysfunction.  A large study involving such patients was terminated after an interim analysis revealed a higher mortality in the group receiving epoprostenol plus standard therapy than in the group receiving standard therapy alone.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6339, 0, 'Epoprostenol', 'Hemorrhage', 'Epoprostenol is a potent inhibitor of platelet aggregation.  Therefore, expect an increased risk for hemorrhagic complications, particularly for patients with other risk factors for bleeding.  Caution and close monitoring is advised.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6340, 0, 'Erlotinib', 'Stevens-Johnson Syndrome', 'Cutaneous reactions, in some cases severe, have been reported with the use of EGFR inhibitors.  Monitor patients who develop dermatologic or soft tissue toxicities while receiving these agents for the development of inflammatory or infectious sequelae.  It is recommended to withhold treatment, and appropriate measures should be instituted as appropriate or discontinue the use of these agents for dermatologic or soft tissue toxicity associated with severe or life-threatening inflammatory or infectious complications.  Advise patients to wear sunscreen and hats and limit sun exposure while receiving therapy with these agents as exposure to sunlight can exacerbate dermatologic toxicities.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6341, 0, 'Erlotinib', 'Gastrointestinal Diseases', 'The use of some EGFR inhibitors may be associated with gastrointestinal perforation and fatal cases have been reported.  Patients receiving concomitant anti-angiogenic agents, corticosteroids, NSAIDs, or taxane-based chemotherapy, or who have prior history of peptic ulceration or diverticular disease may be at increased risk of perforation.  Permanently discontinue these agents in patients who develop gastrointestinal perforation.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6342, 0, 'Erlotinib', 'Eye Diseases', 'Some epidermal growth factor receptor (EGFR) inhibitors should be administered cautiously in patients with ocular disorders such as primary keratitis, ulcerative keratitis, or conjunctivitis.  It is recommended to interrupt or discontinue treatment with these agents if patients present with acute or worsening ocular disorders.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6343, 0, 'Erlotinib', 'Lung Diseases', 'The use of certain EGFR inhibitors has been associated with pulmonary toxicity.  Serious cases of interstitial lung disease (ILD), including fatal cases and interstitial pneumonitis or pulmonary fibrosis have been reported.  Caution is recommended when using these agents in patients with a history of interstitial pneumonitis or pulmonary fibrosis or those patients presenting with acute onset of new or progressive unexplained pulmonary symptoms such as dyspnea, cough, and fever pending diagnostic evaluation.  If ILD is confirmed, permanently discontinue these agents and institute appropriate measures.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6344, 0, 'Erlotinib', 'Heart Failure', 'The use of erlotinib has been associated with hepatotoxicity with or without hepatic impairment including hepatic failure and hepatorenal syndrome, in some cases with fatal outcomes.  Patients with hepatic impairment (total bilirubin > upper limit of normal (ULN) or Child-Pugh A, B and C) should be closely monitored during therapy with erlotinib.  Treatment with erlotinib should be used with extra caution in patients with total bilirubin > 3 x ULN.  Clinical monitoring of hepatic function (transaminases, bilirubin, and alkaline phosphatase) is recommended during treatment and increase frequency of monitoring is required for patients with preexisting-existing hepatic impairment or biliary obstruction.  In patients with preexisting-existing hepatic impairment or biliary obstruction with doubling of bilirubin or tripling of transaminases values over baseline, erlotinib therapy should be withhold and therapy should be discontinued in patients whose abnormal liver tests meeting the above criteria do not improve significantly or resolve within three weeks.  Withhold erlotinib in patients developing severe renal impairment until renal toxicity is resolved.  Monitor renal function and electrolytes, particularly in patients at risk of dehydration.  Withhold erlotinib for severe renal toxicity.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6345, 0, 'Eribulin', 'Infections', 'Because of their cytotoxic effects on rapidly proliferating tissues, antineoplastic agents frequently can, to varying extent, induce myelosuppression.  The use of these drugs may be contraindicated in patients with known infectious diseases.  All patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection during antineoplastic therapy.  Close clinical monitoring of hematopoietic function is recommended.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6346, 0, 'Eribulin', 'Pancytopenia', 'Adverse hematologic effects including neutropenia, and febrile neutropenia (fever >=38.5C with Grade 3 or 4 neutropenia) have been associated with the use of eribulin.  It is recommended to monitor complete blood counts prior to each dose and increase the frequency of monitoring in patients who develop Grade 3 or 4 cytopenias.  Delay administration of therapy and reduce subsequent doses in patients who experience febrile neutropenia or Grade 4 neutropenia lasting longer than 7 days.  Do not administer therapy on Day 1 or Day 8 if ANC < 1,000/mm3, platelets < 75,000/mm3, or grade 3 or 4 non-hematological toxicities.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6347, 0, 'Eribulin', 'Hepatic Insufficiency', 'Pharmacokinetics studies to evaluate the effect of hepatic impairment in patients treated with eribulin demonstrated that patients with mild hepatic impairment (Child-Pugh A) and moderate hepatic impairment (Child-Pugh B) had higher eribulin exposures as compared to patients with normal hepatic function.  It is recommended to reduce the starting dose of eribulin in patients with mild or moderate hepatic impairment according to the manufacturer recommendations.  Eribulin has not been studied in patients with severe hepatic impairment (Child-Pugh C).  Caution and close monitoring should be taken.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6348, 0, 'Eribulin', 'Peripheral Nervous System Diseases', 'In clinical trials, eribulin caused peripheral neuropathy.  Monitor patients closely for signs of peripheral motor and sensory neuropathy.  It is recommended to withhold treatment in patients who experience Grade 3 or 4 peripheral neuropathy, until resolution to Grade 2 or less.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6349, 0, 'Eribulin', 'Long QT Syndrome', 'In clinical trials, eribulin has caused QT prolongation independent of concentration.  Close monitoring should be exercised in patients with congestive heart failure, bradyarrhythmias, those taking drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics, and electrolyte abnormalities.  It is recommended to correct hypokalemia or hypomagnesemia prior to starting therapy and monitor these electrolytes periodically during therapy.  Avoid in patients with congenital long QT syndrome.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6350, 0, 'Eribulin', 'Kidney Diseases', 'Pharmacokinetics studies to evaluate the effect of renal impairment in patients treated with eribulin demonstrated that patients with moderate and severe renal impairment had higher eribulin dose-normalized exposures compared to that in patients with normal renal function.  It is recommended to reduce the starting dose of eribulin in patients with moderate or severe renal impairment (CrCL 15-49 mL/min) according to the manufacturer recommendations.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6351, 0, 'Ergotamine', 'Cardiotoxicity', 'The amine ergot alkaloids, ergonovine and methylergonovine, can cause serious cardiovascular complications because of their vasospastic effects.  Hypertension (more often with ergonovine) has been most commonly reported, particularly when administered IV undiluted or at an excessive rate or when used in conjunction with regional anesthesia or vasoconstrictors.  Headaches, seizures, cerebrovascular accidents and death have been associated with the hypertensive episodes.  Other, less common adverse effects include acute myocardial infarction, transient chest pains, thrombophlebitis, tachycardia and palpitations.  Therapy with ergot alkaloids should generally be avoided, except under special circumstances, in patients with chronic hypertension, preeclampsia or eclampsia, cardiovascular disease, cerebrovascular disease, or peripheral vascular disease.  Caution is advised when these agents are administered to patients with venoatrial shunts, mitral valve stenosis, or sepsis.  Close monitoring of cardiovascular status is highly recommended during therapy.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6352, 0, 'Ergotamine', 'Coronary Vasospasm', 'The use of ergot alkaloids is contraindicated in patients with conditions predisposing them to vasospastic reactions, including, ischemic heart disease (angina, history of myocardial infarction, silent ischemia), peripheral vascular disease, sepsis, shock, vascular surgery, uncontrolled hypertension, and severely impaired hepatic or renal function.  The vasoconstriction produced be ergot alkaloids may exacerbate these conditions.  Ergot alkaloids may cause vasospastic reactions other than coronary artery vasospasm such as peripheral vascular reactions, and colonic ischemia, causing muscle pains, numbness, coldness, pallor, and cyanosis of the digits.  In patients with compromised circulation, persistent vasospasm may result in gangrene or death.  Nitroprusside and heparin have been used to treat ergotamine- induced severe vasoconstriction.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6353, 0, 'Ergoloid mesylate', 'Cardiotoxicity', 'The amine ergot alkaloids, ergonovine and methylergonovine, can cause serious cardiovascular complications because of their vasospastic effects.  Hypertension (more often with ergonovine) has been most commonly reported, particularly when administered IV undiluted or at an excessive rate or when used in conjunction with regional anesthesia or vasoconstrictors.  Headaches, seizures, cerebrovascular accidents and death have been associated with the hypertensive episodes.  Other, less common adverse effects include acute myocardial infarction, transient chest pains, thrombophlebitis, tachycardia and palpitations.  Therapy with ergot alkaloids should generally be avoided, except under special circumstances, in patients with chronic hypertension, preeclampsia or eclampsia, cardiovascular disease, cerebrovascular disease, or peripheral vascular disease.  Caution is advised when these agents are administered to patients with venoatrial shunts, mitral valve stenosis, or sepsis.  Close monitoring of cardiovascular status is highly recommended during therapy.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6354, 0, 'Ergoloid mesylate', 'Psychotic Disorders', 'The use of ergoloid mesylates is contraindicated in patients with acute or chronic psychosis, regardless of etiology.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6355, 0, 'Amikacin', 'Dehydration', 'Adequate hydration is crucial to minimize the risk of oto- and nephrotoxicity associated with the use of aminoglycosides.  Dehydration should preferably be corrected prior to initiation of therapy.  In patients who may be at risk for dehydration, such as those with severe and/or prolonged diarrhea or vomiting, fluid status should be monitored closely.  If signs of renal irritation develop during therapy, hydration should be increased as indicated, accompanied by a reduction in dosage if necessary.  Therapy should be withdrawn if urinary output decreases progressively or azotemia increases.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6356, 0, 'Amikacin', 'Neuromuscular Diseases', 'Aminoglycosides can cause dose-related neuromuscular blockade and muscle weakness, particularly in patients with neuromuscular disease or hypocalcemia and in patients receiving general anesthetics, neuromuscular blocking agents, or massive transfusions of citrate-anticoagulated blood.  Although aminoglycoside- induced neuromuscular blockade is generally self-limiting, it may rarely result in respiratory paralysis.  Neomycin is thought to be the most potent neuromuscular blocking agent in the class.  However, the risk is greatest with intraperitoneal or intrapleural instillation of large doses or rapid intravenous administration of parenteral aminoglycosides.  Therapy with aminoglycosides should be administered cautiously in patients with neuromuscular disorders (e.g., myasthenia gravis, parkinsonian syndrome, botulism) or hypocalcemia.  If signs of respiratory paralysis occur during aminoglycoside therapy, the drug should be discontinued and mechanical respiratory assistance provided if necessary.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6357, 0, 'Amikacin', 'Ototoxicity', 'Aminoglycosides can cause eighth cranial nerve damage, resulting in vestibular and/or auditory toxicities.  Symptoms include dizziness, nystagmus, vertigo, ataxia, tinnitus, and varying degrees of hearing impairment.  Permanent hearing loss may occur, including, rarely, total or partial irreversible bilateral deafness after the drug has been discontinued.  Therapy with aminoglycosides, particularly if prolonged (> 10 days), should be administered cautiously in patients with preexisting vestibular and/or auditory impairment, since it may delay the recognition or confound the diagnosis of a drug-induced ototoxic effect.  To minimize the risk of toxicity, patients should be adequately hydrated, the usual aminoglycoside dosage should not be exceeded, use with other ototoxic agents should be avoided, and peak and trough serum aminoglycoside concentrations should be periodically determined and dosage adjusted to maintain desired levels.  Serial audiograms should be obtained in patients old enough to be tested, since loss of high- frequency perception usually precedes clinical hearing loss.  The dosage should be reduced or therapy withdrawn promptly if signs and symptoms of toxicity develop.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6358, 0, 'Amikacin', 'Kidney Diseases', 'Aminoglycosides are potentially oto- and nephrotoxic.  Eighth cranial nerve damage may manifest as vestibular and/or auditory toxicities, including dizziness, nystagmus, vertigo, ataxia, tinnitus, and varying degrees of hearing impairment.  Nephrotoxicity is usually evidenced by tubular necrosis; increases in BUN, nonprotein nitrogen, and serum creatinine concentration; decreases in urine specific gravity and creatinine clearance; proteinuria; and cells or casts in the urine.  Rarely, renal electrolyte wasting may occur, resulting in hypocalcemia, hypomagnesemia, and hypokalemia that may be associated with paresthesia, tetany, confusion, and positive Chvostek and Trousseau signs.  Although aminoglycoside- induced nephrotoxicity is generally reversible following discontinuation of the drug, death from uremia has occurred rarely.  Therapy with aminoglycosides should be administered cautiously at reduced dosages in patients with renal impairment, since they may be at increased risk for oto- and nephrotoxicity due to drug accumulation.  To minimize the risk of toxicity, patients should be adequately hydrated, the usual aminoglycoside dosage should not be exceeded, use with other neuro- and nephrotoxic agents should be avoided, and peak and trough serum aminoglycoside concentrations should be periodically determined and dosage adjusted to maintain desired levels.  Renal and eighth cranial nerve function should be closely monitored, and the dosage reduced or therapy withdrawn if toxicity develops.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6359, 0, 'Ertapenem', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6360, 0, 'Ertapenem', 'Kidney Diseases', 'Carbapenems are primarily eliminated by the kidney.  Patients with renal impairment may be at greater risk for adverse effects from carbapenems, including seizures and other central nervous system disturbances, due to decreased drug clearance.  Dosage adjustments should be considered, with modifications based on degree of renal impairment and severity of infection in accordance with the individual product package labeling.  Renal function tests should be performed periodically during therapy.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6361, 0, 'Ertapenem', 'Central Nervous System Diseases', 'The intravenous use of carbapenems has been associated with central nervous system adverse effects such as seizures (up to 1.5%) and, less frequently, somnolence, encephalopathy, myoclonus, tremor, paresthesia, confusion, agitation, depression, and hallucinations.  Therapy with carbapenems, regardless of route of administration, should be administered cautiously in patients with or predisposed to seizures or other neurologic disturbances.  The normally recommended dosages should not be exceeded in such patients.  In those with a known seizure disorder, anticonvulsant therapy should be continued during carbapenem therapy.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6362, 0, 'Ertapenem', 'Diseases requiring hemodialysis', 'Ertapenem is partially removed by hemodialysis.  If the recommended daily dose of 500 mg is administered within 6 hours prior to hemodialysis, a supplementary dose of 150 mg is recommended following the dialysis session.  If given at least 6 hours prior to hemodialysis, no supplementary dose is needed.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6363, 0, 'Ertapenem', 'Heart Failure', 'Parenteral ertapenem contains approximately 137 mg (6.0 mEq) of sodium per each gram of ertapenem activity.  The sodium content should be considered in patients with conditions that may require sodium restriction, such as congestive heart failure, hypertension, and fluid retention.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6364, 0, 'Ergocalciferol', 'Cardiotoxicity', 'The amine ergot alkaloids, ergonovine and methylergonovine, can cause serious cardiovascular complications because of their vasospastic effects.  Hypertension (more often with ergonovine) has been most commonly reported, particularly when administered IV undiluted or at an excessive rate or when used in conjunction with regional anesthesia or vasoconstrictors.  Headaches, seizures, cerebrovascular accidents and death have been associated with the hypertensive episodes.  Other, less common adverse effects include acute myocardial infarction, transient chest pains, thrombophlebitis, tachycardia and palpitations.  Therapy with ergot alkaloids should generally be avoided, except under special circumstances, in patients with chronic hypertension, preeclampsia or eclampsia, cardiovascular disease, cerebrovascular disease, or peripheral vascular disease.  Caution is advised when these agents are administered to patients with venoatrial shunts, mitral valve stenosis, or sepsis.  Close monitoring of cardiovascular status is highly recommended during therapy.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6365, 0, 'Ergocalciferol', 'Arrhythmias, Cardiac', 'Vitamin D analogs function to increase serum calcium concentrations and can exacerbate arrhythmias, particularly in patients receiving cardiac glycosides.  Therapy with vitamin D analogs should be administered cautiously in patients with or predisposed to cardiac arrhythmias.  Clinical monitoring of serum electrolyte concentrations and cardiac function is recommended.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6366, 0, 'Ergocalciferol', 'Water-Electrolyte Imbalance', 'Vitamin D analogs administered in the presence of hyperphosphatemia can result in precipitation of calcium-phosphate deposits within the vascular or  renal systems or other soft tissue calcifications.  A solubility product (Serum Calcium X Phosphate) should not exceed 70.  Serum electrolyte concentrations should be corrected prior to vitamin D analog therapy and monitored during therapy.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6367, 0, 'Ergocalciferol', 'Hypercalcemia', 'Vitamin D analogs such as calciferol and ergocalciferol should not be given to patients with hypercalcemia, malabsorption syndrome, or evidence of vitamin D toxicity.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6368, 0, 'Ergocalciferol', 'Kidney Diseases', 'Ergocalciferol, cholecalciferol, and calcifediol undergo renal biotransformation during metabolic activation.  Renal impairment can alter metabolic and therapeutic activity of certain vitamin D analogs.  Alternative vitamin D analogs such as dihydrotachysterol (hepatic activation) and calcitriol (active form) may be considered in patients with compromised renal function.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6369, 0, 'Ergocalciferol', 'Liver Diseases', 'Vitamin D analogs are fat soluble and oral formulations require bile for adequate intestinal absorption.  Hepatic and/or biliary dysfunction decrease the absorption of vitamin D analogs.  Metabolites of vitamin D analogs are primarily excreted in bile and feces.  Ergocalciferol, cholecalciferol, and dihydrotachysterol undergo hepatic hydroxylation during metabolic activation.  Hepatic impairment can alter the metabolic and therapeutic activity of certain vitamin D analogs.  Alternative vitamin D analogs such as calcifediol (requires renal activation) and calcitriol (active form) may be considered in patients with compromised hepatic function.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6370, 0, 'Eprosartan', 'Diabetes Mellitus', 'The coadministration of some angiotensin II receptor blocker agents with aliskiren is contraindicated in patients with diabetes.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6371, 0, 'Eprosartan', 'Angioedema', 'The use of these agents is contraindicated in patients with a history of angioedema related to previous angiotensin-converting enzyme (ACE) inhibitor or angiotensin II receptor blocker (ARB) therapy or in patients with hereditary angioedema.  Patients with a history of angioedema unrelated to these agents may be at increased risk of angioedema while receiving angiotensin II receptor (AR) antagonists.  Patients should be advised to immediately report any signs or symptoms suggestive of angioedema (swelling of face, extremities, eyes, lips, or tongue, or difficulty swallowing or breathing) and to stop taking the medication until otherwise directed by their physician.  Emergency therapy and/or measures to prevent airway obstruction are required for angioedema involving the tongue, glottis, or larynx.  Treatment with angiotensin II receptor (AR) antagonists should be discontinued permanently if angioedema develops in association with therapy.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6372, 0, 'Eprosartan', 'Hypotension', 'Angiotensin II receptor (AR) antagonists can cause symptomatic hypotension in patients with an activated renin-angiotensin system, such as volume- and/or sodium-depleted patients.  Therapy with AR antagonists should be administered cautiously in such patients and in those predisposed to hypovolemic or hyponatremic states (e.g., patients on diuretic therapy, especially if high doses were used or if recently instituted; those on dietary salt restriction; renal dialysis patients).  Volume and/or sodium depletion should be corrected prior to initiating therapy with AR antagonists, and the patient should be hemodynamically stable.  Ideally, patients at risk for excessive hypotension should initiate AR antagonist therapy under close medical supervision, preferably with a lower dose, and followed closely for the first 2 weeks of treatment and whenever the dosage of AR antagonist or diuretic is increased.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6373, 0, 'Eprosartan', 'Heart Failure', 'Angiotensin II receptor (AR) antagonists can cause renal impairment in patients whose renal function depends on the activity of the renin-angiotensin-aldosterone system.  In addition, symptomatic hypotension can occur in susceptible individuals, which may compromise renal and myocardial perfusion.  In patients with severe congestive heart failure (CHF), treatment with AR antagonists has been associated with oliguria and/or progressive azotemia and, rarely, renal failure, myocardial ischemia, and death.  Therapy with AR antagonists should be initiated cautiously in patients with severe CHF, especially when accompanied by volume and/or sodium depletion.  In patients who experience a decline in renal function, discontinuation of AR antagonist therapy is usually not required provided there is symptomatic improvement of the heart failure and renal deterioration is well-tolerated.  Transient hypotension is also not a contraindication to further treatment with AR antagonists, since therapy can usually be reinstated without difficulty after blood pressure stabilizes.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6374, 0, 'Eprosartan', 'Hyperkalemia', 'Drugs that inhibit the renin-angiotensin, such as angiotensin II receptor antagonist system can cause hyperkalemia.  Concomitant use of these agents with drugs that increase potassium levels may increase the risk of hyperkalemia.  Use caution when using these agents together and monitor serum potassium periodically.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6375, 0, 'Eprosartan', 'Renal Artery Obstruction', 'In patients with bilateral renal artery stenosis or renal artery stenosis in a solitary kidney, angiotensin II receptor (AR) antagonists may reduce renal perfusion to a critically low level.  Increases in serum creatinine or blood urea nitrogen have been reported with ACE inhibitors, a class of drugs that also block the renin-angiotensin-aldosterone system.  Although there are no long-term data on the use of AR antagonists in patients with renal artery stenosis, a similar effect should be anticipated.  Renal function should be monitored closely for the first few weeks of therapy.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6376, 0, 'Eprosartan', 'Kidney Diseases', 'Changes in renal function including acute renal failure can be caused by drugs that inhibit the renin-angiotensin system and by diuretics.  Patients whose renal function may depend in part on the activity of the renin-angiotensin system (e.g., patients with renal artery stenosis, chronic kidney disease, severe congestive heart failure, or volume depletion) may be at particular risk of developing acute renal failure with these agents.  Monitor renal function periodically in these patients.  Consider withholding or discontinuing therapy in patients who develop a clinically significant decrease in renal function with these agents.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6377, 0, 'Eprosartan', 'Liver Diseases', 'Eprosartan is partially metabolized by the liver, and both parent drug and metabolites are eliminated by biliary excretion (90%) as well as by the kidney (7%).  Dosage adjustments are not necessary in patients with mild renal impairment unless they are also volume-depleted, in which case therapy should be initiated under medical supervision.  Likewise, patients with mild hepatic impairment or biliary obstruction generally do not require a dosage adjustment.  However, reduced dosages may be appropriate in patients with severe renal, liver, and/or biliary disease, since the clearance may be decreased and unbound drug increased in these states.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6378, 0, 'Epirubicin', 'Heart Diseases', 'The use of epirubicin is contraindicated in patients with severe myocardial insufficiency, recent myocardial infarction, and severe arrhythmias.  Myocardial toxicity, manifested in its most severe form by potentially fatal congestive heart failure (CHF), may occur either during therapy with epirubicin or months to years after termination of therapy.  Risk factors may increase the risk of cardiac toxicity.  Cardiac toxicity with epirubicin may occur at lower cumulative doses whether or not cardiac risk factors are present, so extreme caution is advised.  Initial treatment with epirubicin should be preceded by a careful baseline assessment of cardiac function as measured by left ventricular ejection function (LVEF).  Close cardiac monitoring during treatment is suggested.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6379, 0, 'Epirubicin', 'Liver Diseases', 'Patients with severe hepatic dysfunction should not be treated with epirubicin.  The major route of elimination of epirubicin is the hepatobiliary system.  Serum total bilirubin and AST levels should be evaluated before and during treatment with epirubicin.  Patients with elevated bilirubin or AST may experience slower clearance of drug with an increase in overall toxicity.  Lower doses are recommended in these patients.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6380, 0, 'Epirubicin', 'Neutropenia', 'Patients should not be treated with epirubicin if they have a baseline neutrophil count < 1500 cells/mm3.  A dose-dependent, reversible leukopenia and/or neutropenia is the predominant manifestation of hematologic toxicity associated with epirubicin and represents the most common acute dose-limiting toxicity of this drug.  Myelosuppression requires careful monitoring.  Total and differential WBC, red blood cell (RBC), and platelet counts should be assessed before and during each cycle of therapy with epirubicin.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6381, 0, 'Epirubicin', 'Bone Marrow Failure Disorders', 'Before beginning treatment with epirubicin, patients should recover from any acute toxicities, such as stomatitis, neutropenia, thrombocytopenia, and generalized infections, of prior cytotoxic treatment.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6382, 0, 'Epirubicin', 'Kidney Diseases', 'Serum creatinine should be assessed before and during therapy with epirubicin.  Dosage adjustment is necessary in patients with serum creatinine >5 mg/dL.  Patients undergoing dialysis have not been studied.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6383, 0, 'Ertugliflozin', 'Liver Diseases', 'Sodium-glucose cotransporter 2 (SGLT2) inhibitors ertugliflozin and canagliflozin are not recommended for use in patients with severe hepatic impairment due to lack of clinical data.  Dapagliflozin has not been studied in patients with severe hepatic impairment and caution is recommended.  Dosage adjustments are not necessary in patients with mild or moderate hepatic impairment.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6384, 0, 'Ertugliflozin', 'Kidney Diseases', 'The glucose lowering effects of sodium-glucose cotransporter 2 (SGLT2) inhibitors is decreased in patients with worsening renal function.  Additionally, patients with renal impairment function (eGFR less than 60 mL/min/1.73 m2) the elderly, and patients on loop diuretics may be more likely to experience adverse reactions related to volume depletion such as hypotension and acute kidney injury during therapy.  Renal function should be evaluated prior to treatment initiation and monitored regularly in at-risk patients.  Assess volume status and correct volume depletion before initiating therapy.  The use of SGLT-2 inhibitors in patients undergoing dialysis is contraindicated.  In both patients with and without type 2 diabetes, beneficial effects in chronic kidney disease and heart failure have been observed with SGLT2 inhibitor therapy.  The manufacturer''s product labeling should be consulted for indication specific renal dosing for SGLT2 inhibitors.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6385, 0, 'Ertugliflozin', 'Hypotension', 'Sodium-glucose cotransporter 2 (SGLT-2) inhibitors cause intravascular volume contraction which may lead to symptomatic hypotension after treatment initiation especially in the elderly, in patients with impaired renal function, patients with low systolic blood pressure, or those using diuretics .  Volume status should be assessed and corrected before starting treatment and patients should be monitored during therapy.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6386, 0, 'Ertugliflozin', 'Infections', 'An increase in the risk of genital mycotic infections has been reported with the use of a sodium-glucose cotransporter 2 (SGLT-2) inhibitors.  Care should be exercised when using this agent in patients who have a history of genital mycotic infections or who are uncircumcised as these patients are more likely to develop genital mycotic infections.  Monitor and treat appropriately.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6387, 0, 'Amikacin (liposome)', 'Neuromuscular Diseases', 'Aminoglycosides can cause dose-related neuromuscular blockade and muscle weakness, particularly in patients with neuromuscular disease or hypocalcemia and in patients receiving general anesthetics, neuromuscular blocking agents, or massive transfusions of citrate-anticoagulated blood.  Although aminoglycoside- induced neuromuscular blockade is generally self-limiting, it may rarely result in respiratory paralysis.  Neomycin is thought to be the most potent neuromuscular blocking agent in the class.  However, the risk is greatest with intraperitoneal or intrapleural instillation of large doses or rapid intravenous administration of parenteral aminoglycosides.  Therapy with aminoglycosides should be administered cautiously in patients with neuromuscular disorders (e.g., myasthenia gravis, parkinsonian syndrome, botulism) or hypocalcemia.  If signs of respiratory paralysis occur during aminoglycoside therapy, the drug should be discontinued and mechanical respiratory assistance provided if necessary.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6388, 0, 'Amikacin (liposome)', 'Ototoxicity', 'Aminoglycosides can cause eighth cranial nerve damage, resulting in vestibular and/or auditory toxicities.  Symptoms include dizziness, nystagmus, vertigo, ataxia, tinnitus, and varying degrees of hearing impairment.  Permanent hearing loss may occur, including, rarely, total or partial irreversible bilateral deafness after the drug has been discontinued.  Therapy with aminoglycosides, particularly if prolonged (> 10 days), should be administered cautiously in patients with preexisting vestibular and/or auditory impairment, since it may delay the recognition or confound the diagnosis of a drug-induced ototoxic effect.  To minimize the risk of toxicity, patients should be adequately hydrated, the usual aminoglycoside dosage should not be exceeded, use with other ototoxic agents should be avoided, and peak and trough serum aminoglycoside concentrations should be periodically determined and dosage adjusted to maintain desired levels.  Serial audiograms should be obtained in patients old enough to be tested, since loss of high- frequency perception usually precedes clinical hearing loss.  The dosage should be reduced or therapy withdrawn promptly if signs and symptoms of toxicity develop.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6389, 0, 'Amikacin (liposome)', 'Kidney Diseases', 'Aminoglycosides are potentially oto- and nephrotoxic.  Eighth cranial nerve damage may manifest as vestibular and/or auditory toxicities, including dizziness, nystagmus, vertigo, ataxia, tinnitus, and varying degrees of hearing impairment.  Nephrotoxicity is usually evidenced by tubular necrosis; increases in BUN, nonprotein nitrogen, and serum creatinine concentration; decreases in urine specific gravity and creatinine clearance; proteinuria; and cells or casts in the urine.  Rarely, renal electrolyte wasting may occur, resulting in hypocalcemia, hypomagnesemia, and hypokalemia that may be associated with paresthesia, tetany, confusion, and positive Chvostek and Trousseau signs.  Although aminoglycoside- induced nephrotoxicity is generally reversible following discontinuation of the drug, death from uremia has occurred rarely.  Therapy with aminoglycosides should be administered cautiously at reduced dosages in patients with renal impairment, since they may be at increased risk for oto- and nephrotoxicity due to drug accumulation.  To minimize the risk of toxicity, patients should be adequately hydrated, the usual aminoglycoside dosage should not be exceeded, use with other neuro- and nephrotoxic agents should be avoided, and peak and trough serum aminoglycoside concentrations should be periodically determined and dosage adjusted to maintain desired levels.  Renal and eighth cranial nerve function should be closely monitored, and the dosage reduced or therapy withdrawn if toxicity develops.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6390, 0, 'Amikacin (liposome)', 'Lung Diseases', 'Higher frequency of exacerbations of underlying pulmonary disease has been reported with amikacin liposome treatment.  Monitor closely patients with pulmonary impairment and treat as medically appropriate if this occurs during treatment with amikacin liposome.  Pre- treatment with short-acting selective beta- 2 agonists should be considered for patients with known hyperreactive airway disease, chronic obstructive pulmonary disease, asthma, or bronchospasm.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6391, 0, 'Escitalopram', 'Depressive Disorder', 'Adult and pediatric patients with depression and other psychiatric disorders may experience worsening of their symptoms and may have the emergence of suicidal thoughts and behavior.  Patients should be monitored appropriately and observed closely for worsening of their symptoms, suicidality or changes in their behavior, especially during the first few months of treatment, and at times of dose changes.  Families and caregivers should be advised of the need for close observation and communication with the treating physician.  Discontinuing the medication should be considered if symptoms are persistently worse, or abrupt in onset.  It may be prudent to refrain from dispensing large quantities of medication to these patients.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6392, 0, 'Escitalopram', 'Kidney Diseases', 'Citalopram (racemic) and escitalopram (the more pharmacologically active S-enantiomer) are extensively metabolized and only small amounts are excreted unchanged in the urine.  No dosage adjustments are necessary in patients with mild to moderate renal impairment, as the oral clearance of citalopram has been shown to decrease only modestly (17%) in these patients compared to those with normal renal function.  There is no information on the pharmacokinetics of citalopram or escitalopram in patients with severe renal impairment (CrCl < 20 mL/min).  Therapy with these agents should be administered cautiously in such patients.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6393, 0, 'Escitalopram', 'Hyponatremia', 'Treatment with SSRI antidepressants can cause hyponatremia.  Caution should be used when treating patients with hyponatremia or at greater risk of hyponatremia such as the elderly, patients taking diuretics or who are volume depleted.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6394, 0, 'Escitalopram', 'Liver Diseases', 'Selective serotonin reuptake inhibitors (SSRIs) are primarily metabolized by the liver.  The plasma concentrations of SSRIs and their metabolites may be increased and the half-lives prolonged in patients with impaired hepatic function.  Dosage adjustments may be necessary in accordance with the individual product package labeling.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6395, 0, 'Escitalopram', 'Mania', 'Selective serotonin reuptake inhibitors (SSRIs), like other antidepressants, may occasionally cause or activate mania or hypomania.  The reported incidence ranged from 0.1% to 2% in premarketing testing of several SSRIs.  Patients with bipolar disorder are generally more likely to experience mania from antidepressants.  Therapy with SSRIs should be administered cautiously in patients with a history of mania or bipolar disorder.  Prior to initiating treatment, it is recommended to adequately screen patients for bipolar disorder, including a family history of suicide, bipolar disorder, and depression.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6396, 0, 'Escitalopram', 'Blood Platelet Disorders', 'The use of selective serotonin reuptake inhibitors (SSRIs) has been associated with altered platelet function.  Petechiae, purpura, ecchymosis, increased bleeding times, epistaxis and gastrointestinal hemorrhage have been reported.  Therapy with SSRIs should be administered cautiously in patients with severe active bleeding or a hemorrhagic diathesis.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6397, 0, 'Escitalopram', 'Epilepsy', 'Selective serotonin reuptake inhibitors (SSRIs) may trigger seizures in approximately 0.2% of patients, and some of them are not recommended in patients with unstable epilepsy.  Therapy with SSRIs should be administered cautiously in patients with seizure disorders.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6398, 0, 'Escitalopram', 'Inappropriate ADH Syndrome', 'The use of selective serotonin reuptake inhibitors (SSRIs) has rarely been associated with hyponatremia, sometimes secondary to development of the syndrome of inappropriate secretion of antidiuretic hormone (SIADH).  These events have generally been reversible following discontinuation of SSRI therapy and/or medical intervention.  SSRI-related hyponatremia may be more common in elderly female patients and those who are volume-depleted or receiving concomitant diuretic therapy.  Caution may be warranted when SSRI therapy is administered in these patients and patients with preexisting hyponatremia or SIADH.  Serum electrolytes, especially sodium as well as BUN and plasma creatinine, should be monitored regularly.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6399, 0, 'Escitalopram', 'Weight Loss', 'The use of selective serotonin reuptake inhibitors (SSRIs) may occasionally cause significant weight loss, which may be undesirable in patients suffering from anorexia, malnutrition or excessive weight loss.  Anorexia may occur in approximately 5% to 10% of patients.  Weight change should be monitored during therapy if an SSRI is used in these patients.', '1', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6400, 0, 'Erythropoietin', 'Seizures', 'The use of erythropoiesis stimulating agents increases the risk of seizures in patients with chronic renal failure.  Seizure development may be related to the rate of rise in hematocrit, which is also associated with blood pressure elevations.  It is recommended to monitor patients closely for the development of premonitory neurologic symptoms during the first several months after the administration of these agents.  Patients with epilepsy or predisposed to seizures should be monitored closely for blood pressure changes and neurologic symptoms during therapy with these agents.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6401, 0, 'Erythropoietin', 'Diseases requiring hemodialysis', 'The increase in hematocrit and decrease in plasma volume associated with erythropoiesis-stimulating agents therapy may, theoretically, affect dialysis efficiency.  Patients may require adjustments in their dialysis prescription after initiation of erythropoiesis stimulating agents.  During hemodialysis, patients may require increased anticoagulation with heparin to prevent clotting.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6402, 0, 'Erythropoietin', 'Hypertension', 'The use of erythropoiesis-stimulating agents is contraindicated in patients with uncontrolled hypertension.  These agents may cause blood pressure to rise.  Hypertensive encephalopathy and seizures have been observed in patients with chronic renal failure treated with these agents.  Blood pressure should be adequately controlled prior to initiation of therapy, and monitored closely during treatment.  Aggressive antihypertensive measures may be necessary, particularly early on in treatment when the hematocrit is increasing.  It is recommended to reduce or withhold the use of these agents if blood pressure becomes difficult to control.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6403, 0, 'Erythropoietin', 'Thromboembolism', 'The use of erythropoiesis-stimulating agents may be associated with an increased risk of thrombotic events and mortality.  During clinical trials, an increased risk was observed in:  1) patients with chronic renal failure (CRF) and ischemic heart disease or congestive heart failure targeted to a maintenance hematocrit of 42%, and 2) in patients without CRF undergoing coronary artery bypass surgery.  Although a causal relationship has not been established, therapy with these agents should be administered cautiously in patients with preexisting cardiovascular disease and/or a history of thrombotic events.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6404, 0, 'Erythropoietin', 'Porphyrias', 'The use of epoetin alfa has rarely been associated with exacerbation of porphyria in patients with chronic renal failure.  In healthy volunteers, however, epoetin alfa has not been shown to cause increased urinary excretion of porphyrin metabolites.  Nevertheless, therapy with epoetin alfa should be administered cautiously in patients with porphyria.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6405, 0, 'Esketamine', 'Hypertension', 'Esketamine causes an increase in systolic and/or diastolic blood pressure at all recommended doses.  The increase peaks approximately 40 minutes after administration of esketamine, and lasts for about 4 hours.  Blood pressure should be monitored prior and after administration.  If baseline blood pressure is elevated before administering (e.g., >140 mmHg systolic, >90 mmHg diastolic), consider the risks of short term increases in blood pressure and benefit of treatment in patients with treatment- resistant depression (TRD).  Do not administer esketamine if an increase in blood pressure or intracranial pressure poses a serious risk.  Esketamine is contraindicated in patients with aneurysmal vascular disease (including thoracic and abdominal aorta, intracranial, and peripheral arterial vessels), arteriovenous malformations, or a history of intracerebral hemorrhage.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6406, 0, 'Esketamine', 'Psychotic Disorders', 'Esketamine can cause dissociative or perceptual changes (including distortion of time, space and illusions), derealization and depersonalization.  Patients with psychosis must be carefully assessed before administering esketamine, and treatment should be initiated only if the benefit outweighs the risk.  Patients must be monitored by a healthcare provider for at least 2 hours at each treatment session, followed by an assessment to determine when the patient is considered clinically stable and ready to leave the healthcare setting.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6407, 0, 'Esketamine', 'Substance-Related Disorders', 'Esketamine, is a Schedule III controlled substance (CIII), and may be subject to abuse and diversion.  Assess each patient''s risk for abuse or misuse prior to prescribing esketamine and monitor all patients receiving treatment for the development of these behaviors or conditions, including drug- seeking behavior, while on therapy.  Individuals with a history of drug abuse or dependence are at greater risk; therefore, use careful consideration prior to treatment of individuals with a history of substance use disorder and monitor for signs of abuse or dependence.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6408, 0, 'Esketamine', 'Hepatic Insufficiency', 'Esketamine has not been studied in patients with severe hepatic impairment (Child-Pugh class C).  Use in this population is not recommended.  Additionally, the mean esketamine AUC and t1/2 values were higher in patients with moderate hepatic impairment compared to those with normal hepatic function.  Patients with moderate hepatic impairment may need to be monitored for adverse reactions for a longer period of time.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6409, 0, 'Esomeprazole', 'Clostridium Infections', 'Published observational studies suggest that proton pump inhibitor (PPI) use may be associated with an increased risk of Clostridium difficile-associated diarrhea (CDAD), especially in hospitalized patients.  This diagnosis should be considered for diarrhea that does not improve.  It is recommended that patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated.  Close monitoring is recommended in patients with diarrhea and in those taking antibacterial agents as CDAD has been reported with the use of nearly all these agents.  Treatment with antibacterial agents alters the normal flora of the colon, leading to overgrowth of C.  difficile.  C.  difficile produces toxins A and B, which contribute to the development of CDAD.  Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C.  difficile, and surgical evaluation should be instituted as clinically indicated.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6410, 0, 'Esomeprazole', 'Liver Diseases', 'Esomeprazole is primarily metabolized by the liver.  In patients with mild to moderate hepatic impairment (Child Pugh Class A and B), little drug accumulation has been observed following once-daily, multiple-dose administration.  No dosage adjustments are necessary in these patients.  In severe hepatic impairment (Child Pugh Class C), however, substantial increases in plasma drug concentrations have been demonstrated.  The manufacturer recommends a maximum dosage of 20 mg once daily in patients with severe liver disease.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6411, 0, 'Esomeprazole', 'Fractures, Bone', 'Various published observational studies have reported that PPI therapy may be associated with an increased risk for osteoporosis related fractures of the hip, wrist or spine.  The risk was increased in patients who received high doses (multiple daily doses), and long term treatment (a year or longer).  Patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated.  Caution should be used in patients at risk for osteoporosis related fractures and should be managed according to established treatment guidelines.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6412, 0, 'Esomeprazole', 'Hypomagnesemia 1, Intestinal', 'Symptomatic and asymptomatic hypomagnesemia has been reported rarely in patients treated with PPIs for at least 3 months, in most cases after a year of therapy.  Serious adverse events can include tetany, seizures, and arrhythmias.  Caution should be used in patients prone to magnesium imbalances such as patients taking other medications that can cause hypomagnesemia (e.g., diuretics).  Regular monitoring is recommended.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6413, 0, 'Esterified estrogens', 'Uterine Hemorrhage', 'The use of estrogens is contraindicated in patients with undiagnosed, abnormal vaginal bleeding.  Prolonged (> 1 year), unopposed estrogen use (i.e. estrogen without concomitant progestin therapy) has been associated with a significant, dose-related risk of endometrial carcinoma.  The risk may be offset substantially by the addition of a progestin but may not be completely abolished.  Prior to initiating estrogen therapy, appropriate diagnostic tests should be performed in patients with abnormal vaginal bleeding to rule out endometrial malignancy.  The same applies if recurrent or persistent bleeding develops during estrogen therapy.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6414, 0, 'Esterified estrogens', 'Breast Neoplasms', 'The use of estrogens is generally contraindicated in patients with known or suspected estrogen-dependent neoplasia such as breast and endometrial cancer, since it may stimulate tumor proliferation.  High dosages of estrogens may be used for the palliative treatment of inoperable, metastatic breast cancer, but only in appropriately selected men and postmenopausal women.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6415, 0, 'Esterified estrogens', 'Hypertension', 'The risk of myocardial infarction and strokes, including those associated with oral contraceptive use and some estrogen use, is increased in patients with hypertension.  Moreover, estrogens (and progestogens) may elevate blood pressure and worsen the hypertension, thus compounding the risk.  Clinically significant blood pressure increases have been reported during estrogen therapy, particularly in patients receiving high dosages or treated with oral contraceptive combinations having high progestational activity.  These effects also increase with duration of therapy and patient age.  Therapy with estrogens should be administered cautiously in patients with preexisting hypertension.  Patients should be monitored for changes in cardiovascular status, and their antihypertensive regimen adjusted or estrogen therapy withdrawn as necessary.  In patients requiring contraception, alternative methods should be considered for those who are hypertensive, over age 35, and smoke.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6416, 0, 'Esterified estrogens', 'Thromboembolism', 'The use of estrogens is considered by manufacturers and some authorities to be contraindicated in patients with active thrombotic or thromboembolic disorders.  The use of estrogen-containing oral contraceptives is additionally deemed contraindicated in patients with a history of such disorders and/or current cerebrovascular or coronary artery disease.  Females with a history of migraines with aura are at an increased risk for stroke and this stroke risk may be further increased in females who have migraines with aura with use of combination oral contraceptives.  Hypercoagulability and changes in various clotting factors and blood components have been observed in women receiving estrogen therapy.  Although the clinical significance of these effects is unknown, epidemiological data suggest it may be dose-dependent.  The risk is probably slight with the use of newer, low-dose oral contraceptives in the absence of known risk factors (e.g., smoker, particularly over the age of 35; hypertension; hyperlipidemia; obesity; diabetes; age over 40).  However, a much more significant risk has been reported with higher dosages, such as those used to treat prostate or metastatic breast cancer or those used in older formulations of birth control pills.  Therapy with estrogens should be administered cautiously in the lowest effective dosage and only after careful consideration of risks and benefits.  Estrogens should be avoided in patients with a history of thrombotic and thromboembolic disorders associated with estrogen use, except when used in the treatment of breast or prostatic malignancy.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6417, 0, 'Esterified estrogens', 'Liver Neoplasms', 'The use of oral contraceptives is contraindicated in patients with liver tumors.  An increased risk of benign hepatic adenomas and hepatocellular carcinomas has been associated with long-term, oral estrogen- progestin contraceptive use of at least 4 years and 8 years, respectively.  Although these tumors are rare and have not been reported with other types of estrogen or progestogen therapies, any preparation containing estrogens and/or progestogens should probably be avoided in patients with existing tumors of the liver.  Hepatic hemangiomas and nodular hyperplasia of the liver have been reported with isolated estrogen therapy.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6418, 0, 'Esterified estrogens', 'Angioedema', 'The use of exogenous estrogens may induce or exacerbate symptoms of angioedema, particularly in women with hereditary angioedema.  Close monitoring is recommended when prescribing these agents to patients predisposed to angioedema.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6419, 0, 'Esterified estrogens', 'Gallbladder Diseases', 'A two- to four-fold increase in risk of gallbladder disease has been noted in women receiving postmenopausal estrogen therapy.  The risk for gallbladder disease may be less for premenopausal women using oral contraceptives containing low-dose estrogens and/or progestins.  Therapy with estrogens should be administered cautiously in patients with preexisting gallbladder disease.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6420, 0, 'Esterified estrogens', 'Hypercalcemia', 'Estrogens influence the metabolism of calcium and phosphorus.  Intestinal absorption and retention of calcium are increased, which may occasionally result in hypercalcemia.  Therapy with estrogens should be administered cautiously in patients with preexisting hypercalcemia, renal dysfunction, or metabolic bone diseases that are associated with hypercalcemia.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6421, 0, 'Esterified estrogens', 'Hyperlipidemias', 'Although estrogens have generally favorable effects on plasma lipids, including increases in HDL and decreases in total cholesterol and LDL, they have also been associated with significant elevations in triglyceride levels, particularly when high dosages are used.  Severe hyperlipidemia is known to sometimes cause pancreatitis.  Patients with preexisting hyperlipidemia may require closer monitoring during estrogen therapy, and adjustments made accordingly in their lipid-lowering regimen.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6422, 0, 'Esterified estrogens', 'Liver Diseases', 'Estrogens are primarily metabolized by the liver.  Patients with impaired hepatic function may be at increased risk for adverse effects associated with estrogen administration due to decreased drug clearance.  Therapy with estrogens should be administered cautiously in patients with liver disease.  In addition, clinicians should be aware that estrogen therapy may affect liver function tests.  Increased sulfobromophthalein retention has been reported with the use of estrogen-containing oral contraceptives and may be expected with larger doses of estrogens.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6423, 0, 'Esterified estrogens', 'Melanosis', 'The use of exogenous estrogens may occasionally cause chloasma, especially in women with a history of chloasma gravidarum.  Women with a tendency to chloasma should avoid exposure to the sun or ultraviolet radiation while taking combination oral contraceptives.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6424, 0, 'Esterified estrogens', 'Depressive Disorder', 'The use of oral contraceptives has been associated with an increased incidence of depression.  It is uncertain whether this effect is related to the estrogenic or the progestogenic component of the contraceptive, although excess progesterone activity is associated with depression.  Patients with a history of depression receiving estrogen and/or progestogen therapy should be followed closely.  The manufacturer of medroxyprogesterone recommends monitoring patients who have a history of depression and to not re- administer medroxyprogesterone if depression recurs.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6425, 0, 'Esterified estrogens', 'Water-Electrolyte Imbalance', 'Estrogens and progestogens may cause fluid retention, particularly when given in high dosages or for prolonged periods.  Therapy with these agents should be administered cautiously in patients who have preexisting problems with excess fluid.  In addition, patients with conditions that may be adversely affected by fluid accumulation, such as asthma, epilepsy, migraine, and cardiovascular or renal dysfunction, should be observed for exacerbation of their condition during estrogen and/or progestogen therapy.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6426, 0, 'Esterified estrogens', 'Glucose Intolerance', 'Impaired glucose tolerance has been observed in some patients administered oral contraceptives and appears to be related primarily to the estrogen dose.  However, progestogens can increase insulin secretion and produce insulin resistance to varying degrees, depending on the agent.  Patients with diabetes mellitus should be monitored more closely during therapy with estrogens and/or progestogens, and adjustments made accordingly in their antidiabetic regimen.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6427, 0, 'Esterified estrogens', 'Eye Diseases', 'Estrogens and progestogens may cause retinal thrombosis.  Oral contraceptives should be discontinued if there is unexplained partial or complete loss of vision; onset of proptosis or diplopia; papilledema; or retinal vascular lesions.  Therapy with these agents should be administered cautiously in patients who have preexisting ocular problems and appropriate diagnostic and therapeutic measures should be instituted.  Contact lens wearers who develop visual changes or changes in lens tolerance should be assessed by an ophthalmologist.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6428, 0, 'Esterified estrogens', 'Thyroid Diseases', 'When administering estrogen and/or progestogen therapy in patients with thyroid disorders, clinicians should be aware that these hormones may affect thyroid function tests.  Changes have mostly been reported with the use of combination oral contraceptives.  Specifically, thyroid-binding globulin (TBG) may be increased, resulting in elevated circulating total thyroid hormone, as measured by PBI (protein-bound iodine), T4 by column or radioimmunoassay, or T3 by radioimmunoassay.  Free T3 resin uptake may be decreased.  On the contrary, a decrease in TBG and, consequently, thyroxine concentration, has been reported by the manufacturers of the progestin-only (norethindrone) oral contraceptives.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6429, 0, 'Eslicarbazepine', 'Depressive Disorder', 'Antiepileptic drugs can increase depression and suicidal thoughts or behaviors in patients receiving these drugs for any indication.  Patients should be monitored for the emergence or worsening of depression, suicidal thoughts and unusual changes in mood or behavior.  Caregivers and family should be alert for the emergence or worsening of symptoms.  Behaviors of concern should be reported immediately to the healthcare providers.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6430, 0, 'Eslicarbazepine', 'Liver Diseases', 'Most anticonvulsants are primarily metabolized by the liver.  Metabolic activity may be decreased in patients with liver disease, resulting in elevated drug levels and increased risk of toxicity.  Therapy with anticonvulsants should be administered cautiously in patients with mild and moderate liver impairment.  Therapy with these drugs is mostly not recommended in patients with severe liver impairment.  Caution is also advised when treating patients with a history of liver disease, since the use of some anticonvulsants has been associated with hepatotoxicity.  Baseline and periodic evaluation of liver function is recommended.  Therapy should be discontinued and not readministered if evidence of liver damage is observed and felt to be drug-related.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6431, 0, 'Eslicarbazepine', 'Kidney Diseases', 'Most anticonvulsants are primarily excreted by the kidney.  The plasma clearance may be decreased and the half-life prolonged in patients with impaired renal function.  Therapy with anticonvulsants should be administered cautiously in patients with significant renal dysfunction.  In most cases it is recommended to adjust the dosage in patients with CrCl <50 mL/min to half the usual starting dose and then increase slowly to achieve the desired clinical response.  The renal function should be monitored regularly in patients receiving therapy.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6432, 0, 'Eslicarbazepine', 'Hyponatremia', 'Some anticonvulsants can cause clinically significant hyponatremia (Na < 125 mmol/L).  Therapy with these drugs should be administered cautiously in patients with conditions predisposing to hyponatremia, such as SIADH, use of diuretics or drugs associated with inappropriate antidiuretic hormone secretion, adrenal insufficiency, hypothyroidism, primary polydipsia, and edema (e.g., due to liver cirrhosis, congestive heart failure, or nephrotic syndrome).  Serum sodium levels should be monitored during maintenance therapy, and patients should be monitored for signs and symptoms possibly indicating hyponatremia such as nausea, malaise, headache, lethargy, confusion, obtundation, and increase in seizure frequency or severity.  If hyponatremia occurs, conservative measures such as fluid restriction, a reduction in dosage, or discontinuation of therapy will usually suffice.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6433, 0, 'Eslicarbazepine', 'Thyroid Diseases', 'Dose-dependant decreases in thyroid function tests (serum T3 and T4) have been observed in patients taking eslicarbazepine.  These changes were not associated with other abnormal thyroid function tests suggesting hypothyroidism.  Abnormal thyroid function should be evaluated and clinicians should be cognizant of these effects when prescribing or administering eslicarbazepine therapy to patients with thyroid disorders.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6434, 0, 'Estazolam', 'Alcoholic Intoxication', 'The use of benzodiazepines with alcohol is not recommended.  Patients with acute alcohol intoxication exhibit depressed vital signs.  The central nervous system depressant effects of benzodiazepines may be additive with those of alcohol, and severe respiratory depression and death may occur.  Therapy with benzodiazepines should be administered cautiously in patients who might be prone to acute alcohol intake.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6435, 0, 'Estazolam', 'Glaucoma, Angle-Closure', 'The manufacturers consider the use of benzodiazepines to be contraindicated in patients with acute angle-closure glaucoma or untreated open-angle glaucoma.  These agents do not possess anticholinergic activity but have very rarely been associated with increased intraocular pressure.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6436, 0, 'Estazolam', 'Substance-Related Disorders', 'Benzodiazepines have the potential to cause dependence and abuse.  Tolerance as well as physical and psychological dependence can develop, particularly after prolonged use and/or excessive dosages.  However, abrupt cessation following continual use of as few as 6 weeks at therapeutic levels has occasionally precipitated withdrawal symptoms.  Addiction- prone individuals, such as those with a history of alcohol or substance abuse, should be under careful surveillance when treated with benzodiazepines.  It may be prudent to refrain from dispensing large quantities of medication to these patients.  After prolonged use or if dependency is suspected, withdrawal of benzodiazepine therapy should be undertaken gradually using a dosage- tapering schedule.  If withdrawal symptoms occur, temporary reinstitution of benzodiazepines may be necessary.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6437, 0, 'Estazolam', 'Liver Diseases', 'Benzodiazepines are metabolized by the liver, and the metabolites are excreted in the urine.  Chlordiazepoxide, clorazepate, diazepam, flurazepam and quazepam undergo oxidative N-dealkylation to active metabolites that are substantially longer-acting than the parent compound.  These metabolites then undergo further biotransformation to pharmacologically inactive products before excretion by the kidney.  Therapy with benzodiazepines should be administered cautiously at lower initial dosages in patients with impaired renal and/or hepatic function.  Agents that are converted to weakly active, short-acting, or inactive metabolites may be preferable in hepatic impairment.  Lorazepam, oxazepam and temazepam are conjugated to inactive metabolites, while alprazolam, estazolam and triazolam undergo hydroxylation to weakly active or inactive metabolites.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6438, 0, 'Estazolam', 'Respiratory Insufficiency', 'Benzodiazepines may cause respiratory depression and apnea, usually when given in high dosages and/or by intravenous administration.  However, some patients may be susceptible at commonly used dosages, including the elderly, debilitated or severely ill patients, those receiving other CNS depressants, and those with limited ventilatory reserve, chronic pulmonary insufficiency or other respiratory disorders.  Therapy with benzodiazepines should be administered cautiously in these patients.  Appropriate monitoring and individualization of dosage are particularly important, and equipment for resuscitation should be immediately available if the parenteral route is used.  Benzodiazepines, especially injectable formulations, should generally be avoided in patients with sleep apnea, severe respiratory insufficiency, or hypoxia.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6439, 0, 'Estazolam', 'Seizures', 'The use of benzodiazepines in patients with seizure disorders may increase the incidence or precipitate the onset of generalized tonic-clonic seizures (grand mal).  Appropriate anticonvulsant medication might need to be initiated or the dosage increased.  Abrupt cessation of benzodiazepine therapy may precipitate seizures and other withdrawal symptoms, particularly after prolonged use and/or excessive dosages.  Status epilepticus may occur in patients with a history of seizures withdrawn rapidly from benzodiazepine therapy.  Following chronic administration, cessation of benzodiazepine therapy should occur gradually with incrementally reduced dosages.  Patients should be advised not to discontinue medication without first consulting with the physician.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6440, 0, 'Estazolam', 'Depressive Disorder', 'Benzodiazepines depress the central nervous system and may cause or exacerbate mental depression and cause suicidal behavior and ideation.  Episodes of mania and hypomania have also been reported in depressed patients treated with some of these agents.  Therapy with benzodiazepines should be administered cautiously in patients with a history of depression or other psychiatric disorders.  Patients should be monitored for any changes in mood or behavior.  It may be prudent to refrain from dispensing large quantities of medication to these patients.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6441, 0, 'Estazolam', 'Obesity', 'The plasma half-lives of benzodiazepines may be prolonged in obese patients, presumably due to increased distribution into fat.  Marked increases in distribution (> 100%) have been reported for diazepam and midazolam, and moderate increases (25% to 100%) for alprazolam, lorazepam, and oxazepam.  Therapy with benzodiazepines should be administered cautiously in obese patients, with careful monitoring of CNS status.  Longer dosing intervals may be appropriate.  When dosing by weight, loading doses should be based on actual body weight, while maintenance dose should be based on ideal body weight to avoid toxicity.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6442, 0, 'Estazolam', 'Psychotic Disorders', 'Paradoxical reactions, including excitability, irritability, aggressive behavior, agitation, nervousness, hostility, anxiety, sleep disturbances, nightmares and vivid dreams, have been reported with the use of benzodiazepines in psychiatric patients and pediatric patients with hyperactive aggressive disorders.  Such patients should be monitored for signs of paradoxical stimulation during therapy with benzodiazepines.  The manufacturers do not recommend the use of benzodiazepines for the treatment of psychosis.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6443, 0, 'Esmolol', 'Atrioventricular Block', 'The use of beta-adrenergic receptor blocking agents (aka beta-blockers) is contraindicated in patients with sinus bradyarrhythmia or heart block greater than the first degree (unless a functioning pacemaker is present).  Due to their negative inotropic and chronotropic effects on the heart, the use of beta-blockers is likely to exacerbate these conditions.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6444, 0, 'Esmolol', 'Shock, Cardiogenic', 'The use of beta-adrenergic receptor blocking agents (aka beta-blockers) is contraindicated in patients with hypotension or cardiogenic shock.  Due to their negative inotropic and chronotropic effects on the heart, the use of beta-blockers is likely to further depress cardiac output and blood pressure, which can be detrimental in these patients.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6445, 0, 'Esmolol', 'Heart Failure', 'Beta-adrenergic receptor blocking agents (aka beta-blockers) in general should not be used in patients with overt congestive heart failure (CHF).  Sympathetic stimulation may be important in maintaining the hemodynamic function in these patients, thus beta-blockade can worsen the heart failure.  However, therapy with beta-blockers may be beneficial and can be administered cautiously in some CHF patients provided they are well compensated and receiving digitalis, diuretics, an ACE inhibitor, and/or nitrates.  Carvedilol, specifically, is indicated for use with these agents in the treatment of mild to severe heart failure of ischemic or cardiomyopathic origin.  There is also increasing evidence that the addition of a beta-blocker to standard therapy can improve morbidity and mortality in patients with advanced heart failure, although it is uncertain whether effectiveness varies significantly with the different agents.  Data from one meta-analysis study suggest a greater reduction of mortality risk for nonselective beta-blockers than for beta-1 selective agents.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6446, 0, 'Esmolol', 'Diabetes Mellitus', 'Beta-adrenergic receptor blocking agents (aka beta-blockers) may mask symptoms of hypoglycemia such as tremors, tachycardia and blood pressure changes.  In addition, the nonselective beta-blockers (e.g., propranolol, pindolol, timolol) may inhibit catecholamine-mediated glycogenolysis, thereby potentiating insulin-induced hypoglycemia and delaying the recovery of normal blood glucose levels.  Since cardioselectivity is not absolute, larger doses of beta-1 selective agents may demonstrate these effects as well.  Therapy with beta-blockers should be administered cautiously in patients with diabetes or predisposed to spontaneous hypoglycemia.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6447, 0, 'Esmolol', 'Hypersensitivity', 'The use of beta-adrenergic receptor blocking agents (aka beta-blockers) in patients with a history of allergic reactions or anaphylaxis may be associated with heightened reactivity to culprit allergens.  The frequency and/or severity of attacks may be increased during beta-blocker therapy.  In addition, these patients may be refractory to the usual doses of epinephrine used to treat acute hypersensitivity reactions and may require a beta-agonist such as isoproterenol.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6448, 0, 'Esmolol', 'Myocardial Ischemia', 'Heightened sensitivity to catecholamines may occur after prolonged use of beta-adrenergic receptor blocking agents (aka beta-blockers).  Exacerbation of angina, myocardial infarction and ventricular arrhythmias have been reported in patients with coronary artery disease following abrupt withdrawal of therapy.  Cessation of beta-blocker therapy, whenever necessary, should occur gradually with incrementally reduced dosages over a period of 1 to 2 weeks in patients with coronary insufficiency.  Patients should be advised not to discontinue treatment without first consulting with the physician.  In patients who experience an exacerbation of angina following discontinuation of beta-blocker therapy, the medication should generally be reinstituted, at least temporarily, along with other clinically appropriate measures.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6449, 0, 'Esmolol', 'Peripheral Vascular Diseases', 'Due to their negative inotropic and chronotropic effects on the heart, beta-adrenergic receptor blocking agents (aka beta-blockers) reduce cardiac output and may precipitate or aggravate symptoms of arterial insufficiency in patients with peripheral vascular disease.  In addition, the nonselective beta-blockers (e.g., propranolol, pindolol, timolol) may attenuate catecholamine-mediated vasodilation during exercise by blocking beta-2 receptors in peripheral vessels.  Therapy with beta-blockers should be administered cautiously in patients with peripheral vascular disease.  Close monitoring for progression of arterial obstruction is advised.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6450, 0, 'Esmolol', 'Cerebrovascular Disorders', 'Beta-adrenergic blocking agents (beta-blockers), should be used with caution in patients with cerebrovascular insufficiency because of their potential effects relative to blood pressure and pulse.  If signs or symptoms suggesting reduced cerebral blood flow are observed, consideration should be given to discontinuing these agents.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6451, 0, 'Esmolol', 'Glaucoma', 'Systemic beta-adrenergic receptor blocking agents (aka beta-blockers) may lower intraocular pressure.  Therefore, patients with glaucoma or intraocular hypertension may require adjustments in their ophthalmic regimen following a dosing change or discontinuation of beta-blocker therapy.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6452, 0, 'Esmolol', 'Hyperthyroidism', 'When beta-adrenergic receptor blocking agents (aka beta-blockers) are used to alleviate symptoms of hyperthyroidism such as tachycardia, anxiety, tremor and heat intolerance, abrupt withdrawal can exacerbate thyrotoxicosis or precipitate a thyroid storm.  To minimize this risk, cessation of beta-blocker therapy, when necessary, should occur gradually with incrementally reduced dosages over a period of 1 to 2 weeks.  Patients should be advised not to discontinue treatment without first consulting with the physician.  Close monitoring is recommended during and after therapy withdrawal.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6453, 0, 'Esmolol', 'Myasthenia Gravis', 'Beta-adrenergic receptor blocking agents (aka beta-blockers) may potentiate muscle weakness consistent with certain myasthenic symptoms such as diplopia, ptosis, and generalized weakness.  Several beta-blockers have been associated rarely with aggravation of muscle weakness in patients with preexisting myasthenia gravis or myasthenic symptoms.  Use cautiously in patients with myasthenia gravis.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6454, 0, 'Esmolol', 'Pheochromocytoma', 'Administration of beta-blockers alone in the setting of pheochromocytoma has been associated with a paradoxical increase in blood pressure due to the attenuation of beta-mediated vasodilatation in skeletal muscle.  In patients with pheochromocytoma, an alpha-blocking agent should be initiated prior to the use of any beta-blocking agent.  Caution should be taken in the administration of these agents to patients suspected of having pheochromocytoma.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6455, 0, 'Esmolol', 'Psoriasis', 'The use of beta-blockers in psoriatic patients should be carefully weighed since the use of these agents may cause an aggravation in psoriasis.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6456, 0, 'Esmolol', 'Tachycardia', 'Beta-adrenergic blockade in patients with Wolff-Parkinson-White syndrome and tachycardia has been associated with severe bradycardia requiring treatment with a pacemaker.  In one case, this result was reported after an initial dose of 5 mg propranolol.  The use of beta-adrenergic receptor blocking agents (aka beta-blockers) should be administered cautiously in these patients.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6457, 0, 'Esmolol', 'Asthma', 'Patients with bronchospastic disease, should, in general, not receive beta blockers, including cardioselective beta-blockers.  Because of the relative beta-1 selectivity, cardioselective beta-blockers may be used in patients with bronchospastic disease who do not respond to, or cannot tolerate, other antihypertensive treatment.  Because beta-1 selectivity is not absolute, the lowest possible dose of these agents should be used.  Consider administering in smaller doses to avoid the higher plasma levels associated with the longer dosing intervals.  If dosage must be increased, dividing the dose should be considered to achieve lower peak blood levels.  It is recommended to have bronchodilators, including beta-2 agonists, readily available or administered concomitantly if necessary.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6458, 0, 'Esmolol', 'Kidney Diseases', 'Esmolol is metabolized in the cytosol of red blood cells.  The resultant acid metabolite is slightly active and is primarily eliminated by the kidney.  The clearance of this metabolite is significantly decreased in patients with renal impairment, although the clinical consequences of metabolite accumulation are unknown.  Therapy with esmolol should be administered cautiously in patients with renal dysfunction.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6459, 0, 'Estradiol (topical)', 'Uterine Hemorrhage', 'The use of estrogens is contraindicated in patients with undiagnosed, abnormal vaginal bleeding.  Prolonged (> 1 year), unopposed estrogen use (i.e. estrogen without concomitant progestin therapy) has been associated with a significant, dose-related risk of endometrial carcinoma.  The risk may be offset substantially by the addition of a progestin but may not be completely abolished.  Prior to initiating estrogen therapy, appropriate diagnostic tests should be performed in patients with abnormal vaginal bleeding to rule out endometrial malignancy.  The same applies if recurrent or persistent bleeding develops during estrogen therapy.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6460, 0, 'Estradiol (topical)', 'Breast Neoplasms', 'The use of estrogens is generally contraindicated in patients with known or suspected estrogen-dependent neoplasia such as breast and endometrial cancer, since it may stimulate tumor proliferation.  High dosages of estrogens may be used for the palliative treatment of inoperable, metastatic breast cancer, but only in appropriately selected men and postmenopausal women.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6461, 0, 'Estradiol (topical)', 'Hypertension', 'The risk of myocardial infarction and strokes, including those associated with oral contraceptive use and some estrogen use, is increased in patients with hypertension.  Moreover, estrogens (and progestogens) may elevate blood pressure and worsen the hypertension, thus compounding the risk.  Clinically significant blood pressure increases have been reported during estrogen therapy, particularly in patients receiving high dosages or treated with oral contraceptive combinations having high progestational activity.  These effects also increase with duration of therapy and patient age.  Therapy with estrogens should be administered cautiously in patients with preexisting hypertension.  Patients should be monitored for changes in cardiovascular status, and their antihypertensive regimen adjusted or estrogen therapy withdrawn as necessary.  In patients requiring contraception, alternative methods should be considered for those who are hypertensive, over age 35, and smoke.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6462, 0, 'Estradiol (topical)', 'Thromboembolism', 'The use of estrogens is considered by manufacturers and some authorities to be contraindicated in patients with active thrombotic or thromboembolic disorders.  The use of estrogen-containing oral contraceptives is additionally deemed contraindicated in patients with a history of such disorders and/or current cerebrovascular or coronary artery disease.  Females with a history of migraines with aura are at an increased risk for stroke and this stroke risk may be further increased in females who have migraines with aura with use of combination oral contraceptives.  Hypercoagulability and changes in various clotting factors and blood components have been observed in women receiving estrogen therapy.  Although the clinical significance of these effects is unknown, epidemiological data suggest it may be dose-dependent.  The risk is probably slight with the use of newer, low-dose oral contraceptives in the absence of known risk factors (e.g., smoker, particularly over the age of 35; hypertension; hyperlipidemia; obesity; diabetes; age over 40).  However, a much more significant risk has been reported with higher dosages, such as those used to treat prostate or metastatic breast cancer or those used in older formulations of birth control pills.  Therapy with estrogens should be administered cautiously in the lowest effective dosage and only after careful consideration of risks and benefits.  Estrogens should be avoided in patients with a history of thrombotic and thromboembolic disorders associated with estrogen use, except when used in the treatment of breast or prostatic malignancy.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6463, 0, 'Estradiol (topical)', 'Liver Neoplasms', 'The use of oral contraceptives is contraindicated in patients with liver tumors.  An increased risk of benign hepatic adenomas and hepatocellular carcinomas has been associated with long-term, oral estrogen- progestin contraceptive use of at least 4 years and 8 years, respectively.  Although these tumors are rare and have not been reported with other types of estrogen or progestogen therapies, any preparation containing estrogens and/or progestogens should probably be avoided in patients with existing tumors of the liver.  Hepatic hemangiomas and nodular hyperplasia of the liver have been reported with isolated estrogen therapy.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6464, 0, 'Estradiol (topical)', 'Angioedema', 'The use of exogenous estrogens may induce or exacerbate symptoms of angioedema, particularly in women with hereditary angioedema.  Close monitoring is recommended when prescribing these agents to patients predisposed to angioedema.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6465, 0, 'Estradiol (topical)', 'Gallbladder Diseases', 'A two- to four-fold increase in risk of gallbladder disease has been noted in women receiving postmenopausal estrogen therapy.  The risk for gallbladder disease may be less for premenopausal women using oral contraceptives containing low-dose estrogens and/or progestins.  Therapy with estrogens should be administered cautiously in patients with preexisting gallbladder disease.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6466, 0, 'Estradiol (topical)', 'Hypercalcemia', 'Estrogens influence the metabolism of calcium and phosphorus.  Intestinal absorption and retention of calcium are increased, which may occasionally result in hypercalcemia.  Therapy with estrogens should be administered cautiously in patients with preexisting hypercalcemia, renal dysfunction, or metabolic bone diseases that are associated with hypercalcemia.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6467, 0, 'Estradiol (topical)', 'Hyperlipidemias', 'Although estrogens have generally favorable effects on plasma lipids, including increases in HDL and decreases in total cholesterol and LDL, they have also been associated with significant elevations in triglyceride levels, particularly when high dosages are used.  Severe hyperlipidemia is known to sometimes cause pancreatitis.  Patients with preexisting hyperlipidemia may require closer monitoring during estrogen therapy, and adjustments made accordingly in their lipid-lowering regimen.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6468, 0, 'Estradiol (topical)', 'Liver Diseases', 'Estrogens are primarily metabolized by the liver.  Patients with impaired hepatic function may be at increased risk for adverse effects associated with estrogen administration due to decreased drug clearance.  Therapy with estrogens should be administered cautiously in patients with liver disease.  In addition, clinicians should be aware that estrogen therapy may affect liver function tests.  Increased sulfobromophthalein retention has been reported with the use of estrogen-containing oral contraceptives and may be expected with larger doses of estrogens.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6469, 0, 'Estradiol (topical)', 'Melanosis', 'The use of exogenous estrogens may occasionally cause chloasma, especially in women with a history of chloasma gravidarum.  Women with a tendency to chloasma should avoid exposure to the sun or ultraviolet radiation while taking combination oral contraceptives.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6470, 0, 'Estradiol (topical)', 'Depressive Disorder', 'The use of oral contraceptives has been associated with an increased incidence of depression.  It is uncertain whether this effect is related to the estrogenic or the progestogenic component of the contraceptive, although excess progesterone activity is associated with depression.  Patients with a history of depression receiving estrogen and/or progestogen therapy should be followed closely.  The manufacturer of medroxyprogesterone recommends monitoring patients who have a history of depression and to not re- administer medroxyprogesterone if depression recurs.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6471, 0, 'Estradiol (topical)', 'Water-Electrolyte Imbalance', 'Estrogens and progestogens may cause fluid retention, particularly when given in high dosages or for prolonged periods.  Therapy with these agents should be administered cautiously in patients who have preexisting problems with excess fluid.  In addition, patients with conditions that may be adversely affected by fluid accumulation, such as asthma, epilepsy, migraine, and cardiovascular or renal dysfunction, should be observed for exacerbation of their condition during estrogen and/or progestogen therapy.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6472, 0, 'Estradiol (topical)', 'Glucose Intolerance', 'Impaired glucose tolerance has been observed in some patients administered oral contraceptives and appears to be related primarily to the estrogen dose.  However, progestogens can increase insulin secretion and produce insulin resistance to varying degrees, depending on the agent.  Patients with diabetes mellitus should be monitored more closely during therapy with estrogens and/or progestogens, and adjustments made accordingly in their antidiabetic regimen.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6473, 0, 'Estradiol (topical)', 'Eye Diseases', 'Estrogens and progestogens may cause retinal thrombosis.  Oral contraceptives should be discontinued if there is unexplained partial or complete loss of vision; onset of proptosis or diplopia; papilledema; or retinal vascular lesions.  Therapy with these agents should be administered cautiously in patients who have preexisting ocular problems and appropriate diagnostic and therapeutic measures should be instituted.  Contact lens wearers who develop visual changes or changes in lens tolerance should be assessed by an ophthalmologist.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6474, 0, 'Estradiol (topical)', 'Thyroid Diseases', 'When administering estrogen and/or progestogen therapy in patients with thyroid disorders, clinicians should be aware that these hormones may affect thyroid function tests.  Changes have mostly been reported with the use of combination oral contraceptives.  Specifically, thyroid-binding globulin (TBG) may be increased, resulting in elevated circulating total thyroid hormone, as measured by PBI (protein-bound iodine), T4 by column or radioimmunoassay, or T3 by radioimmunoassay.  Free T3 resin uptake may be decreased.  On the contrary, a decrease in TBG and, consequently, thyroxine concentration, has been reported by the manufacturers of the progestin-only (norethindrone) oral contraceptives.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6475, 0, 'Estradiol', 'Uterine Hemorrhage', 'The use of estrogens is contraindicated in patients with undiagnosed, abnormal vaginal bleeding.  Prolonged (> 1 year), unopposed estrogen use (i.e. estrogen without concomitant progestin therapy) has been associated with a significant, dose-related risk of endometrial carcinoma.  The risk may be offset substantially by the addition of a progestin but may not be completely abolished.  Prior to initiating estrogen therapy, appropriate diagnostic tests should be performed in patients with abnormal vaginal bleeding to rule out endometrial malignancy.  The same applies if recurrent or persistent bleeding develops during estrogen therapy.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6476, 0, 'Estradiol', 'Breast Neoplasms', 'The use of estrogens is generally contraindicated in patients with known or suspected estrogen-dependent neoplasia such as breast and endometrial cancer, since it may stimulate tumor proliferation.  High dosages of estrogens may be used for the palliative treatment of inoperable, metastatic breast cancer, but only in appropriately selected men and postmenopausal women.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6477, 0, 'Estradiol', 'Hypertension', 'The risk of myocardial infarction and strokes, including those associated with oral contraceptive use and some estrogen use, is increased in patients with hypertension.  Moreover, estrogens (and progestogens) may elevate blood pressure and worsen the hypertension, thus compounding the risk.  Clinically significant blood pressure increases have been reported during estrogen therapy, particularly in patients receiving high dosages or treated with oral contraceptive combinations having high progestational activity.  These effects also increase with duration of therapy and patient age.  Therapy with estrogens should be administered cautiously in patients with preexisting hypertension.  Patients should be monitored for changes in cardiovascular status, and their antihypertensive regimen adjusted or estrogen therapy withdrawn as necessary.  In patients requiring contraception, alternative methods should be considered for those who are hypertensive, over age 35, and smoke.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6478, 0, 'Estradiol', 'Thromboembolism', 'The use of estrogens is considered by manufacturers and some authorities to be contraindicated in patients with active thrombotic or thromboembolic disorders.  The use of estrogen-containing oral contraceptives is additionally deemed contraindicated in patients with a history of such disorders and/or current cerebrovascular or coronary artery disease.  Females with a history of migraines with aura are at an increased risk for stroke and this stroke risk may be further increased in females who have migraines with aura with use of combination oral contraceptives.  Hypercoagulability and changes in various clotting factors and blood components have been observed in women receiving estrogen therapy.  Although the clinical significance of these effects is unknown, epidemiological data suggest it may be dose-dependent.  The risk is probably slight with the use of newer, low-dose oral contraceptives in the absence of known risk factors (e.g., smoker, particularly over the age of 35; hypertension; hyperlipidemia; obesity; diabetes; age over 40).  However, a much more significant risk has been reported with higher dosages, such as those used to treat prostate or metastatic breast cancer or those used in older formulations of birth control pills.  Therapy with estrogens should be administered cautiously in the lowest effective dosage and only after careful consideration of risks and benefits.  Estrogens should be avoided in patients with a history of thrombotic and thromboembolic disorders associated with estrogen use, except when used in the treatment of breast or prostatic malignancy.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6479, 0, 'Estradiol', 'Liver Neoplasms', 'The use of oral contraceptives is contraindicated in patients with liver tumors.  An increased risk of benign hepatic adenomas and hepatocellular carcinomas has been associated with long-term, oral estrogen- progestin contraceptive use of at least 4 years and 8 years, respectively.  Although these tumors are rare and have not been reported with other types of estrogen or progestogen therapies, any preparation containing estrogens and/or progestogens should probably be avoided in patients with existing tumors of the liver.  Hepatic hemangiomas and nodular hyperplasia of the liver have been reported with isolated estrogen therapy.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6480, 0, 'Estradiol', 'Angioedema', 'The use of exogenous estrogens may induce or exacerbate symptoms of angioedema, particularly in women with hereditary angioedema.  Close monitoring is recommended when prescribing these agents to patients predisposed to angioedema.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6481, 0, 'Estradiol', 'Gallbladder Diseases', 'A two- to four-fold increase in risk of gallbladder disease has been noted in women receiving postmenopausal estrogen therapy.  The risk for gallbladder disease may be less for premenopausal women using oral contraceptives containing low-dose estrogens and/or progestins.  Therapy with estrogens should be administered cautiously in patients with preexisting gallbladder disease.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6482, 0, 'Estradiol', 'Hypercalcemia', 'Estrogens influence the metabolism of calcium and phosphorus.  Intestinal absorption and retention of calcium are increased, which may occasionally result in hypercalcemia.  Therapy with estrogens should be administered cautiously in patients with preexisting hypercalcemia, renal dysfunction, or metabolic bone diseases that are associated with hypercalcemia.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6483, 0, 'Estradiol', 'Hyperlipidemias', 'Although estrogens have generally favorable effects on plasma lipids, including increases in HDL and decreases in total cholesterol and LDL, they have also been associated with significant elevations in triglyceride levels, particularly when high dosages are used.  Severe hyperlipidemia is known to sometimes cause pancreatitis.  Patients with preexisting hyperlipidemia may require closer monitoring during estrogen therapy, and adjustments made accordingly in their lipid-lowering regimen.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6484, 0, 'Estradiol', 'Liver Diseases', 'Estrogens are primarily metabolized by the liver.  Patients with impaired hepatic function may be at increased risk for adverse effects associated with estrogen administration due to decreased drug clearance.  Therapy with estrogens should be administered cautiously in patients with liver disease.  In addition, clinicians should be aware that estrogen therapy may affect liver function tests.  Increased sulfobromophthalein retention has been reported with the use of estrogen-containing oral contraceptives and may be expected with larger doses of estrogens.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6485, 0, 'Estradiol', 'Melanosis', 'The use of exogenous estrogens may occasionally cause chloasma, especially in women with a history of chloasma gravidarum.  Women with a tendency to chloasma should avoid exposure to the sun or ultraviolet radiation while taking combination oral contraceptives.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6486, 0, 'Estradiol', 'Depressive Disorder', 'The use of oral contraceptives has been associated with an increased incidence of depression.  It is uncertain whether this effect is related to the estrogenic or the progestogenic component of the contraceptive, although excess progesterone activity is associated with depression.  Patients with a history of depression receiving estrogen and/or progestogen therapy should be followed closely.  The manufacturer of medroxyprogesterone recommends monitoring patients who have a history of depression and to not re- administer medroxyprogesterone if depression recurs.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6487, 0, 'Estradiol', 'Water-Electrolyte Imbalance', 'Estrogens and progestogens may cause fluid retention, particularly when given in high dosages or for prolonged periods.  Therapy with these agents should be administered cautiously in patients who have preexisting problems with excess fluid.  In addition, patients with conditions that may be adversely affected by fluid accumulation, such as asthma, epilepsy, migraine, and cardiovascular or renal dysfunction, should be observed for exacerbation of their condition during estrogen and/or progestogen therapy.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6488, 0, 'Estradiol', 'Glucose Intolerance', 'Impaired glucose tolerance has been observed in some patients administered oral contraceptives and appears to be related primarily to the estrogen dose.  However, progestogens can increase insulin secretion and produce insulin resistance to varying degrees, depending on the agent.  Patients with diabetes mellitus should be monitored more closely during therapy with estrogens and/or progestogens, and adjustments made accordingly in their antidiabetic regimen.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6489, 0, 'Estradiol', 'Eye Diseases', 'Estrogens and progestogens may cause retinal thrombosis.  Oral contraceptives should be discontinued if there is unexplained partial or complete loss of vision; onset of proptosis or diplopia; papilledema; or retinal vascular lesions.  Therapy with these agents should be administered cautiously in patients who have preexisting ocular problems and appropriate diagnostic and therapeutic measures should be instituted.  Contact lens wearers who develop visual changes or changes in lens tolerance should be assessed by an ophthalmologist.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6490, 0, 'Estradiol', 'Thyroid Diseases', 'When administering estrogen and/or progestogen therapy in patients with thyroid disorders, clinicians should be aware that these hormones may affect thyroid function tests.  Changes have mostly been reported with the use of combination oral contraceptives.  Specifically, thyroid-binding globulin (TBG) may be increased, resulting in elevated circulating total thyroid hormone, as measured by PBI (protein-bound iodine), T4 by column or radioimmunoassay, or T3 by radioimmunoassay.  Free T3 resin uptake may be decreased.  On the contrary, a decrease in TBG and, consequently, thyroxine concentration, has been reported by the manufacturers of the progestin-only (norethindrone) oral contraceptives.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6491, 0, 'Amiloride', 'Acidosis', 'Acidosis alters the ratio of extracellular to intracellular potassium and may commonly lead to rapid increases in serum potassium levels.  Conversely, high serum potassium concentrations may potentiate acidosis.  Because of their hyperkalemic effects, therapy with potassium-sparing diuretics should be avoided in patients with metabolic or respiratory acidosis.  These agents should be used cautiously in patients in whom acidosis may occur, such as patients with cardiopulmonary disease, severe respiratory disease, or poorly controlled diabetes.  Acid-base balance and serum potassium levels should be monitored at regular intervals.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6492, 0, 'Amiloride', 'Diabetes Mellitus', 'Potassium-sparing diuretics can cause hyperkalemia, which may result in life-threatening cardiac arrhythmias.  Patients with diabetes mellitus, with or without nephropathy, may be particularly susceptible to the hyperkalemic effect of these drugs due to a defect in the renin-angiotensin-aldosterone axis.  Therapy with potassium-sparing diuretics should be avoided, if possible, in patients with diabetes, especially uncontrolled or insulin-dependent diabetes mellitus.  If these drugs are used, serum potassium levels and renal function should be monitored at regular intervals.  Determination of serum electrolytes is especially important during initiation of therapy, after a dosage adjustment, and during illness that could alter renal function.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6493, 0, 'Amiloride', 'Water-Electrolyte Imbalance', 'All diuretics may cause or aggravate fluid and electrolyte disturbances.  Potassium-sparing diuretics may cause hyperkalemia and, infrequently, hyponatremia.  The latter generally occurs when these agents are combined with other diuretics such as thiazides or used in markedly edematous patients with restricted sodium intake.  Therapy with potassium-sparing diuretics should be administered cautiously in patients with or predisposed to electrolyte abnormalities.  Electrolyte imbalances should be corrected prior to initiating therapy, and serum electrolyte concentrations should be monitored periodically and maintained at normal ranges during therapy.  Determination of serum electrolytes is especially important during initiation of therapy, after a dosage adjustment, and during illness that could alter renal function.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6494, 0, 'Amiloride', 'Hyperkalemia', 'The use of potassium-sparing diuretics is contraindicated in the presence of elevated serum potassium concentrations (> 5.5 mEq/L).  Potassium-sparing diuretics can cause hyperkalemia, which may result in life-threatening cardiac arrhythmias.  Careful monitoring of serum potassium levels is necessary in all patients treated with potassium-sparing diuretics, especially during initiation of therapy, after dosage adjustment, and during illness that could alter renal function.  The diuretic should be withdrawn immediately if hyperkalemia develops, and measures should be initiated to lower serum potassium if it exceeds 6.5 mEq/L.  The combined use of a potassium-sparing diuretic with a kaliuretic diuretic (e.g., thiazides) may decrease the risk of hyperkalemia.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6495, 0, 'Amiloride', 'Liver Diseases', 'Rapid alterations in fluid and electrolyte balance may precipitate hepatic coma in patients with liver disease.  Hepatic encephalopathy has been associated with the use of diuretics, most frequently thiazides but also some potassium-sparing diuretics.  Therapy with all diuretics should be administered cautiously in patients with severely impaired hepatic function.  These patients should be monitored carefully for signs and symptoms of hepatic encephalopathy such as tremors, confusion, increased jaundice, and coma.  Since spironolactone and triamterene are primarily metabolized by the liver, reduced dosages of these drugs may also be necessary in severe hepatic impairment.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6496, 0, 'Amiloride', 'Kidney Diseases', 'The use of potassium-sparing diuretics is contraindicated in patients with anuria, acute or progressive renal insufficiency, or diabetic nephropathy.  Potassium-sparing diuretics can cause hyperkalemia, which may result in life-threatening cardiac arrhythmias.  Patients with impaired renal function may be particularly susceptible to the hyperkalemic effect of these drugs.  Therapy with potassium-sparing diuretics should be administered cautiously in patients with evidence of renal function impairment (BUN > 30 mg/dL or serum creatinine > 1.5 mg/dL).  If these drugs are used, serum potassium levels and renal function should be monitored at regular intervals.  Determination of serum electrolytes is especially important during initiation of therapy, after a dosage adjustment, and during illness that could alter renal function.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6497, 0, 'Estrone sulfate', 'Uterine Hemorrhage', 'The use of estrogens is contraindicated in patients with undiagnosed, abnormal vaginal bleeding.  Prolonged (> 1 year), unopposed estrogen use (i.e. estrogen without concomitant progestin therapy) has been associated with a significant, dose-related risk of endometrial carcinoma.  The risk may be offset substantially by the addition of a progestin but may not be completely abolished.  Prior to initiating estrogen therapy, appropriate diagnostic tests should be performed in patients with abnormal vaginal bleeding to rule out endometrial malignancy.  The same applies if recurrent or persistent bleeding develops during estrogen therapy.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6498, 0, 'Estrone sulfate', 'Breast Neoplasms', 'The use of estrogens is generally contraindicated in patients with known or suspected estrogen-dependent neoplasia such as breast and endometrial cancer, since it may stimulate tumor proliferation.  High dosages of estrogens may be used for the palliative treatment of inoperable, metastatic breast cancer, but only in appropriately selected men and postmenopausal women.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6499, 0, 'Estrone sulfate', 'Hypertension', 'The risk of myocardial infarction and strokes, including those associated with oral contraceptive use and some estrogen use, is increased in patients with hypertension.  Moreover, estrogens (and progestogens) may elevate blood pressure and worsen the hypertension, thus compounding the risk.  Clinically significant blood pressure increases have been reported during estrogen therapy, particularly in patients receiving high dosages or treated with oral contraceptive combinations having high progestational activity.  These effects also increase with duration of therapy and patient age.  Therapy with estrogens should be administered cautiously in patients with preexisting hypertension.  Patients should be monitored for changes in cardiovascular status, and their antihypertensive regimen adjusted or estrogen therapy withdrawn as necessary.  In patients requiring contraception, alternative methods should be considered for those who are hypertensive, over age 35, and smoke.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (6500, 0, 'Estrone sulfate', 'Thromboembolism', 'The use of estrogens is considered by manufacturers and some authorities to be contraindicated in patients with active thrombotic or thromboembolic disorders.  The use of estrogen-containing oral contraceptives is additionally deemed contraindicated in patients with a history of such disorders and/or current cerebrovascular or coronary artery disease.  Females with a history of migraines with aura are at an increased risk for stroke and this stroke risk may be further increased in females who have migraines with aura with use of combination oral contraceptives.  Hypercoagulability and changes in various clotting factors and blood components have been observed in women receiving estrogen therapy.  Although the clinical significance of these effects is unknown, epidemiological data suggest it may be dose-dependent.  The risk is probably slight with the use of newer, low-dose oral contraceptives in the absence of known risk factors (e.g., smoker, particularly over the age of 35; hypertension; hyperlipidemia; obesity; diabetes; age over 40).  However, a much more significant risk has been reported with higher dosages, such as those used to treat prostate or metastatic breast cancer or those used in older formulations of birth control pills.  Therapy with estrogens should be administered cautiously in the lowest effective dosage and only after careful consideration of risks and benefits.  Estrogens should be avoided in patients with a history of thrombotic and thromboembolic disorders associated with estrogen use, except when used in the treatment of breast or prostatic malignancy.', '3', 'DDInter');
